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Abstract 
ABSTRACT 
 
The majority of the worldwide malaria deaths are caused by the Plasmodium falciparum 
parasite and unfortunately parasite strains are emerging that are resistant to not only 
artemisinin, but also the partner drugs used in current antimalarial combination therapy.  The 
intraerythrocytic P. falciparum life stage is characterised by exponential, asexual 
proliferation that could cause the premature death of the human host before the sexual 
gametocytes have had enough time to develop and be taken up by the mosquito vector to 
continue its lifecycle.  It is hypothesised that P. falciparum maintains its population at a level 
low enough to allow for the transmission of these gametocytes by using a form of regulated 
cell death (RCD).  The molecular members of this cell death pathway are currently unclear, 
but a putative P. falciparum inhibitor of apoptosis protein (PfIAP; PF3D7_0519600) has 
previously been identified.  Metazoan IAP proteins play anti-apoptotic roles in cells by 
interacting and inhibiting pro-apoptotic caspases, but also perform other functions. 
Analysis of the PfIAP protein using bioinformatic tools revealed that it contains one 
conserved baculoviral IAP repeat (BIR) domain and that this P. falciparum BIR domain is 
structurally similar to the BIR domains of various human IAP proteins.  mRNA extracted 
from asexual P. falciparum parasites was used to construct a biotin-tagged phage display 
library, which was used in biopanning experiments with two regions of the PfIAP protein, 
expressed as recombinant GST-tagged proteins.  Four binding partners were identified for 
the N-terminal BIR domain of the protein, while two proteins were identified as interacting 
partners for the C-terminal region of PfIAP.  Of these, a double C2-like domain-containing 
protein (PfDOC2) and the high molecular weight rhoptry protein 3 (PfRhopH3) were 
expressed as recombinant His-tagged proteins and verified as PfIAP binding partners by in 
vitro binding assays.  Transgenic P. falciparum parasites were generated expressing a GFP-
tagged PfIAP BIR domain, which localised to the cytoplasm under both normal and high 
temperature conditions which mimic febrile malaria, a physiological trigger of RCD.  
Knockout experiments of the pfiap gene using the CRISPR-Cas9 genome editing tool 
suggested that this gene could be essential for the survival of asexual P. falciparum parasites. 
This study offers the first details of a putative P. falciparum inhibitor of apoptosis protein 
and suggests that it could have non-apoptotic roles in the parasite, given the diverse functions 
of the binding partners that comprise the PfIAP protein-protein network. 
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1.1 The Fight Against Malaria 
There has been a steady decline in the number of malaria deaths over the past number of 
years (29% between 2010 and 2015).  Africa recorded 90% of the estimated 212 million 
worldwide cases of malaria in 2015 and 92% of the estimated 429 000 deaths (World Health 
Organization 2016).  Regrettably 70% of the global malaria deaths were of children younger 
than 5 years old (World Health Organization 2016).  One of the goals of the World Health 
Organisation’s Global Technical Strategy for Malaria 2016–2030 is to reduce the global 
incidence of and mortality from malaria by at least 90% compared to 2015 levels by 2030 
(World Health Organization 2016).  Funding is required to achieve this goal and in 2015 this 
amounted to an estimated US$ 2.9 billion, which unfortunately was less than the estimated 
required amount of US$ 6.4 billion (World Health Organization 2016).  Achieving this 
Global Technical Strategy goal requires a multifaceted approach that confronts not only the 
Plasmodium parasite, but also the infected female Anopheles mosquito.  Vector control 
methods primarily involve the distribution of insecticide-treated mosquito nets (ITNs) and 
protecting homes through indoor residual spraying (Benelli and Beier 2017).  Due to the 
increase in insecticide resistance, particularly pyrethroids which is the only class used in 
ITNs, there is now a pressing need for new vector control tools (World Health Organization 
2016; Benelli and Beier 2017).   
 
Tackling the human malaria parasites: Plasmodium falciparum, P. knowlesi, P. malariae,   
P. ovale and P. vivax involves effective diagnostics and treatment of an infection, but 
ultimately immunisation against the parasite through the deployment of a vaccine.  Rapid 
diagnostic tests (RDTs) allow for cheap and easy investigation of suspected malaria cases, 
but parasites in more than 10 countries with histidine rich protein 2 (HRP2) gene deletions 
can evade detection (World Health Organization 2016).  Only one malaria vaccine has 
completed Phase 3 testing and despite showing only a 39% reduction in clinical incidents in 
young children, the WHO has recommended that the RTS,S/AS01 vaccine be deployed in a 
pilot project to gather more information on its feasibility, safety and impact on mortality 
(World Health Organization 2016). 
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The use of artemisinin-based combination therapy (ACT) is the primary method of treating 
someone infected with malaria, but resistance against artemisinin and its derivatives has 
emerged.  The first artemisinin-resistant P. falciparum parasites were detected in Western 
Cambodia (Dondorp et al. 2009; Noedl et al. 2009).  Since then there are areas of the Greater 
Mekong subregion (Cambodia, parts of China, Laos, Myanmar, Thailand, and Vietnam) 
where increasing artemisinin resistance is compounded by parasite resistance to the partner 
drugs, causing high failure rates of ACT (Dondorp et al. 2017; Woodrow and White 2017).  
The hallmark of artemisinin treatment is the fast clearance of ring stage parasites, so 
artemisinin resistance is best detected as the slow clearance of parasites from the peripheral 
blood (Figure 1.1.1).  There is an urgent need to eliminate resistant P. falciparum from the 
Greater Mekong subregion, before the parasites become untreatable or spread to other parts 
of the world.  To this end the deployment of new antimalarial compounds is required, as is 
the identification of novel parasite drug targets. 
 
Figure 1.1.1: The Greater Mekong Subregion and Artemisinin Resistance 
Adapted from Woodrow and White (2017). 
Top) The percentage of treatment failure rates after treatment with artesunate–mefloquine (MAS3) 
or dihydroartemisinin–piperaquine (DP). 
Bottom) The percentage of parasite positive patients 3 days after the initiation of artemisinin 
combination therapy (ACT), illustrating the current distribution of artemisinin resistance in                  
P. falciparum. 
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1.2 The Plasmodium Life Cycle 
All members of the genus Plasmodium are unicellular protists that cause malaria and have a 
complex life cycle involving a Dipteran insect vector and a vertebrate host (Figure 1.2.1).  
While asexual Plasmodium reproduction occurs in the human host, transmission between 
different humans and Plasmodium sexual reproduction can only occur in the Anopheles 
mosquito.  When a female mosquito takes a blood meal from an infected person, both male 
and female gametocytes are ingested.  In the mosquito midgut, the drop in temperature, 
exposure to xanthurenic acid and change in pH trigger the haploid gametocytes to mature 
into gametes (Sinden et al. 1998).  Using their eight flagellae, the now motile male gametes 
fuse with female gametes to form diploid zygotes that develop into ookinetes.  These motile 
ookinetes traverse the midgut epithelial cell wall and transform into oocysts.  The ultimate 
rupture of the oocysts releases many sporozoites that actively migrate through the 
mosquito’s haemocoel to the salivary glands.  When the mosquito takes its next blood meal, 
these sporozoites are simultaneously injected into the new human host (Hafalla et al. 2011; 
Meibalan and Marti 2017). 
 
Figure 1.2.1: The Life Cycle of the Plasmodium Parasite (Good 2005) 
Diagram showing the various stages of Plasmodium development in the mosquito vector and the 
human host. 
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The newly injected Plasmodium sporozoites travel to the human host’s liver and invade 
hepatocytes.  After replicating as hepatic schizonts, several thousand merozoites are then 
released into the vasculature to infect erythrocytes/red blood cells (RBCs).  In P. ovale and 
P. vivax infections some hepatic parasites remain quiescent, only becoming infective at a 
later stage (White 2011).  When inside the RBC, the merozoite becomes a ring stage parasite, 
develops into a trophozoite and then undergoes asexual replication forming a mature 
schizont (a process referred to as schizogony).  This schizont ruptures the erythrocyte, 
releasing 16-32 merozoites that each invade a new RBC and begin the cycle again (Hafalla 
et al. 2011).  For the P. falciparum parasite this ~48 hour intraerythrocytic process results in 
the clinical manifestations of the symptoms that are associated with the malaria disease 
(Miller et al. 2002). 
 
For the malaria parasite to be able to undergo sexual reproduction in the mosquito vector, 
gametocytes are formed through the process of gametocytogenesis.  Plasmodium falciparum 
gametocytogenesis can take approximately 10-12 days, which is considerably longer than 
other Plasmodium species.  A P. vivax gametocyte requires 48 hours to develop, while the 
rodent malaria P. berghei requires little more than a day to produce a gametocyte (Josling 
and Llinás 2015; Meibalan and Marti 2017).  For the majority of this time the developing   
P. falciparum gametocyte is sequestered in the bone morrow to avoid being removed by the 
spleen.  While only a small proportion of asexual parasites develop into gametocytes, the 
commitment to sexual development occurs before schizogony as all the merozoites within a 
schizont either continue asexual development or differentiate into gametocytes (Bruce et al. 
1990).  The triggers involved in the commitment to gametocytogenesis are not defined, but 
environmental stresses like host immunity (Bousema et al. 2006) or high parasitaemia            
in vitro are associated with a higher rate of gametocytogenesis.  This makes sense, since if 
the host is dying as a result of anaemia caused by a high parasitaemia, then it is in the best 
interest of the parasite to move to a new host (Josling and Llinás 2015). 
 
The problem that arises for P. falciparum is that during the two weeks that are needed for 
gametocytogenesis, the exponential asexual reproduction could easily lead to the premature 
death of the host.  Since the parasite cannot solely rely on the human immune system to 
remove infected RBCs at a high enough rate to counter the exponential asexual growth, it is 
hypothesised that some P. falciparum individuals undergo a form of cell suicide as a way of 
keeping the overall parasitaemia in the host at a manageable level (Deponte and Becker 
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2004).  Cell death in multicellular organisms has been studied for decades and is the best 
available model for P. falciparum cell death. 
 
1.3 The Death of Cells in Multicellular Organisms 
1.3.1 Defining Regulated Cell Death 
Over the course of time, from describing the loss of silk moth intersegmental muscles during 
development (Lockshin and Williams 1964) to the present, it has become clear that 
categorising the death of a cell as having occurred via apoptosis/programmed cell death 
(PCD) or through necrosis is an oversimplification.  The Nomenclature Committee on Cell 
Death (NCCD) recommends that the death process be categorised as either accidental cell 
death (ACD) or regulated cell death (RCD; Galluzzi et al. 2015).  ACD is the unpreventable, 
uncontrolled demise of a cell as a result of extreme physical, chemical or mechanical insults, 
while RCD is facilitated on a molecular level by genetic machinery and thus includes PCD.  
Such a classification is necessary as for example it has become evident that PCD does not 
always fail to induce an inflammatory response, an indicator typical of necrosis.  PCD is 
proposed to now refer to RCD processes that occur as part of development or that preserve 
tissue homeostasis (Galluzzi et al. 2015). 
RCD is a relatively new term and as yet to be fully adopted by all in the scientific world.  
Therefore this study will make use of the cell death terms (apoptosis, autophagy, necrosis 
etc.) used by the authors of published literature, but will use the term RCD when discussing 
the work described here. 
 
1.3.2 The Apoptosis Pathway 
Apoptosis is the best characterised of all the regulated cell death phenotypes and is instigated 
either through extracellular signals (such as environmental stress) or by internal cell signals 
(following infection with a pathogen for example), that both result in a proteolytic cascade 
involving caspases (Figure 1.3.1).  This leads to the death of the cell through morphological 
changes that include DNA fragmentation, mitochondrial outer membrane permeabilisation 
(MOMP) and apoptotic body formation (Elmore 2007).  Apoptosis is a complex process 
involving a range of different participants, one of these is the tumour suppressor protein p53.  
This protein is present in the cytosol but upon DNA damage translocates to the nucleus 
where it functions as a transcription factor and promotes the expression of a variety of pro-
apoptotic proteins  (Elmore 2007).  A simplified description of the process of apoptosis and 
other RCD pathways follows. 
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Figure 1.3.1: The Extrinsic and Intrinsic Pathways of Apoptosis 
Diagram showing some of the major participants involved in metazoan apoptosis.  Red line = protein 
inhibition.  Apaf-1 = Apoptotic protease activating factor 1; BAK = Bcl-2 homologous 
antagonist/killer; BAX = Bcl-2-associated X protein; Bcl-xL = B-cell lymphoma-extra large; BID = 
BH3 interacting-domain death agonist; Cyt C = cytochrome c; FADD = Fas-associated protein with 
death domain; Omi = Omi stress regulated endoprotease; SMAC = second mitochondria-derived 
activator of caspases; XIAP = X-linked inhibitor of apoptosis protein.  Based on Zhang et al. (2005); 
Ashkenazi (2008); Galluzzi et al. (2009); DeAlmagro and Vucic (2012); Czabotar et al. (2013); 
Ichim and Tait (2016). 
 
Any of a multitude of cellular stressors, such as DNA damage, can initiate the intrinsic 
apoptosis pathway.  This pathway is tightly regulated by the B cell lymphoma 2 (Bcl-2) 
protein family, which is comprised of both anti-apoptotic and pro-apoptotic members.  Bcl-
2-associated X protein (BAX) and Bcl-2 homologous antagonist/killer (BAK) are activated 
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in response to apoptotic stimuli and overcome the inhibitory effects of the anti-apoptotic 
Bcl-2 members (such as Bcl-xL).  Translocation to the mitochondria by these activated pro-
apoptotic proteins, leads to the loss of MOMP which results in the release of cytochrome c 
from the mitochondrial inter-membrane space into the cytoplasm.  The proteins 
SMAC/DIABLO (second mitochondria-derived activator of caspases/direct IAP binding 
protein with low pI) and HtrA2/Omi (high temperature requirement A/Omi stress regulated 
endoprotease) are also released from the mitochondria at this stage.  These two pro-apoptotic 
proteins sequester various inhibitor of apoptosis (IAP) proteins, allowing for the release of 
different caspases.  The various caspase proteins are cysteinyl aspartate proteases that are 
present in the cytoplasm of the cell as inactive zymogens (Kumar 2007).  Apoptotic protease 
activating factor 1 (Apaf-1) and the now free initiator pro-caspase-9 come together to form 
the apoptosome (along with cytochrome c) and activate effector caspases-3 and -7.  This 
results in the death of the cell through various processes including the loss of cell skeleton 
integrity, chromatin condensation and fragmentation by nucleases and membrane blebbing. 
Active caspase-3, for example, cleaves the inhibitor of caspase-activated DNase (ICAD), 
which leads to the release of active CAD to mediate the fragmentation of DNA (Kumar 
2007).  The activation of caspases also brings about the accumulation of phosphatidylserine 
(PS) on the intact cell membrane outer leaflet, as opposed to normal conditions when it is 
retained exclusively on the inner leaflet of the membrane.  This “eat me” signal is used to 
ensure the proper clearance of the apoptotic bodies by attracting the attention of phagocytes, 
thereby avoiding an inflammatory response (Elmore 2007; Ashkenazi and Salvesen 2014; 
Fuchs and Steller 2015). 
 
The extrinsic death receptor pathway is initiated following the activation of transmembrane 
death receptors on the cell surface such as the Fas receptor.  This leads to the recruitment of 
cytoplasmic proteins like FADD (Fas-associated protein with death domain), which form 
the death-inducing signalling complex (DISC).  The initiator pro-caspase-8 interacts with 
DISC, is proteolytically cleaved and then directly activates caspase-3.  This effector caspase 
is responsible for the death of the cell and the activation of caspase-7.  The BH3 interacting-
domain death agonist (BID) protein is also cleaved by activated caspase-8, after which the 
truncated BID protein triggers mitochondrial damage through the activation of the pro-
apoptotic BAX (Elmore 2007; Ashkenazi and Salvesen 2014; Fuchs and Steller 2015). 
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Another phenotype of RCD is autophagy which is the mechanism by which superfluous or 
damaged proteins are removed.  The targeted cytoplasmic components are engulfed by 
autophagosomes, which fuse with lysosomes to enable protein degradation and the resupply 
of the cell with building blocks. In a stress environment, autophagy has a pro-survival 
function by being able to delay apoptosis or suppress necrotic cell death (Mariño et al. 2014; 
Swart et al. 2016).  Necrosis is the premature death of a cell that results in the release of 
cytokine interleukin-1 beta and activation of inflammatory responses.  It is typically not 
associated with the activation of caspases or any of the morphological markers of apoptosis 
or autophagy (Elmore 2007; Tait et al. 2014).  Regulated necrosis (necroptosis) on the other 
hand is a mode of cell death that involves death receptor signalling, the necrotic 
morphological features of death, but the inhibition of caspases (Vandenabeele et al. 2010; 
Ashkenazi and Salvesen 2014; Tait et al. 2014). 
 
1.3.3 The Inhibitor of Apoptosis Family of Proteins 
The inhibitor of apoptosis gene was first discovered in baculovirus infected Spodoptera 
frugiperdato insect cells to inhibit apoptosis (Crook et al. 1993) and homologues have since 
been identified in yeast, nematodes through to higher vertebrates.  The inhibitor of apoptosis 
protein is characterised by the presence of one to three baculovirus IAP repeats (BIR) motifs 
that are found in the N-terminal region of the protein.  Other functional regions that can be 
found in IAP proteins are the ~40 amino acid really interesting new gene (RING) domain or 
the caspase-associated recruitment domain (CARD). 
 
There are eight IAP protein in humans with the smallest, survivin, only containing one BIR 
domain, while cellular IAP1 (cIAP1) and cIAP2 contain all of the mentioned domains 
(Figure 1.3.2).  The neuronal apoptosis-inhibitory protein (NAIP) contains a unique 
nucleotide binding oligomerization domain (NOD) and a C-terminal leucine-rich repeat 
(LRR) domain, while the very large Apollon protein has one BIR domain and the C-terminal 
ubiquitin conjugating enzyme (UBC) domain.  Since all of the proteins contain at least one 
BIR domain, they are also referred to as baculoviral IAP repeat containing proteins (BIRCs). 
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Figure 1.3.2: The Human Inhibitor of Apoptosis Proteins 
Diagram showing the various domains of the eight human IAP proteins.  BIR = baculovirus IAP 
repeat; CARD = caspase-associated recruitment domain; LRR = leucine-rich repeat; NOD = 
nucleotide binding oligomerization domain; RING = really interesting new gene; UBC = ubiquitin 
conjugating enzyme.  Numbers = amino acid number.  Adapted from Srinivasula and Ashwell (2008). 
 
The BIR domain is a 70-80 amino acid region that contains the signature CX2CX16HX6C 
sequence, although the better defined CX2CX6WX3DX5HX6C pattern can often apply           
(C = cysteine; D = aspartic acid; H = histidine; W = tryptophan; X = any amino acid;      
Figure 1.3.3; Srinivasula and Ashwell 2008; Garg et al. 2016).  The tertiary structure of this 
domain are a three-stranded β-sheet surrounded by a series of α-helices (Hinds et al. 1999).  
These structures form a hydrophobic core that allows for the coordination of a zinc ion by 
the three cysteines and one histidine (Figure 1.3.3 and Figure 1.3.4). 
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Figure 1.3.3: The Human BIR Domains 
Amino acid alignment of the BIR domains of all of the human IAP proteins.  Green triangles = zinc-
chelating residues; red circles = additional zinc-binding residues.  Amino acids are shaded using the 
Clustal X colour scheme. 
 
 
Figure 1.3.4: A Typical BIR Domain Zinc-Binding Fold (Hinds et al. 1999) 
Visualisation of the cIAP1 BIR3 hydrophobic pocket used to chelate Zn2+.  Pink side chains = zinc-
chelating residues (green triangles in Figure 1.3.3); yellow side chains = surrounding amino acids.  
Green ball = Zn2+ ion. 
 
The binding of IAP proteins directly to caspases leads to either the inactivation of the caspase 
or caspase degradation and the presence of multiple BIR domains in each protein increases 
the range of partners that IAP can bind to (Srinivasula and Ashwell 2008).  Human X-linked 
IAP (XIAP), along with cIAP1 and cIAP2, inhibit caspases-3, -7 and -9 but not caspase-8, 
via their BIR2 and BIR3 domains.  Despite the significant amino acid sequence similarities 
between the BIR domains, there are structural differences between XIAP and cIAP1/2 as the 
latter show a weaker binding affinity to the caspases than the former (Deveraux et al. 1998).  
Subsequent work has shown that although the cIAPs contain the scaffold for caspase-
binding, they either never gained or have since lost the specific residues required for caspase 
inhibition (Eckelman et al. 2006).  XIAP is now regarded as the only mammalian IAP that 
directly inhibits caspase activity, while the mechanism by which the other IAP proteins 
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attenuate apoptosis could involve binding to pro-apoptosis proteins and targeting them for 
ubiquitin degradation (see below; Eckelman et al. 2006). 
 
On the pro-apoptotic side are the mitochondrial proteins HtrA2/Omi and SMAC/DIABLO.  
These proteins are synthesised as precursors and trafficked to the mitochondria, where a 
tetrapeptide IAP-binding motif (IBM) is exposed.  When apoptosis is triggered these pro-
apoptotic proteins are released into the cytosol, where they use their IBM motifs to bind to 
IAP BIR2 and BIR3 domains, liberating the bound caspases (Kocab and Duckett 2016).  The 
hydrophobic, BIR domain IBM-binding groove interacts with caspases or IBMs in a 
mutually exclusive manner – SMAC IBM peptides block the binding of caspase-9 to BIR3 
(Srinivasula et al. 2001). 
 
Another domain that most of the IAP proteins have is the RING domain and so IAP proteins 
are also classed as ubiquitin ligases.  The 8 kDa ubiquitin is activated by the ubiquitin-
activating enzyme (E1), transferred to the ubiquitin-conjugating enzyme (E2) and then 
promoted to move to lysine residues on the target protein by the ubiquitin-protein ligase (E3; 
Figure 1.3.5).  This ubiquitination process results in a protein with a lysine-linked ubiquitin 
chain (the ubiquitin molecules bind to each other at K48), which is the signal for the protein 
to be degraded by a proteasome.  Substrates of this E3 activity range from apoptotic and 
signalling molecules to IAP proteins themselves in an autoubiquitination fashion (Feltham 
et al. 2012). 
 
Figure 1.3.5: The Ubiquitin Pathway 
Diagram showing the polyubiquitination of a protein substrate.  E1 = ubiquitin-activating enzyme; 
E2 = ubiquitin-conjugating enzyme; E3 = ubiquitin-protein ligase; Ub = ubiquitin.  Adapted from 
Feltham et al. (2012). 
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1.4 Regulated Cell Death in Unicellular Organisms 
1.4.1 Unicellular RCD 
For a multicellular organism to have a way of removing unwanted or damaged cells (via 
RCD mechanisms) is of clear evolutionary benefit.  This same benefit is not as obvious in 
the context of a unicellular organism – using cellular machinery to kill the cell, results in the 
cell’s death.  This phenomenon does not agree with Darwinian ideas in which an organism 
will evolve ways to maximise its proliferation, not its death (Pollitt et al. 2010).  Questions 
arise about not only how such processes would evolve and persist through generations, but 
why a unicellular organism would be willing to commit suicide?  With respect to the initial 
part of the question, the apoptosis pathway is conserved in metazoans and many of the 
constituent proteins have been shown to also have non-death related functions.  The 
hypothesis has been put forward that these cell death proteins evolved their function from 
proteins involved in normal cellular activities (Dick and Megeney 2013). 
 
Multiple apoptotic markers have been seen in unicellular organisms such as Saccharomyces 
cerevisiae, many of whose apoptotic elements are similar to those in mammals (Deponte and 
Becker 2004; Kaczanowski et al. 2011).  This list has grown to include parasitic protozoan 
organisms like Leishmania or Trypanosoma that show mammalian apoptosis characteristics 
(Kaczanowski et al. 2011; Proto et al. 2012). 
 
The exponential P. falciparum asexual reproduction could result in premature host death 
during the two weeks required for gametocytogenesis to be completed.  To counter this the 
parasite could limit its population in the host by reducing the number of merozoites produced 
each cycle, impairing the ability of merozoites to invade new RBCs, produce more 
gametocytes (decreasing the number of asexual participants) or actively reduce its 
population through cell death (Deponte and Becker 2004; Reece et al. 2009).  There is 
evidence that P. falciparum exhibits density dependent processes for limiting uncontrolled 
growth of the parasites, akin to quorum sensing (Mutai and Waitumbi 2010).  The use of cell 
suicide as a means of population control to ensure transmission to the next host could be 
altruistic, for the benefit of the colonial parasite line, perhaps undertaken by parasites with 
an inferior phenotype (Reece et al. 2011).  The use of paracrine signals to activate cell death 
pathways in neighbours by commandeering proteins with important cellular roles is a means 
of population control employed by Leishmania and Trypanosoma (Dick and Megeney 2013). 
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1.4.2 The Phenotype of RCD in P. falciparum 
Since Picot et al. (1997) linked the well-known “crisis form” morphological phenomenon of 
P. falciparum to apoptosis, various studies tried to definitively classify the cell death 
phenotype of P. falciparum, with mixed results.  This work has been performed by looking 
at metazoan biochemical and morphological markers of cell death such as mitochondrial 
dysregulation, PS externalization on the surface of the host RBC, DNA laddering and 
cytoplasmic vacuolization.  From these studies there is evidence that RCD does occur in      
P. falciparum, but the reported cell death phenotypes vary from apoptosis to necrosis or from 
apoptosis-like to autophagy-like.  A cause of these discrepancies could be the technical 
diversity across these various studies (Engelbrecht et al. 2012).  Another reason could be the 
fact that metazoan attributes are being enforced onto a unicellular organism that may go 
about RCD in a unique way.  That said, until a definitive phenotype (unique or not) can be 
elucidated, comparing observations against multicellular RCD characteristics is a good 
starting point (Engelbrecht et al. 2012). 
 
Depending on a range of different factors, various RCD phenotypes have been observed.  
Specific evidence for the occurrence of RCD in P. falciparum, with particular focus on the 
intraerythrocytic stages of the parasite’s life cycle, was reviewed by Engelbrecht et al. 
(2012).  Subsequent work includes the observation that an apoptosis-like cell death occurs 
in asexual P. falciparum cultures while under proteasome inhibition (Rathore et al. 2015).  
Ring stage P. falciparum parasites also exhibit an apoptosis-like cell death phenotype under 
heat stress, but late stage parasites exhibit an autophagy-like phenotype (Engelbrecht and 
Coetzer 2013).  High parasitaemia in P. falciparum cultures resulted in a growth reduction, 
but the eventual recovery of the parasites.  This decline in parasitaemia was brought about 
via an apoptosis-like phenotype of RCD with the collapse of the mitochondrial 
transmembrane potential and PS externalisation, followed by DNA fragmentation 
(Engelbrecht and Coetzer 2016).  On the other hand exposure of in vitro P. falciparum 
cultures to natural sunlight resulted in the death of a portion of the parasite population 
(particularly the late stage parasites) and the induction of a unique form of RCD in which 
DNA fragmentation preceded mitochondrial hyperpolarization (Engelbrecht and Coetzer 
2015).  Haematological complications for the host during P. falciparum infection can be 
partially attributed to the fact that apoptosis can be induced in uninfected RBCs by plasma 
from P. falciparum (but not P. vivax) infected individuals (Totino et al. 2014; also noted by 
Engelbrecht and Coetzer 2016). 
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1.4.3 P. falciparum RCD Homologues 
In spite of the observed RCD biochemical and morphological markers, to date no cell death 
protein network has been experimentally validated in P. falciparum.  After looking for RCD 
genes within the P. falciparum genome using bioinformatics, such as a novel evolutionary 
rate-based alignment algorithm, some putative plasmodial homologues of metazoan proteins 
involved in RCD have been identified, including: ataxia-telangiectasia mutated, IAP, 
metacaspase (MCA1 - PF13_0289) and p53 (Wu et al. 2003; Nedelcu 2009; Coetzer et al. 
2010; Figure 1.4.1).  Laboratory experiments are now needed to investigate whether these 
proteins function like their metazoan counterparts, have unique Plasmodium roles related to 
RCD or are only involved in normal cellular functions. 
 
Figure 1.4.1: The Phylogenetic Tree of Various Caspase Proteins (Wu et al. 2003) 
Phylogenetic tree of caspases, inferred by the neighbour-joining method based on the amino acid 
sequences with Poisson corrected distance.  Bootstrap values of >50% are presented.  Scale bar 
indicates the number of amino acid substitutions per site.  Protozoan sequences are underlined. 
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While no caspases are present in Plasmodium, three related metacaspase proteins        
(MCA1-3) have been described in P. falciparum, P. vivax and P. berghei.  MCA1 is the only 
protein that contains the required histidine and cysteine catalytic dyad (Meslin et al. 2011b).  
Plasmodium falciparum metacaspase expression was observed in all intraerythrocytic life 
stages, but its level was dependent on parasite density (Mutai and Waitumbi 2010).  PfMCA1 
has been shown to exhibit calcium-dependent, arginine-specific protease activity and 
induces yeast cell death while under oxidative stress, when expressed in S. cerevisae (Meslin 
et al. 2011a).  The prodomain of PfMCA1 is removed through an autoprocessing mechanism 
when examined in vitro and this could be an important part of the protein’s in vivo cell death 
functioning (Meslin et al. 2007).  PbMCA1 (expressed in female gametocytes and the 
mosquito stages, but not in the asexual stages) was knocked out with no apparent loss-of-
function phenotype, possibly because PbMCA2/3 offer some functional redundancy (LeChat 
et al. 2007). 
 
The nuclear, anti-apoptotic mammalian mouse double minute 2 homolog (MDM2) contains, 
amongst others, a SWI/SNF complex B (SWIB)/MDM2 domain.  This domain is used to 
bind to the N-terminal region of p53 (preventing p53 from binding to DNA), induce nuclear 
export and p53 degradation.  The SWIB/MDM2 domain has also been identified elsewhere, 
for example in the SWItch/Sucrose Non-Fermentable (SWI/SNF) nucleosome remodelling 
complex.  Two proteins containing SWIB/MDM2 domains have been identified in                  
P. falciparum designated PfMDM2 and PfSWIB.  PfMDM2 (PlasmoDB ID: 
PF3D7_0518200) localized to the mitochondria under normal and heat stress conditions and 
so is hypothesised to be involved in mitochondrial maintenance after not showing any RCD 
activity (Vieira and Coetzer 2016).  PfSWIB (PF3D7_0611400) translocated from the 
cytoplasm to the nucleus in some late stage parasites in response to heat stress and so it is 
postulated that PfSWIB has a pro-survival function (Vieira and Coetzer 2016). 
 
Analysis of a P. falciparum p53 homologue identified a putative DNA binding and a 
tetramerization domain within the protein.  Tetramerization experiments using recombinant 
Pfp53 though were inconclusive and the protein failed to bind a canonical p53 DNA binding 
sequence (Vieira 2015). 
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In light of the recent nomenclature changes (Galluzzi et al. 2015), there is now indecision as 
to whether Plasmodium cell death is regulated or accidental (Sow et al. 2015).  The academic 
need to classify cellular processes according to criteria, which can easy evolve with the 
increase of available knowledge, can be viewed as an unnecessary preoccupation in light of 
increasing P. falciparum artemisinin drug resistance (Sow et al. 2015).  However, it could 
be well worth it to utilise the available information about Plasmodium RCD in the design of 
new drugs to kill the malaria parasite (Sow et al. 2015). 
 
1.5 Study Objectives 
With the ultimate goal of presenting a new cell death-related target to which an anti-malarial 
drug could be designed, this study aimed to characterise a putative P. falciparum inhibitor 
of apoptosis (PfIAP) protein (PF3D7_0519600) and investigate its role in RCD. 
 
The objectives of this study were to: 
- Analyse the PfIAP protein using available bioinformatic tools 
- Express and purify various PfIAP domains as recombinant proteins 
- Create a biotin-tagged P. falciparum cDNA phage display library 
- Identify binding partners for the various PfIAP domains through biopanning experiments 
- Verify these interactions by performing in vitro binding assays 
- Determine the cellular localisation of the PfIAP BIR domain using transgenic parasites 
expressing a GFP tag 
- Assess the effect that RCD stimulation has on the localisation of the GFP-tagged BIR 
domain 
- Determine if the pfiap gene is essential for P. falciparum parasite survival through 
knockout experiments. 
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CHAPTER 2: The Characterisation of PfIAP 
2.  
2.1 Introduction 
2.1.1 Protein-Protein Interactions 
The interactome of a cell represents all of the molecular interactions that occur in the cell.  
While this can refer to interactions between genes, it primarily refers to the physical 
interactions between molecules such as proteins.  Characterising the protein-protein 
interactions (PPIs) of a cell is an important step in the understanding of a cell’s biology.  
Although some of these proteins can operate in relative isolation, most proteins (over 80%) 
are predicted to work with others in complexes, with many PPIs forming part of the networks 
that are responsible for cellular structure or function (Berggård et al. 2007).  These functions 
can range from cell-cycle control to signalling or transport.  PPIs can be characterised in a 
number of ways by contrasting their structural and functional characteristics, for example as 
either being stable or transient.  Stable interactions are typically associated with proteins that 
make up multi-subunit complexes, while transient interactions are used to control cellular 
processes in a temporary manner when certain conditions are met.  The function of an 
unknown protein can be implied through PPI studies, where the unknown protein is 
associated with proteins with known functions. 
 
2.1.1.1 Methods to Detect Protein-Protein Interactions 
Methods to detect PPIs can be classified as either being in vivo, in vitro or in silico.  In vivo 
techniques are performed using a whole living organism itself, while in vitro systems occur 
outside a living organism in a controlled environment.  In silico predictions are made via 
computer simulations or through computer analysis that has been developed to support some 
of the experimental approaches (Rao et al. 2014).   
The yeast two-hybrid method (Fields and Song 1989) is a classic in vivo example and allows 
for the direct recognition of an interaction between two proteins.  A transcription factor is 
separated into two domains: a DNA-binding domain (BD) and an activation domain (AD).  
Both domains are required to be in close proximity to each other for the transcription factor 
to be able to activate a downstream reporter gene.  The bait protein of interest is joined to 
the BD, while various prey proteins are fused to the AD.  Only if the bait and prey proteins 
interact with each other will the transcription factor be able to activate the reporter gene.  
The yeast two-hybrid technique has been used to identify novel PPIs in the P. falciparum 
parasite (LaCount et al. 2005). 
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There are a number of different approaches that can be taken when performing in silico PPI 
predictions.  A structure-based method for example uses the structure (primary, secondary 
or tertiary) of the proteins involved to make predictions based on the known interactions of 
other proteins with similar structures.  The gene expression approach on the other hand uses 
the idea that proteins, whose genes belong to the same expression cluster, are more likely to 
interact with each other than with proteins from another gene cluster (Rao et al. 2014). 
Other methods of PPI detection include: affinity chromatography, co-immunoprecipitation, 
protein microarrays and phage display.  An attractive feature of using co-
immunoprecipitation in live cells to identify a PPI is that the proteins are present in their 
native form and so should reflect natural interactions as the protein complex is captured from 
whole cell extract (Berggård et al. 2007).  A protein array involves fixing a bait protein to a 
support surface, applying different prey proteins and determining which protein pair forms 
an interaction (Rao et al. 2014).  Phage display was chosen for this study and is discussed in 
more detail below. 
 
2.1.2 Phage Display 
2.1.2.1 Phage Display Technology 
From the first use of the filamentous bacteriophage f1 (Smith 1985), the PPI investigative 
technique of using phage display libraries has developed and diversified.  Phage display 
technology involves incorporating foreign DNA into a gene encoding one of the coat 
proteins of the phage.  Infection of a bacterial host with these modified phage results in these 
fusion peptides being expressed on the bacteriophage capsid surface.  After exposing this 
library of peptides to a bait protein (a process termed biopanning), any resulting PPIs can be 
identified.  This phenotype-genotype link is the power of phage display technology: the 
displayed peptide (phenotype) can be directly linked to the DNA sequence responsible for 
the peptide (genotype; Aghebati-Maleki et al. 2016). 
 
Phage display systems can be classed as being either non-lytic or lytic.  Vectors derived from 
filamentous phage (such as M13 or fd) are referred to as non-lytic.  A frequently used 
technique is to present the peptide coupled to the minor coat protein pIII of M13 phage, 
although other capsid proteins (e.g. pVI and pVIII) are also used (Li and Caberoy 2010; 
Georgieva and Konthur 2011).  Another approach involves the use of phagemids which are 
plasmid vectors that encode the fusion coat protein and phage packaging signal.  A helper 
phage is needed to provide the wild type coat protein and the other genes required for the 
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assembly of the phage (Pande et al. 2010).  While the M13 non-lytic phage display system 
is easy to manipulate there is a major drawback – the displayed peptide needs to be secreted 
through the Escherichia coli membrane which can result in bias towards peptides with a 
signal sequence, compromising the successful display of the desired proteins (Li 2012; 
Sundell and Ivarsson 2014).  This is not a problem for lambda, T7 or other lytic phage as no 
protein secretion is required, instead the bacteriophage assemble within the cytoplasm of the 
bacteria and simply rupture the cell after replication (Danner and Belasco 2001), making 
these phage systems particularly suitable for the unbiased display of mammalian proteins 
(Li 2012).  When comparing the diversity of 12-mer and disulphide-constrained 7-mer 
peptides displayed by both M13 and T7 phage display libraries, the T7 system outperformed 
the M13 system across numerous metrics (Krumpe et al. 2006). 
 
T7 phage have numerous properties that make them attractive for use as a phage display 
vector including the fact that the bacteriophage are very easy to grow and that they replicate 
more rapidly than either filamentous or lambda bacteriophage (Rosenberg et al. 1996).  The 
linear, double-stranded DNA T7 phage has an icosahedral capsid shell made up of 415 copies 
of the capsid protein (gene 10), attached to a conical tail (genes 11 and 12) and 6 tail fibres 
(gene 17) via the head-tail connector (gene 8) (Figure 2.1.1a; Rosenberg et al. 1996).  The 
phage capsid can be composed entirely of protein 10A (344 amino acids; aa) or protein 10B 
(397 aa) or different ratios of these proteins, although capsid protein 10B (produced by a 
translational frameshift at amino acid 341) normally makes up only 10% of the capsid 
(Condron et al. 1991).  The implication of this mosaic composition is that the T7 capsid is 
flexible and that external amino acids can be inserted into these capsid proteins.  This fact 
has been commercialised by Novagen and released as the T7Select® phage display system.  
In the T7Select®10-3b vector the natural frameshift site has been removed and multiple 
cloning sites have been inserted, allowing for the cloning of the peptides to be displayed 
(Figure 2.1.1b).  Only a single form of the capsid protein is now made, but because the size 
or sequence of the displayed peptide could negatively affect viral assembly, the 
bacteriophage are amplified in E. coli cells that contain a plasmid expressing multiple copies 
of the 10A protein (Rosenberg et al. 1996). 
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Figure 2.1.1: The T7 Bacteriophage used for Phage Display 
a) Schematic representation of a T7 bacteriophage. 
b) Diagram showing the T7Select®10-3b vector.  The frameshift at amino acid 341, responsible for 
the 10B capsid protein, has been removed and a multiple cloning site has been included after amino 
acid 348 to allow for the insertion of foreign DNA.  Numbers = amino acid number.  Adapted from 
Rosenberg et al. (1996). 
 
An unfortunate consequence of creating a phage display library from cDNA is that there is 
no guarantee that the sequence will be inserted into the phage vector in-frame.  As an 
example, less than 10% of clones sequenced from a cDNA T7 phage display library were 
in-frame (Kalniņa et al. 2008).  The effect of non-open reading frames is that they encode 
unnatural peptides which have no relevance to the real protein network being investigated 
(Li and Caberoy 2010).  An advantage of using the T7Select® System to create the phage 
display library is that directional linkers are ligated to the cDNA prior to bacteriophage 
assembly.  These linkers ensure that the inserts can only be introduced into the vector in one 
of three frames, as opposed to one of six frames.  In an effort to further improve the 
likelihood that only in-frame peptides are expressed, various strategies have been proposed.  
In an approach that uses phagemids, the cDNA inserts are followed by a β-lactamase gene, 
flanked by two homologous lox sites.  After ampicillin screening (only the in-frame inserts 
would result in antibiotic resistance), the β-lactamase gene was then removed using the Cre 
recombinase enzyme (Zacchi et al. 2003).  A similar method involves the preselection of 
open reading frames using a C-terminal β-lactamase gene in a plasmid (Faix et al. 2004).  It 
is necessary to remove the β-lactamase gene as it reduces the efficiency of foreign peptide 
display (Zacchi et al. 2003; Faix et al. 2004).  A different approach involves tailing the 
cDNA insert with a biotinylation sequence which results in the expression of a C-terminal 
biotin tag if the insert is in-frame.  Selection of these in-frame phage is then performed using 
immobilised streptavidin (Ansuini et al. 2002; Caberoy et al. 2009). 
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Phage display can be utilised for different purposes, using various sources of display 
peptides.  In enzymology, phage libraries can determine substrate specificity or design 
modulators to the active site of an enzyme.  Identifying the epitope of an antigen that binds 
an antibody of interest can be rapidly achieved using phage display.  Random peptide 
libraries or peptides derived from cDNA can be used to identify novel binding partners of a 
protein of interest (Pande et al. 2010). 
 
2.1.2.2 Phage Display in Malaria Research 
Phage display is an effective tool that has been used in different ways to investigate the 
Plasmodium parasite (reviewed by Lanzillotti and Coetzer 2008).  Investigations into host-
parasite interactions using a P. falciparum cDNA phage display library were first performed 
in the Coetzer laboratory (Lauterbach et al. 2003) and identified thirteen P. falciparum 
proteins that bound to human erythrocyte membrane protein spectrin and protein 4.1 
(Lauterbach et al. 2003; Lanzillotti and Coetzer 2004).  Other P. falciparum cDNA phage 
display libraries have identified a novel interaction between the merozoite surface protein 1 
(MSP1) and the erythrocyte glycophorin A (GPA) protein (Baldwin et al. 2015), a GPA-
interacting peptide that partially inhibited merozoite invasion (Li et al. 2008) and the region 
within the erythrocyte-binding ligand protein that recognised glycophorin B (GPB) and 
partially inhibited merozoite invasion (Li et al. 2012).  A P. falciparum cDNA phage display 
library has also been used in basic parasite biology studies to identify binding partners for 
both the P. falciparum MDM2 and SWIB proteins (Vieira and Coetzer 2016) and identify 
two novel apical membrane antigen-1 (AMA1) interacting proteins (Churchyard 2017). 
 
Recent examples of other phage display work include the use of random peptide libraries to 
identify a 12-mer peptide that inhibited P. berghei sporozoite entry into Kupffer cell         
(Cha et al. 2015) and the female gamete peptide 1 which bound to the surface of female       
P. berghei gametes and interfered with oocyst formation (Vega-Rodriguez et al. 2015).  
Work on a Plasmodium vaccine has also utilised a peptide library to identify two P. knowlesi 
MSP1 epitopes that generated an immune response when used to immunise mice (Cheong 
et al. 2016), while an antibody phage display library was used to identify two unique human 
single chain antibody clones that bound recombinant P. falciparum HRP2 and could be used 
in the development of the next generation of RDTs (Leow et al. 2014). 
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Phage display libraries have proven to be a valuable tool in malaria research and so phage 
display technology was used in this study to identify novel binding partners of a putative 
PfIAP protein. 
 
2.1.3 Objectives 
The objectives of this chapter were to: 
- Utilise bioinformatics tools to analyse a P. falciparum IAP protein and identify domains 
- Express and purify selected PfIAP domains as recombinant proteins 
- Create a biotin-tagged P. falciparum cDNA phage display library 
- Identify PfIAP binding partners through biopanning experiments  
- Express and purify these binding partners as recombinant proteins 
- Verify these protein-protein interactions by employing in vitro binding assays 
- Create a transgenic parasite line expressing a GFP-tag PfIAP BIR domain 
- Determine the cellular localisation of PfIAPbir-GFP under normal and RCD simulating 
conditions using fluorescence microscopy 
 
2.2 Materials and Methods 
2.2.1 Bioinformatics 
2.2.1.1 Gene Identification and Sequence Alignment 
Using novel bioinformatics methods a putative P. falciparum inhibitor of apoptosis has been 
identified (Coetzer et al. 2010).  The Plasmodium database, PlasmoDB v34 
(http://plasmodb.org/plasmo/; Aurrecoechea et al. 2009), lists this PfIAP protein as a 
putative zinc finger protein with the identifier PF3D7_0519600.  Nucleotide and amino acid 
sequences of PfIAP and other Plasmodium proteins were obtained from PlasmoDB, while 
the UniProt protein database (http://www.uniprot.org/) was used to obtain all eukaryotic 
sequences.  Using the OrthoMCL database v5 (http://orthomcl.org/orthomcl/home.do;          
Li et al. 2003) Plasmodium orthologues within PlasmoDB were identified.  The Simple 
Modular Architecture Research Tool (SMART; http://smart.embl.de/; Letunic et al. 2015) 
was used to identify the domains present in these proteins, while sequence alignments were 
performed using the European Molecular Biology Laboratory European Bioinformatics 
Institute MUltiple Sequence Comparison by Log-Expectation program (EMBL-EBI 
MUSCLE; http://www.ebi.ac.uk/Tools/msa/muscle/; Edgar 2004a; Edgar 2004b).  Multiple 
sequence alignments were visually represented using Jalview v2.10 (Waterhouse et al. 
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2009).  Percentage identity and similarity was calculated using EMBOSS Needle 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/). 
 
2.2.1.2 Analysis of Protein Structure  
Secondary Structure.  The secondary structure of the PfIAP protein was assessed using 
SWISS-MODEL (https://swissmodel.expasy.org/; Arnold et al. 2006; Bordoli et al. 2009; 
Biasini et al. 2014), the Protein Homology/analogY Recognition Engine v2.0 (Phyre2; 
http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index; Kelley et al. 2015), PSIPRED 
v3.3 (http://bioinf.cs.ucl.ac.uk/psipred/; Jones 1999; Buchan et al. 2013), JPred4 
(http://www.compbio.dundee.ac.uk/jpred4; Drozdetskiy et al. 2015) and SSpro v5.2 
(http://scratch.proteomics.ics.uci.edu/; Cheng et al. 2005).  The probability of the presence 
of a particular secondary structure (α-helix or β-strand) within the PfIAP BIR domain was 
determined by comparing the various secondary structural predictions. 
 
Tertiary Structure.  Three-dimensional modelling of the PfIAP BIR domain was carried out 
using SWISS-MODEL (Arnold et al. 2006; Bordoli et al. 2009; Biasini et al. 2014) and 
Phyre2 (Kelley et al. 2015).  Crystal structures of various human IAP domains were obtained 
from the Protein Data Bank (http://www.rcsb.org/).  The quality of the generated 3D models 
was estimated using QMEAN (https://swissmodel.expasy.org/qmean/; Benkert et al. 2009; 
Benkert et al. 2011).  Visualisation and colouring of the various 3D models was done using 
Jmol 14.8.0 (http://www.jmol.org/). 
 
Protein Properties and Solubility Predictions.  The isoelectric point (pI) and molecular 
weight of various P. falciparum proteins was calculated using the ExPASy compute pI/Mw 
tool (http://web.expasy.org/compute_pi/; Bjellqvist et al. 1993; Bjellqvist et al. 1994; 
Gasteiger et al. 2005), while Protein Calculator v3.4 (http://protcalc.sourceforge.net/) was 
used to determine the overall charge of proteins.  The predicated solubility of the                       
P. falciparum proteins that were expressed in as recombinant proteins was determined using 
PROSO II (http://mbiljj45.bio.med.uni-muenchen.de:8888/prosoII/prosoII.seam; 
Smialowski et al. 2012) and SOLpro (http://scratch.proteomics.ics.uci.edu/; Magnan et al. 
2009). 
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2.2.2 P. falciparum Parasite Culture 
All parasite culture work was carried out in a laminar flow hood following aseptic techniques 
to maintain sterility.  All glassware was autoclaved, while culture medium and solutions 
were filter sterilised prior to use (0.8/0.2 μm Acrodisc® PF or Vacucap® 90 PF filter units).  
Chemical and equipment suppliers are available in APPENDIX E. 
 
2.2.2.1 Preparation of Red Blood Cells 
Fresh whole blood was collected from human volunteers in 6 mL acid citrate dextrose tubes.  
These tubes were centrifuged at 2 500 ×g for 10 minutes at 4°C (Eppendorf centrifuge     
5702 R) before the plasma and buffy coat were aspirated.  The packed RBCs were washed 
using phosphate buffered saline (PBS; 10 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, 
2.7 mM KCl; pH 7.4).  The RBC pellets were resuspended in a 1:1 ratio with incomplete 
RPMI-1640 medium (containing 25 mM HEPES, 0.05 mg/mL hypoxanthine and                 
0.02 mg/mL gentamycin) and stored at 4°C for up to two weeks. 
 
2.2.2.2 Continuous Parasite Culture 
Asexual P. falciparum 3D7 strain parasites were cultured in vitro using a modification of 
the method described by Trager and Jensen (1976),  as serum was replaced with Albumax.  
Cultures were maintained at a 5% haematocrit in fresh RBCs and complete medium 
(incomplete medium with 0.5% (w/v) Albumax and 0.2% (w/v) NaHCO3).  Three different 
sized culture flasks (25 cm3, 80 cm3 or 175 cm3) were used containing 5 mL, 20 mL and     
35 mL of complete medium, respectively.  Cultures were gassed with a mixture of 2% O2,        
5% CO2 and 93% N2 for 30 to 60 seconds, before being sealed and incubated at 37°C. 
Every 24 hours, spent medium was aspirated and replaced with fresh complete medium.  The 
parasitaemia of the culture was assessed daily by a blood smear (stained using the RapiDiff 
Stain Set as per manufacturer’s instructions) that was viewed using a Zeiss Axiostar 
microscope under oil immersion at 1 000X magnification.  Parasitaemia was calculated as 
the percentage of infected RBCs out of the total number of erythrocytes, and parasite cultures 
were maintained at a parasitaemia of less than 8%. 
 
2.2.2.3 Freezing of Parasite Cultures 
Parasite cultures were prepared and stored in liquid nitrogen as described by Normark 
(2008), with slight modification of the components of the freezing solution.  A medium       
(20 mL) parasite culture containing greater than 4% ring stage parasites was divided between 
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two 15 mL centrifuge tubes.  After centrifuging at 1 400 ×g for 5 minutes at room 
temperature, the supernatant was aspirated and the RBC pellet was resuspended 1:1 with 
freezing solution (60% (v/v) glycerol in freezing PBS (83 mM Na2HPO4, 32 mM KH2PO4, 
123 mM NaCl; pH 7.4)).  The suspension was mixed, transferred (~1 mL) to a sterile 2 mL 
cryotube and allowed to incubate for 5 minutes at room temperature before being stored in 
liquid nitrogen. 
 
2.2.2.4 Thawing of Frozen Parasite Cultures 
Frozen parasite cultures were removed from liquid nitrogen storage and thawed using a 
modified form of the method described by Blomqvist (2008), with an extra NaCl and glucose 
wash step.  A culture was warmed to 37°C, before one-tenth volume (~100 μL) of 12% (w/v) 
NaCl was added dropwise.  The suspension was incubated for 5 minutes at room 
temperature, before being transferred to a 15 mL centrifuge tube containing 9 mL of 1.6% 
(w/v) NaCl.  Following gentle mixing, the suspension was centrifuged at 400 ×g for                  
5 minutes at room temperature.  The supernatant was removed and the RBC pellet was 
resuspended in nine volumes of 0.9% (w/v) NaCl and 0.2% (w/v) glucose.  After 
centrifuging again and removing the supernatant, the volume of the pellet was made up to 
750 μL with 1:1 diluted RBCs before being transferred to a small culture flask with 5 mL of 
complete medium (with 1% (w/v) Albumax for the next 7 days).  The culture was then gassed 
and incubated at 37°C as described in 2.2.2.2. 
 
2.2.2.5 Synchronising Parasite Cultures 
Parasite cultures with predominantly ring stage parasites were synchronised by sorbitol 
treatment (Lambros and Vanderberg 1979).  D-sorbitol lyses late stage infected RBCs due 
to their increased permeability when compared to early stage parasites. 
 
A small (5 mL) parasite culture containing at least 3% ring stage parasites was transferred 
to a 15 mL centrifuge tube and centrifuged at 1 400 ×g for 5 minutes at room temperature.  
The supernatant was removed and ten volumes of 5% (w/v) D-sorbitol was added to the tube.  
After incubating for 5 minutes at 37°C, the tube was gently inverted before being centrifuged 
again.  The supernatant was aspirated and the pellet was resuspended in complete medium 
with fresh 1:1 RBCs (5 mL culture with a haematocrit of 5%) before being transferred to a 
small culture flask.  The culture was then gassed and incubated at 37°C as described in 
2.2.2.2. 
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2.2.3 P. falciparum Genomic DNA Extraction 
Genomic DNA was extracted from P. falciparum parasite cultures with a greater than 5% 
parasitaemia and a ratio of approximately 3:2 (trophozoite:rings), according to the hypotonic 
lysis method (Cowman et al. 2008). 
 
A small (5 mL) parasite culture was transferred to a 15 mL centrifuge tube and centrifuged 
at 1 000 ×g for 5 minutes at 4°C.  The supernatant was aspirated and the pellet was 
resuspended in 5 mL of PBS before being centrifuged again.  After removing the 
supernatant, the pellet was disrupted by the addition of four volumes (~1 mL) of hypotonic 
solution (5 mM K2HPO4/KH2PO4; pH 7.4) which lysis the RBCs.  One volume (~250 μL) 
of 18% (w/v) sodium dodecyl sulfate (SDS) was added and the solution was briefly vortexed 
before being incubated for 3 minutes at room temperature.  Eight volumes of                             
1:1 phenol/chloroform were added to the tube, mixed briefly and centrifuged at 3 000 ×g for 
10 minutes at 4°C.  The top aqueous phase, containing the genomic DNA, was carefully 
collected and distributed between 1.5 mL Eppendorf tubes (~400 μL).  To precipitate the 
DNA, one-tenth volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes of ice cold 100% 
ethanol were added to each aliquot.  These tubes were mixed by inversion and incubated for 
30 minutes or overnight at -70°C.  The tubes were centrifuged at 16 000 ×g for 30 minutes 
at 4°C (Eppendorf centrifuge 5415 R) and the supernatant was decanted.  One millilitre of 
cold 70% (v/v) ethanol was added and the tubes were centrifuged at 16 000 ×g for 5 minutes 
at 4°C.  After removing the supernatant, the pellets were allowed to air-dry before they were 
dissolved and pooled into a final volume of 600 μL of Tris EDTA buffer (TE; 10 mM Tris-
HCl, 1 mM EDTA; pH 8).  RNase A (final concentration of 0.1 mg/mL) was added and 
allowed to incubate for 30 minutes at 37°C, before one volume of 1:1 phenol/chloroform 
was added.  After mixing, the tube was centrifuged at 16 000 ×g for 5 minutes at 4°C and 
the aqueous phase was carefully transferred to a 1.5 mL Eppendorf tube.  One volume of 
chloroform was added to the tube which was mixed and centrifuged again.  The aqueous 
phase was transferred to a 2 mL Eppendorf tube in which the genomic DNA was again 
precipitated and washed.  The air-dried pellet was resuspended in 25 μL of TE buffer and 
stored at -20°C. 
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2.2.3.1 DNA Analysis 
Spectrophotometric Analysis.  The concentration and purity of extracted DNA was 
determined using a NanoDrop® ND-1000 spectrophotometer (with integrated ND-1000 
3.8.1 software) by measuring the light absorbed at 230 nm (A230), 260 nm (A260) and 280 nm 
(A280). 
 
Agarose Gel Electrophoresis.  Extracted DNA samples were assessed by agarose gel 
electrophoresis.  A 1% (w/v) agarose gel was prepared by dissolving agarose in 1x Tris 
acetate EDTA buffer (TAE; 40 mM Tris-acetate, 1 mM EDTA; pH 8) by boiling.  After 
cooling, ethidium bromide (final concentration of 0.5 μg/mL) was added and the gel was 
cast.  The samples, together with a reference MassRuler™ DNA Ladder Mix (80 -          
10 000 bp), were loaded and the gel was resolved in 1x TAE buffer at 100V for                          
50 - 60 minutes.  The gel was then visualised under ultraviolet (UV) light using the SynGene 
Gel Doc system and images were acquired with the GeneSnap 7.04 analysis software.  
Genomic DNA should resolve as a single band with a molecular weight greater than 10 kb, 
but will appear as a smear if the DNA is degraded. 
 
2.2.4 Polymerase Chain Reaction (PCR) 
2.2.4.1 PCR Primer Design 
Plasmodium falciparum gene sequences were obtained from PlasmoDB (Aurrecoechea         
et al. 2009) and used to design PCR primers with the aid of Integrated DNA Technologies 
OligoAnalyzer 3.1 (Integrated DNA Technologies 2016).  Endonuclease restriction sites 
were included at the 5’ end of all primers to facilitate directional cloning into the vectors: 
pGEX-4T-2 (GE Healthcare, UK), pET-15b (Millipore, USA) and pARL2-GFP (donated by 
Dr. Jude Przyborski of the University of Marburg, Germany).  pGEX-4T-2 and pET-15b 
reverse primers contained a stop codon prior to the restriction site and all oligonucleotides 
were synthesised by Inqaba Biotec™, South Africa.  Primer sequences are available in 
APPENDIX A. 
 
2.2.4.2 Polymerase Chain Reaction 
To enhance the accuracy of all PCR amplification reactions prior to cloning, high fidelity 
DNA polymerases were used as directed by the manufacturer.  Phusion Flash or High 
Fidelity PCR Mixes were used with 100 - 200 ng of P. falciparum genomic DNA and           
0.2 μM of forward/reverse primers.  All PCR reactions were carried out using an Eppendorf 
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Mastercycler Gradient Thermocycler and were divided into two sections:  the first five cycles 
were performed at the lowest annealing temperature (Ta) of the P. falciparum specific 
regions of the primers, while the following 25 cycles were at the Ta of the full length primers.  
PCR cycling conditions are available in APPENDIX A. 
Table 2.2.1: PCR Parameters for the Amplification of Various P. falciparum Genes 
Domain Name Vector 
P. falciparum 
Specific Ta (°C) 
Full Length 
Primer Ta (°C) 
PCR Product 
(bp) 
PfIAP1 (BIR Domain) 
pGEX-4T-2 
48.0 62.0 471 
PfIAP2 (Middle Region) 48.0 62.0 561 
PfIAP3 (Terminal Region) 48.0 62.0 984 
PfDOC2 (Binding Region) 
pET-15b 
41.0 55.0 1 011 
PfRhopH3 (Binding Region) 44.0 55.0 510 
PfIAP1 (BIR Domain) pARL2-GFP 48.0 55.0 468 
 
PCR amplicons were then purified using either the QIAquick® PCR Purification or 
NucleoSpin® Gel and PCR Clean-Up Kits as per the manufacturers’ instructions and eluted 
into 50 μL of nuclease-free water. 
 
2.2.5 Isolation of Expression Plasmids 
The pGEX-4T-2, pET-15b or pARL2-GFP vectors (available in APPENDIX B) were 
isolated either using an alkaline lysis method (Bimboim and Doly 1979) or by commercial 
kits.  The GenElute™ Plasmid Miniprep or NucleoSpin® Plasmid Kits were used as per the 
manufacturers’ instructions and plasmids were eluted into 50 μL of nuclease-free water. 
 
A 5 mL Luria Broth (LB; 1% (w/v) tryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract,         
10 mM Tris-HCl; pH 8.0) culture in a 50 mL Erlenmeyer flask, containing 100 μg/mL 
ampicillin was inoculated with a scraping of a glycerol stock of E. coli cells containing the 
desired plasmid and incubated at 250 rpm for 18 hours at 37°C (Labotec orbital shaker).  The 
optical density (OD) of the bacterial culture was measured using a Thermo Biomate 5 
Spectrophotometer at 600nm (OD600) and if the OD was greater than 3.0, then 25 mL of LB 
medium was seeded with 500 μL of the initial culture (in a 100 mL Erlenmeyer flask, 
containing 100 μg/mL ampicillin).  After incubating for 18 hours at 37°C, the culture was 
divided between two 15 mL centrifuge tube and centrifuged at 3 000 ×g for 10 minutes at 
4°C. 
The supernatant was aspirated and 500 μL of cold resuspension solution (50 mM glucose, 
10 mM EDTA, 25 mM Tris; pH 8.0) was added to each tube.  The pellets were disrupted by 
repeat pipetting and incubated for 5 minutes at room temperature.  One millilitre of lysis 
solution (0.2 M NaOH, 1% (w/v) SDS) was added to each tube and the suspensions were 
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mixed by inversion, before being incubated for 5 minutes at room temperature.  The SDS 
and NaOH lyse the bacterial cells and denature the high molecular weight chromosomal 
DNA (Bimboim and Doly 1979).  Cold neutralisation solution (750 μL; 1.6 M potassium 
acetate and 3.2 M acetic acid; pH 4.8) was added to each tube, which was mixed by inversion 
and then incubated for 5 minutes on ice.  During neutralisation the SDS-protein complexes 
and the high molecular weight RNA precipitate, while the chromosomal DNA renatures and 
forms an insoluble aggregate (Bimboim and Doly 1979).  The samples were centrifuged at     
3 000 ×g for 20 minutes at 4°C and the supernatants were divided between 2.0 mL Eppendorf 
tubes.  One millilitre of 1:1 phenol/chloroform was added to each aliquot and the solutions 
were mixed by inversion, vortexed and then centrifuged at 16 000 ×g for 5 minutes at 4°C.  
The aqueous phases were transferred to new 2.0 mL Eppendorf tubes and the plasmid was 
precipitated as described in 2.2.3.  The pellets were allowed to air-dry, before being 
resuspended in TE buffer and pooled to a final volume of 400 μL. 
RNase A (final concentration of 0.1 mg/mL) was added to the sample, which was then 
incubated for 30 minutes at 37°C.  One volume of 1:1 phenol/chloroform was added to the 
solution, which was mixed and centrifuged at 16 000 ×g for 5 minutes at 4°C.  The aqueous 
phase was transferred to a new 1.5 mL Eppendorf tube and one volume of chloroform was 
added to the tube, which was mixed and centrifuged again.  The aqueous phase was then 
transferred to a 2 mL Eppendorf tube and the vector was precipitated as described in 2.2.3.  
The pellet was allowed to air-dry and resuspended in 50 μL of TE buffer. 
 
2.2.6 Cloning 
2.2.6.1 Restriction Enzyme Digestion  
Purified PCR amplicons and isolated expression vectors were digested for 30 minutes at 
37°C using specific FastDigest® restriction endonucleases: 
- pGEX-4T-2 vector and inserts  - FastDigest® BamHI and XhoI 
- pET-15b vector and inserts       - FastDigest® BamHI and NdeI 
- pARL2-GFP vector and inserts - FastDigest® AvrII and XhoI 
The plasmids were also simultaneously subjected to FastAP™ Thermosensitive Alkaline 
Phosphatase to be dephosphorylated.  The treated PCR products and vectors were then 
purified using commercial kits (see 2.2.4.2) as per the manufacturers’ instructions and eluted 
in 10 μL of nuclease-free water. 
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2.2.6.2 Ligation Reaction 
The prepared PCR product and expression vector were quantified by agarose gel 
electrophoresis (2.2.3.1).  The amount of insert and plasmid required for the ligation reaction 
was calculated using the In-Fusion® Molar Ratio Calculator (Clontech Laboratories 2016). 
 
The ligation reaction was prepared using the Rapid DNA Ligation Kit as per the 
manufacturer’s specifications, which included not exceeding 200 ng of total DNA per 
reaction and using a molar ratio of one vector unit to three insert units.  The ligation was 
then carried out by incubating the reaction for 30 minutes at 16°C.  To test the effectiveness 
of the vector dephosphorylation and restriction enzyme digestion, a control ligation reaction 
was also prepared that did not contain the PCR product. 
 
2.2.6.3 Transformation of DH5α and XL10 E. coli Cells 
In-house, chemically competent DH5α E. coli cells (provided by Dr Sonja Lauterbach) were 
transformed using half (10 μL) of the pGEX-4T-2 and pET-15b ligation reactions.  A          
100 μL E. coli aliquot was incubated with the ligation reaction for 30 minutes on ice, before 
being heat-shocked at 42°C for 90 seconds.  The transformation mixture was then incubated 
for 5 minutes on ice, before being spread onto two 1.5% (w/v) agar plates (containing          
100 μg/mL ampicillin) and incubated overnight at 37°C.  The ‘low’ plate contained 20 μL 
of the transformation mixture, made to 80 μL with LB medium, while the remaining mixture 
was applied to the other ‘high’ plate. 
 
Following ligation, the pARL2-GFP_PfIAPbir construct was used to transform commercial 
XL10 E. coli as per the manufacturer’s instructions, with slight modification as NZY+ broth 
was replaced with LB.  Briefly, a 50 μL aliquot of XL10 cells was thawed on ice and then 
incubated with 2 μL of β-mercaptoethanol for 10 minutes.  Ten microlitres of the ligation 
reaction was added and the cells were incubated for 30 minutes on ice.  Heat-shock was 
performed at 42°C for 30 seconds, after which the transformation mixture was incubated for 
2 minutes on ice.  Four hundred and fifty microlitres of pre-warmed LB (42°C) was added 
and the cells were incubated for 1 hour at 37°C, before being plated on 1.5% (w/v) agar 
plates (containing 100 μg/mL ampicillin) and incubated overnight at 37°C. 
 
Individual E. coli colonies, transformed with either the pGEX-4T-2, pET-15b or pARL2-
GFP vector constructs, were picked from the transformation plates and suspended in 10 μL 
of nuclease-free water to prepare for an overnight LB grow and for colony PCR (see 2.2.6.4).  
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Five microlitres of the suspension was used to inoculate 2 mL of LB medium (in a 14 mL 
BD Falcon™ tube, containing 100 μg/mL ampicillin) and was incubated at 250 rpm for        
18 hours at 37°C.  Glycerol stocks of the individual colonies were created by adding 500 μL 
of each overnight grow to 500 μL of sterile 60% (v/v) glycerol and storing at -70°C.  The 
remaining E. coli grow was used to perform a plasmid isolation using either the GenElute™ 
Plasmid Miniprep or NucleoSpin® Plasmid Kits as per the manufacturers’ instructions, 
eluting into 50 μL of nuclease-free water. 
 
2.2.6.4 Verification of Bacterial Transformation 
Colony PCR.  Five microlitres of E. coli suspension (2.2.6.3) was boiled at 94°C for                  
5 minutes to lyse the bacterial cells.  DreamTaq Green PCR Master Mix was used as per the 
manufacturers’ instruction, with the bacterial lysate providing the DNA template, to detect 
the presence of the inserts.  Vector- or insert-specific primer details are available in 
APPENDIX A. 
 
Restriction Enzyme Digestion.  The previously isolated plasmid constructs were digested for 
30 minutes at 37°C using restriction endonucleases: 
- pGEX-4T-2 vector  - FastDigest® BamHI and XhoI 
- pET-15b vector       - FastDigest® EcoRV 
- pARL2-GFP vector - FastDigest® EcoRI 
The resulting digestion patterns were analysed using agarose gel electrophoresis as described 
in 2.2.3.1.  Vector constructs that demonstrated the expected banding pattern were sent to 
Inqaba Biotec™, South Africa for sequencing to verify the integrity of the desired insert. 
 
2.2.7 Recombinant Protein Expression 
2.2.7.1 Transformation of Rosetta™ 2 (DE3) E. coli Cells 
Commercial Rosetta™ 2 (DE3) E. coli contain the chloramphenicol-resistant pRARE 
plasmid.  This bacterial strain is used to enhance the expression of eukaryotic proteins by 
providing sevens transfer RNAs (tRNAs; AUA, AGG, AGA, CUA, CCC, GGA and CGG) 
that are rarely used in E. coli (Novagen 2004). 
 
Rosetta™ 2 (DE3) cells were transformed with the pGEX-4T-2 and pET-15b vector 
constructs as per the manufacturer’s instructions.  After overnight growth on 1.5% (w/v) 
agar plates (containing 100 μg/mL ampicillin and 50 μg/mL chloramphenicol), single 
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colonies were picked and treated as described in 2.2.6.3 to create glycerol stocks.  Colony 
PCR was utilised to verify the transformation of the E. coli as described in 2.2.6.4. 
 
2.2.7.2 Recombinant Protein Expression and Purification 
High-level protein expression was achieved using Overnight Express™ Instant TB Media, 
which has been designed for use with isopropyl β-D-1-thiogalactopyranoside (IPTG)-
inducible expression plasmids.  Components in the medium induce protein expression from 
a lac promoter and are metabolized differentially so as to promote increased cell mass and 
target protein yield, when compared with conventional IPTG induction protocols (Grabski 
et al. 2005). 
 
A 5 mL LB culture (in a 50 mL Erlenmeyer flask, containing 100 μg/mL ampicillin and       
50 μg/mL chloramphenicol) was inoculated with a glycerol scraping of Rosetta™ 2 (DE3) 
E. coli cells containing the desired plasmid construct and incubated at 250 rpm overnight at 
37°C.  Twenty millilitres of Overnight Express™ Instant TB Media was seeded with 500 µL 
of the initial culture (in 100 mL Erlenmeyer flasks) and incubated at 250 rpm for 22 hours 
at room temperature (Hoefer PR250 mini orbital shaker).  The OD600 of each culture was 
measured and if greater than 3 the bacterial cells were centrifuged at 3 000 ×g for 10 minutes 
at 4°C, before being stored at -70°C.  E. coli cells were also used to seed 20 mL of                   
2% (w/v) glucose in LB as an uninduced protein expression control.  The presence of glucose 
means that the lac operon is not fully induced, preventing the expression of the recombinant 
proteins (Rosano and Ceccarelli 2014). 
 
GST-Tagged Protein Purification.  Glutathione S-transferase (GST) tagged proteins were 
purified using paramagnetic MagneGST™ Glutathione Particles by applying the following 
protocol (Promega 2014). 
 
The bacterial pellet containing the pGEX-4T-2 plasmid was thawed for 5 minutes at 37°C 
before being resuspended in 1.5 mL of GST-Binding/Wash buffer (4.2 mM Na2HPO4,             
2 mM KH2PO4, 140 mM NaCl, 10mM KCl; pH 7.2), containing 1.5μl of Protease Inhibitor 
Cocktail Set III and 1.5μl of DNase I.  The bacterial suspension was frozen for 15 minutes 
at -70°C, thawed again and then transferred to a 15 mL centrifuge tube.  Three cycles of 
sonication (30 seconds of 1.0 second pulses with 0.5 second rests; Bandelin Sonopuls HD 
3100 with microtip MS 73) was used to lyse the bacterial cells, after which 75 μL was 
removed as the ‘total’ protein fraction and added to 75 μL of GST-Binding/Wash buffer.  
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The lysate was transferred to a 2.0 mL Eppendorf tube and centrifuged at 16 000 ×g for       
20 minutes at 4°C.  The supernatant was set aside (75 μL of which was removed as the 
‘soluble’ protein fraction and added to 75 μL of GST-Binding/Wash buffer) and the pellet 
was resuspended using 1.5 mL of GST Binding/Wash buffer (75 μL was removed as the 
‘insoluble’ protein fraction and added to 75 μL of GST-Binding/Wash buffer). 
Ten microlitres of the MagneGST™ particle slurry was washed three times using 100 μL of 
the GST-Binding/Wash Buffer and a magnetic separator.  The particles were resuspended in 
100 μL of the GST-Binding/Wash buffer before being applied to the previously set aside 
soluble fraction.  The mixture was incubated overnight at 4°C on an Intelli-mixer, after 
which the supernatant was removed (75 μL of which was removed as the ‘unbound’ protein 
fraction and added to 75 μL of GST-Binding/Wash buffer).  The MagneGST™ particles 
were washed five times using 1.5 mL of the GST-Binding/Wash buffer (150 μL of each wash 
was removed as the ‘wash’ fraction), before the recombinant GST-tagged protein was eluted 
for 15 minutes at room temperature using 100 μL of the GST-Elution buffer (500 mM            
L-glutathione, 500 mM NaCl, 50 mM Tris-HCl; pH 8.1).  The remaining MagneGST™ 
particles were resuspended in 100 μL of the GST-Binding/Wash buffer as the ‘bead’ fraction.  
All protein fractions were processed and visualised as described in 2.2.7.3 and 2.2.7.4. 
 
His-Tagged Protein Purification.  His-tagged proteins were purified using paramagnetic pre-
charged MagneHis™ nickel particles (Promega 2009) according to the GST-Tagged Protein 
Purification protocol above with the following differences: 
- His-Binding buffer (50 mM Na2HPO4/NaH2PO4, 150 mM NaCl; pH 8) containing 1.5μl of 
Protease Inhibitor Cocktail Set III and 1.5μl of DNase I was used to resuspend the thawed 
bacterial pellet. 
- Twenty-five microlitres of MagneHis™ particle slurry was prepared using 100 μL of the 
His-Binding buffer, to which imidazole was added to a final concentration of 1 mM. 
- Beads with bound proteins were washed using 1.5 mL of His-Wash buffer (His-Binding 
buffer containing: 35 mM imidazole for PfRhopH3 and 50 mM imidazole for PfDOC2) 
and eluted using 100 μL of His-Elution buffer (His-Binding buffer containing 0.5 M 
imidazole; pH 7.5). 
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2.2.7.3 SDS-PAGE Analysis 
One volume of sample solution (40 μL of 5X suspension solution (50 mM Tris-HCl, 5 mM 
EDTA, 5% (w/v) SDS, 25% (w/v) sucrose; pH 8.0), 5 μL of dye mix (2.5% (w/v) sucrose, 
0.5% (w/v) bromophenol blue) and 5 μL of β-mercaptoethanol) was added to three volumes 
of the protein fractions described in 2.2.7.2.  These protein mixtures were vortexed, boiled 
for 5 minutes and then resolved using SDS-polyacrylamide gel electrophoresis (SDS-PAGE; 
Laemmli 1970). 
 
A 6 cm 12% resolving gel (see Table 2.2.2) was cast using a Hoefer Mighty Small II SE 250 
gel cassette and overlaid with a 2 cm 4% stacking gel.  After sample loading, the gel was 
electrophoresed at a constant current of 20 mA (with a maximum voltage of 250 V) in 
Laemmli running buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS) and cooled to 4°C 
using a Labcon CPE 50 circulator.   A human red blood cell membrane reference ladder, 
prepared in-house by Dr Kuben Naidoo, was also included. 
Table 2.2.2: Laemmli SDS-PAGE Gel Set-Up 
Component 12% Resolving Gel* 4% Stacking Gel* 
30% (w/v) Acrylamide 4.0 mL (12%) 433 µL (4%) 
1% (w/v) Bis-acylamide 1.1 mL (0.11%) 333 µL (0.1%) 
4X Resolving Buffer (1.5 M Tris-HCl; pH 8.8) 2.5 mL (1X) - 
4X Stacking Buffer (0.5 M Tris-HCl; pH 6.8) - 833 µL (1X) 
10% (w/v) SDS 53.0 µL (0.05%) 6.7 µL (0.02%) 
10% (w/v) Ammonium Persulfate 67.0 µL (0.07%) 67.0 µL (0.2%) 
TEMED 5.0 µL (0.05%) 2.5 µL (0.08%) 
Nuclease-Free Water 2.3 mL 1.63 mL 
Total 10.0 mL 3.3 mL 
*() = final concentration. 
 
Following electrophoresis, the SDS-PAGE gel was stained using Coomassie Blue (0.05% 
(w/v) Coomassie Brilliant Blue R-250, 25% (v/v) isopropanol, 10% (v/v) acetic acid) 
overnight and then destained in 10% (v/v) acetic acid/10% (v/v) methanol, followed by 10% 
(v/v) acetic acid. The gel was photographed using the SynGene Gel Doc system.  Protein 
quantification was performed through the use of a bovine serum albumin (BSA) standard.  
Known amounts of BSA (100 – 500 ng) were loaded onto the SDS-PAGE gel, together with 
the recombinant protein.  The Coomassie Blue stained gel was analysed using densitometry 
and the SynGene Gel Doc system, with the GeneSnap 7.04 analysis software being used to 
quantify the known BSA standards.  From these data, a linear BSA standard curve was 
constructed to determine the amount of expressed protein present on the SDS-PAGE gel. 
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2.2.7.4 Western Blot Analysis 
The proteins of an unstained SDS-PAGE gel were transferred to Hybond-C Extra 
nitrocellulose membrane using a liquid transfer method at 35 V overnight at 4°C in transblot 
buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS, 20% (v/v) methanol; Towbin et al. 
1979).  Afterwards, the gel was stained using Coomassie Blue to detect if any proteins had 
failed to transfer to the membrane.  The nitrocellulose membrane was washed in                    
Tris buffered saline (TBS; 50 mM Tris-HCl, 0.9% (w/v) NaCl; pH 7.5) for five minutes and 
then stained with Ponceau S (1% (w/v) Ponceau S, 7% (v/v) glacial acetic acid) to verify 
that protein transfer had occurred.  The non-permanent Ponceau S was washed away using 
water, before the membrane was rinsed in TBS for 10 minutes.  The various bands of the 
Spectra™ Multicolor Broad Range Protein Ladder were then marked on the membrane. 
The nitrocellulose membrane was blocked, to prevent non-specific antibody binding, by 
either incubation in a 3% (w/v) BSA Fraction V in TBS blocking solution (GST-tagged 
proteins) or a commercial anti-His horseradish peroxidase (HRP) conjugated blocking 
solution (His-tagged proteins) for one hour at room temperature on a shaking platform.  A 
volume (25-50 mL) of either a 1:100 000 dilution of anti-GST HRP conjugated primary 
antibody in 1% (w/v) BSA in TBS or a 1:2 000 dilution of anti-His HRP conjugated primary 
antibody was used to cover the membrane and allowed to incubate for one hour at room 
temperature with gentle shaking.  The membrane was then washed five times in 0.25% (v/v) 
Tween20-TBS (0.25% TBST) and once in TBS for five minutes each with vigorous shaking. 
A volume of 1.5 mL of SuperSignal™ West Pico Chemiluminescent Substrate was used to 
cover the membrane and allowed to incubate for 5 minutes at room temperature, before the 
chemiluminescent signal was detected using the SynGene Gel Doc system.  After 
visualisation the membrane was stained using amido black (0.1% (w/v) amido black, 10% 
(v/v) acetic acid, 25% (v/v) isopropanol) for five minutes and then destained with 10% (v/v) 
acetic acid/10% (v/v) methanol, followed by 10% (v/v) acetic acid. 
 
2.2.8 P. falciparum Phage Display Library Creation 
A P. falciparum phage display library was created using the OrientExpress™ cDNA 
Synthesis and T7Select®10-3 Cloning Kits as per the manufacturer’s instructions, although 
different suppliers were used during the reverse transcription and second-strand synthesis 
steps.   
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2.2.8.1 Total RNA Extraction 
Total RNA was extracted from parasite cultures with a greater than 5% parasitaemia and a 
ratio of approximately 4:1 (trophozoite:rings).  All instruments and surfaces were cleaned 
with RNaseZap™ prior to use to create an RNase-free environment.  Parasites were isolated 
from RBCs by saponin lysis and RNA was extracted using TRI Reagent® as per the 
manufacturer’s instruction.  The use of TRI Reagent® separates the sample into three phases: 
a red organic phase, an interphase and a colourless upper aqueous phase (each containing 
proteins, DNA and RNA respectively). 
 
Total RNA was extracted from a total of ten large (35 mL) parasite cultures, in batches of 
three/four flasks at a time.  Each flask was divided between three 15 mL centrifuge tubes 
and centrifuged at 1 000 ×g for 10 minutes at 4°C.  The supernatants were removed and each 
pellet (~500 μL) was resuspended in 1.5 mL of 0.05% (w/v) saponin in PBS, before the 
mixture was transferred to a 2 mL Eppendorf tube.  After incubating for 10 minutes at room 
temperature, the tubes were centrifuged at 16 000 ×g for 5 minutes at 4°C.  The supernatants 
were removed and the pellets were resuspended in 1.8 mL of 0.05% (w/v) saponin in PBS, 
before being incubated and centrifuged again.  The resulting pellets were then washed with 
1.8 mL of PBS.  The parasite pellets were resuspended in 1.5 mL of TRI Reagent® and 
incubated for 5 minutes at room temperature, before 400 μL of chloroform was added.  After 
mixing vigorously, the tubes were incubated for 15 minutes at room temperature and 
centrifuged at 12 000 ×g for 15 minutes at 4°C.  The aqueous phase of each tube (~900 μL) 
was carefully transferred to a 2 mL Eppendorf tube and 900 μL of isopropanol was added, 
before the samples were mixed.  After incubating for 10 minutes at room temperature, the 
tubes were centrifuged at 12 000 ×g for 10 minutes at 4°C.  The RNA pellets were washed 
with 1.5 mL of 75% (v/v) ethanol and centrifuged at 12 000 ×g for 5 minutes at 4°C.  After 
air-drying, the three pellets were dissolved using 25 μL of nuclease-free water by incubating 
each of pellet for    2 minutes at 60°C.  The extracted, total RNA was then stored at -70°C. 
 
RNA Analysis.  The concentration and purity of each extracted RNA sample was determined 
by spectrophotometric analysis as described in 2.2.3.1, before the RNA samples were pooled 
together.  An agarose gel (see 2.2.3.1) was used to visualise the three major bands of 
ribosomal RNA to assess if the sample was degraded. 
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2.2.8.2 mRNA Isolation 
Messenger RNA (mRNA) was isolated from the extracted total P. falciparum RNA using 
the Dynabeads® mRNA Purification Kit.  The kit relies on the binding of the poly(A) tail, 
found at the 3’ end of mRNA strands, to the oligo (dT)25 residues on the surface of the 
magnetic Dynabeads®. 
 
Four hundred microlitres of 5 mg/mL Dynabeads® were washed using 200 μL of Binding 
Buffer (20 mM Tris-HCl, 1.0 M LiCl, 2 mM EDTA; pH 7.5) and then resuspended in          
200 μL of Binding Buffer.  The extracted total RNA was incubated for 2 minutes at 65°C to 
disrupt any secondary structures present, before being added to the Dynabeads® mixture.  
After incubating for 5 minutes at room temperature, the supernatant was set aside (as the 
‘unbound’ fraction) and the beads were washed twice with 400 μL of Washing Buffer B    
(10 mM Tris-HCl, 150 mM LiCl, 1 mM EDTA; pH 7.5).  Ten microlitres of 10 mM Tris-
HCl (pH 7.5) was then applied to the beads, which were incubated for 2 minutes at 65°C to 
elute the mRNA.  This elution step was repeated, before the ‘unbound’ fraction was 
reapplied to the beads and the process was repeated until eight elutions had been collected.  
The isolated mRNA was quantified as described in 2.2.3.1. 
 
2.2.8.3 cDNA Synthesis 
Isolated mRNA was reverse transcribed using anchored primers (5’ T10VX 3’; V = A, G or 
C; X = A, T, G or C) in the presence of 5-methyl dCTP to protect any internal EcoRI or 
HindIII restriction sites from later restriction endonuclease digestion.  First-strand cDNA 
synthesis was carried out using 4 μg of P. falciparum mRNA, as multiple 500 ng reactions. 
Table 2.2.3: First-Strand Synthesis Reaction Set-Up 
Component Volume Final Concentration Manufacturer 
Isolated mRNA x μL 500 ng - 
12mer Anchored Primer Mix 0.5 μL 250 ng - 
10 mM Methylated dNTP Mix 1.0 μL 0.5 mM (in final reaction) Fermentas 
Nuclease-Free Water y μL - - 
Total 14.0 μL   
 
The first-strand mixture was incubated at 65°C for 5 minutes and then incubated on ice for 
1 minute, before being used in the reverse transcription reaction. 
Component Volume Final Concentration Manufacturer 
First-Strand Synthesis Mixture 14.0 μL - - 
5X First-Strand Buffer 4.0 μL 1X Invitrogen 
100 mM DTT 1.0 μL 5 mM Invitrogen 
200 U/μL SuperScript™ III RT 1.0 μL 200 U Invitrogen 
Total 20.0 μL   
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The reverse transcription reactions were carried out at 55°C for 1 hour, followed by 
incubation at 70°C for 15 minutes to inactivate the enzyme.  Second-strand cDNA synthesis 
was then carried out for each of the 500 ng reverse transcription reactions. 
Table 2.2.4: Second-Strand Synthesis Reaction Set-Up 
Component Volume Final Concentration Manufacturer 
Reverse Transcription Mixture 20.0 μL - - 
10X Reaction Buffer 8.0 μL 0.8X Fermentas 
10 mM Methylated dNTP Mix 1.0 μL 0.1 mM Fermentas 
5.0 U/μL RNase H 0.5 μL 2.5 U Fermentas 
10 U/μL DNA Polymerase I 2.5 μL 25 U Fermentas 
Nuclease-Free Water 68.0 μL - - 
Total 100.0 μL   
 
The second-strand cDNA reaction mixtures were incubated at 15°C for 2 hours.  The reaction 
mixtures were then combined, purified using the QIAquick® PCR Purification Kit as per 
the manufacturer’s instructions and eluted into 21 μL of TE buffer. 
 
2.2.8.4 cDNA End Modification 
A single EcoRI/HindIII Directional Linker (GCTTGAATTCAAGC) was ligated to both 
sides of the double-stranded DNA (Figure 2.2.1). The Linker contains an internal EcoRI site, 
while a HindIII site is created at the 3’ end of the P. falciparum insert by deriving two As 
from the cDNA.  Digestion with EcoRI and HindIII thus allows for directional insertion of 
the P. falciparum dsDNA into the T7Select®10-3b Vector Arms.  The T7Select®10-3b 
vector map is available in APPENDIX B. 
 
Figure 2.2.1: Ligation and Digestion of the EcoRI/HindIII Directional Linker 
Diagram showing the ligation of the EcoRI/HindIII Directional Linker to the P. falciparum double-
stranded cDNA insert and the subsequent digestion of the construct.  Blue = EcoRI/HindIII 
Directional Linker; green = P. falciparum cDNA insert; red = EcoRI and HindIII restriction sites. 
 
T4 DNA Polymerase was used to blunt the double-stranded cDNA ends. 
Table 2.2.5: cDNA End Modification Set-Up 
Component Volume Final Concentration Manufacturer 
Double-Stranded cDNA 20.0 μL - - 
10X Flushing Buffer 3.0 μL 1X Novagen 
100 mM DTT 1.5 μL 5 mM Novagen 
1 mM dNTP Mixture 3.0 μL 0.1 mM Novagen 
2.5 U/μL T4 DNA Polymerase 0.6 μL 1.5 U Novagen 
Nuclease-Free Water 1.9 μL - - 
Total 30.0 μL   
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The blunting reaction was carried out at 11°C for 20 minutes, after which the reaction 
mixture was purified using the QIAquick® PCR Purification Kit as per the manufacturer’s 
instructions and eluted into 10 μL of TE buffer.  The EcoRI/HindIII Directional Linker was 
phosphorylated by a T4 polynucleotide kinase immediately before being ligated to the blunt-
ended cDNA. 
Table 2.2.6: EcoRI/HindIII Directional Linker Ligation Set-Up 
Component Volume Final Concentration Manufacturer 
Blunt-Ended cDNA 10.0 μL - - 
10X Ligation Buffer 2.0 μL 1X Novagen 
100 mM DTT 2.0 μL 10 mM Novagen 
1 mM ATP Mixture 2.0 μL 0.1 mM Novagen 
50 pmol/μL EcoRI/HindIII 
Directional Linker 
2.0 μL 100 pmol Novagen 
10 U/μL T4 Polynucleotide Kinase 0.5 μL 5 U Novagen 
The phosphorylation reaction was incubated at 37°C for 5 minutes, cooled on ice for                 
1 minute before the T4 DNA ligase was added. 
4 U/μL T4 DNA Ligase 2.0 μL 8 U Novagen 
Total 20.5 μL   
 
Ligation of the Directional Linkers occurred at 16°C for 20 hours, after which the ligase was 
inactivated by incubating at 70°C for 10 minutes.  The reaction mixture was then allowed to 
cool to room temperature, before the construct was sequentially digested with HindIII and 
EcoRI restriction enzymes. 
Table 2.2.7: Restriction Enzyme Reaction Set-Up 
Component Volume Final Concentration Manufacturer 
DNA Insert 20.0 μL - - 
10X HindIII Buffer 10.0 μL 1X Novagen 
20 U/μL HindIII 5.0 μL 100 U Novagen 
Nuclease-Free Water 65.0 μL - - 
The initial HindIII digestion reaction was carried out at 37°C for 2 hours. 
10X EcoRI Adjustment Buffer 10.0 μL 1X Novagen 
20 U/μL EcoRI 5.0 μL 100 U Novagen 
Total 115.0 μL   
 
The total digestion reaction was incubated at 37°C for 4 hours, before excess Directional 
Linker and small cDNA products were removed by size fractionation.  Two millilitres of Gel 
Filtration Resin (Sepharose® 4B) was applied to an empty mini-column and allowed to pack 
under gravity flow.  The mini-column was equilibrated four times using 1 mL of 1X Column 
Buffer (0.3 M sodium acetate), before the 115 μL of cDNA mixture was applied.  After the 
DNA had settled into the resin, the mini-column was washed with 200 μL of 1X Column 
Buffer.  Two hundred and fifty microlitres of 1X Column Buffer was applied to the mini-
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column and the eluate was collected.  This volume represents the void fraction of the mini-
column and contains the largest cDNA fragments.  These fragments were concentrated using 
the QIAquick® PCR Purification Kit as per the manufacturer’s instructions and eluted into 
10 μL of TE buffer.  An aliquot of this DNA fragment solution was visualised using an 
agarose gel to determine the range of DNA sizes present. 
 
2.2.8.5 Biotin Cassette Creation 
To express biotinylated P. falciparum proteins as part of the T7 bacteriophage capsid, a 
biotinylation sequence (AviTag™) was inserted into the T7Select®10-3b vector (Figure 
2.2.2a) based on the work done by Caberoy et al. 2009.  When grown in E. coli, the lysine 
residue of the AviTag™ is biotinylated by the bacteria’s natural BirA biotin-protein ligase, 
thus allowing for selection of bacteriophage via the unique biotin-streptavidin interaction.  
This should result in the selection of bacteriophage containing P. falciparum inserts that are 
in-frame. 
 
Modification of the T7Select®10-3b Vector Arms to include a biotinylation sequence was 
generously carried out by Dr Sonja Lauterbach.  The AviTag™ cassette was synthesised by 
GeneArt®, Invitrogen (Figure 2.2.2b).  The stop codon between the EcoRI and HindIII 
restriction sites prevents the expression of the AviTag™ when no P. falciparum inserts are 
present in the T7 bacteriophage, while the restriction sites themselves facilitate the cloning 
of P. falciparum cDNA into the modified T7Select10-3b vector through the use of the 
Directional Linkers. 
The AviTag™ cassette was digested with BamHI and SalI and inserted into the BamHI and 
XhoI restriction sites of the T7Select®10-3b vector (Figure 2.2.2c; SalI and XhoI result in the 
same sticky end pattern).  The T7 bacteriophage were packaged and then propagated, 
following which the integrity of the AviTag™ cassette was verified by sequencing.  The 
modified T7Select10-3b vector arms were then digested using EcoRI and HindIII to allow 
for the insertion of the prepared P. falciparum cDNA. 
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Figure 2.2.2: The T7Select®10-3b Multiple Cloning Site and AviTag™ Cassette 
a) Diagram showing the multiple cloning site of the T7Select®10-3b vector.  Blue = forward and 
reverse primers used for sequencing reactions; red = various restriction sites; bold = STOP codon. 
b) Diagram of the synthesised AviTag™ cassette.  Green = AviTag™ sequence; red = various 
restriction sites; bold = STOP codons. 
c) Diagram showing the multiple cloning site of the T7Select10-3b vector, now containing the 
AviTag™ biotinylation sequence.  Blue = forward and reverse primers used for sequencing reactions; 
green = AviTag™ sequence; red = various restriction sites; bold = STOP codons. 
 
2.2.8.6 Ligation and Viral Packaging 
The optimal molar ratio for the ligation of the prepared cDNA inserts and the T7Select® 
Vector Arms is between 1:1 to 3:1 (insert:vector).  The amount of vector arm used per 
reaction should be 0.02 pmol, while between 0.02-0.06 pmol of insert can be used (and is 
estimated based on the average length of the inserts after DNA synthesis). 
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Table 2.2.8: Insert and Vector Arm Ligation Set-Up 
Component Volume Final Concentration Manufacturer 
cDNA Inserts x μL 0.06 pmol - 
Digested Biotin-Tagged Vector Arms y μL 0.02 pmol - 
10X Ligase Buffer 0.5 μL 1X Novagen 
10 mM ATP 0.5 μL 1 mM Novagen 
100 mM DTT 0.5 μL 10 mM Novagen 
2 U/μL T4 DNA Ligase 1.5 μL 0.6 U Novagen 
Nuclease-Free Water z μL - - 
Total 5.0 μL   
 
The ligation reaction was carried out at 16°C for 16 hours and then stored at 4°C.  One           
25 μL T7®Select Packaging Extract was thawed on ice, before the ligation reaction was 
added and the mixture was incubated at room temperature for 2 hours.  The packaging 
reaction was terminated by the addition of 270 μL of LB medium.  A plaque assay was 
performed to determine the number of recombinant T7 bacteriophage generated. 
 
2.2.8.7 Plaque Assay 
The total number of plaque forming units (pfu) was determined using a plaque assay.  A         
5 mL M9LB (22 mM KH2PO4, 22 mM Na2HPO4, 18.7 mM NH4Cl, 1 mM MgSO4,            
0.4% (w/v) glucose in LB containing 50 μg/mL ampicillin) culture in a 50 mL Erlenmeyer 
flask was inoculated with a glycerol scraping of BLT5403 E. coli cells.  The culture was 
incubated at 250 rpm at 37°C overnight before being used to seed a new flask with 5 mL of 
fresh M9LB medium.  The BLT5403 E. coli were incubated at 37°C until an OD600 of 1.0 
had been achieved.  The newly packaged bacteriophage were serially diluted to a total 
volume of 1.0 mL using LB to a range of 10-3-10-6.  One hundred microlitres of each phage 
dilution was added to 250 μL of the BLT5403 E. coli in M9LB.  These phage/cell mixtures 
were each combined with 3 mL of melted top agarose (50°C; 1 % (w/v) tryptone, 0.5% (w/v) 
NaCl, 0.5% (w/v) yeast extract, 0.6% (w/v) agarose) and then applied to 1.5% (w/v) agar 
plates containing 50 μg/mL ampicillin.  After allowing the top agarose to solidify, the plates 
were inverted and incubated for 3-4 hours at 37°C.  The phage titre, library size and the 
efficiency of the packaging reaction were then determined by counting the resultant number 
of plaques: 
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𝑝ℎ𝑎𝑔𝑒 𝑡𝑖𝑡𝑟𝑒 (
𝑝𝑓𝑢
𝑚𝐿
) = (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑜𝑛 𝑝𝑙𝑎𝑡𝑒)  × (𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟) × 10 
where 10 takes into account the 0.1 mL of the dilution plated 
𝑙𝑖𝑏𝑟𝑎𝑟𝑦 𝑠𝑖𝑧𝑒 (𝑝𝑓𝑢) = 𝑝ℎ𝑎𝑔𝑒 𝑡𝑖𝑡𝑟𝑒 (
𝑝𝑓𝑢
𝑚𝐿
) × 𝑡𝑜𝑡𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿) 
where the total sample volume is the 0.3 mL final packaging reaction volume 
𝑝𝑎𝑐𝑘𝑎𝑔𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (
𝑝𝑓𝑢
𝜇𝑔
) =  
𝑙𝑖𝑏𝑟𝑎𝑟𝑦 𝑠𝑖𝑧𝑒 (𝑝𝑓𝑢)
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 𝐷𝑁𝐴 𝑢𝑠𝑒𝑑 (𝑢𝑔)
  
where 0.5 μg of vector DNA was used during the packaging reaction 
 
2.2.8.8 Plate Lysate Amplification 
Before the phage display library can be used in a biopanning experiment, the bacteriophage 
need to undergo a single round of amplification.  Amplification is necessary as it allows the 
cloned sequences to be expressed and displayed on the surface of the bacteriophage particles.  
For a library consisting of less than 5 × 106 recombinants, the plate lysis method of 
amplification is preferred.  The packaged bacteriophage (see 2.2.8.6) were added to 7 mL of 
fresh BLT5403 E. coli cells in LB (with an OD600 of 1.0).  The phage/cell mixture was 
divided into 1 mL aliquots, to which 10 mL of melted top agarose was added.  Each aliquot 
was poured onto a 150 mm 1.5% (w/v) agar plate containing 50 μg/mL ampicillin and spread 
evenly across the plate.  After allowing the top agarose to solidify, the plates were inverted 
and incubated at room temperature overnight.  Ten millilitres of phage extraction buffer     
(20 mM Tris-HCl, 100 mM NaCl, 6 mM MgSO4; pH 8.0) was applied to each plate and 
incubated at 4°C for 3 hours.  The amplified bacteriophage were harvested by collecting the 
phage in the extraction buffer and adding 500 μL of chloroform.   The lysate was clarified 
by centrifugation at 3 000 ×g for 5 minutes at 4°C and the supernatant was collected and 
stored at 4°C.  The titre of the amplified phage display library was determined by plaque 
assay using up to a 10-9 serial dilution (see 2.2.8.7), while glycerol stocks of the library were 
created by adding 0.1 volume of 80% (v/v) glycerol to phage aliquots and storing them at     
-70°C. 
 
2.2.8.9 P. falciparum DNA Insert Analysis 
Individual plaque plugs were selected from the plaque assay plates and placed in 50 μL of 
10 mM EDTA; pH 8.  The samples were vortexed briefly, incubated for 10 minutes at 65°C 
and then cooled to room temperature.  PCR was then carried out using the DreamTaq Green 
PCR Master Mix as per the manufacturer’s instructions, with 1 μL of the phage plug solution, 
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T7SelectUP2 and T7SelectDOWN primers (primer details are available in APPENDIX A), 
at an annealing temperature of 50°C.  Bacteriophage with the biotin cassette, but not 
containing a P. falciparum insert are expected to produce a PCR product of 237 bp. 
 
2.2.8.10 Streptavidin Selection 
To isolate bacteriophage expressing a biotin tag, Streptavidin Magnetic Particles were used 
with modification.  These particles allow for the isolation of a variety of biotin-labelled 
molecules, relying on the strong non-covalent interaction between streptavidin and biotin.   
To determine what volume of the bacteriophage library should be applied to the particles, 
the multiplicity of infection (MOI) calculation was applied: 
𝑣𝑜𝑙𝑢𝑚𝑒 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 =  
𝑙𝑖𝑏𝑟𝑎𝑟𝑦 𝑠𝑖𝑧𝑒 (𝑝𝑓𝑢) × 𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑖𝑡𝑦
𝑎𝑚𝑝𝑙𝑖𝑓𝑖𝑒𝑑 𝑝ℎ𝑎𝑔𝑒 𝑡𝑖𝑡𝑟𝑒 (
𝑝𝑓𝑢
𝑚𝐿 )
 
A MOI of 1 means that each unique P. falciparum DNA insert is only represented by one 
bacteriophage in a given sample. 
 
One hundred microlitres of streptavidin magnetic particles was washed three times with    
500 μL of PBS.  The calculated volume of bacteriophage at an MOI of 5 was added to           
1.0 mL of 0.2% (v/v) Tween20-PBS (0.2% PBST), which was then applied to the 
streptavidin particles.  The mixture was incubated for 1 hour at room temperature on an 
Intelli-mixer.  The supernatant was removed and the particles were washed six times using 
1.9 mL of 0.2% (v/v) PBST for 5 minutes at room temperature to remove any bacteriophage 
binding non-specifically.  The biotin expressing bacteriophage were eluted off the 
streptavidin magnetic particles using 250 μL of 1% (w/v) SDS-PBS for 10 minutes at room 
temperature.  The eluted bacteriophage were added to 50 mL of log phase BLT5403 E. coli 
in M9LB at an OD600 of 1.0.  The cells were incubated at 250 rpm at 37°C until bacterial 
lysis was noted to allow for the amplification of the bacteriophage expressing biotin.  Sodium 
chloride, at a final concentration of 0.5 M, was then added to the bacterial cells to aid in lysis 
before the culture was centrifuged at 10 000 ×g for 10 minutes at 4°C (Beckman Coulter 
Avanti® J-E centrifuge).  The supernatant was collected and stored at 4°C before being used 
as the starting library in the biopanning experiments.  The titre of the amplified biotin 
expressing phage display library was determined by plaque assay using up to a 10-8 serial 
dilution (see 2.2.8.7), while glycerol stocks of the library were created by adding 0.1 volume 
of 80% (v/v) glycerol to bacteriophage aliquots and storing them at -70°C. 
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2.2.8.11 Plaque Lift 
Following Streptavidin Selection, bacteriophage expressing a biotin tag were visualised by 
means of a plaque lift.  A plate from the Plaque Assay (see 2.2.8.7), with between 100 and 
200 plaques, was chilled for 1 hour at 4°C to minimise the tendency of the top agarose to 
stick to nitrocellulose membrane.  A membrane was gently applied to the plate for 1 minute 
at room temperature, during which time the edge of both the membrane and plate were 
marked.  The membrane was then inverted and allowed to air-dry, before been blocked with 
5% (w/v) BSA Fraction V in 0.1% (v/v) TBST for 30 minutes at room temperature.  A 
solution of    1:100 000 biotin polyclonal antibody-HRP conjugate with 0.5% (w/v) BSA in 
0.1% (v/v) TBST was then applied to the membrane for 30 minutes at room temperature.  
The membrane was washed three times using 0.1% (v/v) TBST for 5 minutes at room 
temperature.  One and a half millilitres of SuperSignal® West Pico Chemiluminescent 
Substrate was applied to the membrane for 5 minutes at room temperature before the 
chemiluminescent signal was visualised using the SynGene Gel Doc system. 
 
2.2.9 Biopanning with a Biotin-Tagged P. falciparum Phage Display Library 
2.2.9.1 Biopanning 
The streptavidin screened, biotin-tagged P. falciparum cDNA phage display library was used 
in biopanning experiments by probing against the recombinant GST-tagged PfIAP proteins 
(see 2.2.7.2).  Using the titre of the amplified library, 1 × 107 pfu were prepared in a final 
volume of 500 μL of TBS.   This was applied to ~8 μg of MagneGST™ bound, recombinant 
GST protein for 1 hour at room temperature on an Intelli-mixer.  This background screening 
step serves to remove any of the bacteriophage that bind to either the GST protein or the 
MagneGST™ particles.  The unbound bacteriophage were collected, mixed with ~8 μg of 
MagneGST™ bound PfIAP protein and incubated as described above.  After removing the 
supernatant, the protein-bacteriophage complex was washed five times with 2 mL of     
0.05% (v/v) TBST for 10 minutes at room temperature to remove any non-specific binders.  
The washed particles were added to 50 mL of log phase BLT5403 E. coli in M9LB and the 
bacteriophage were allowed to amplify overnight.  The amplified phage were then collected 
as described in 2.2.8.10.  A plaque assay (see 2.2.8.7) with serial dilutions up to 10-9 was 
carried out, before the bacteriophage were used for another round of biopanning (Figure 
2.2.3).  In total, four rounds of biopanning were performed for each of the GST-tagged PfIAP 
proteins.  Each successive round of biopanning enriches for the bacteriophage that bind the 
strongest to the bait protein. 
 
46 
Chapter 2: The Characterisation of PfIAP 
 
Figure 2.2.3: The Biopanning Process 
Diagram showing how to perform biopanning with a phage display library.  The bacteriophage 
library, expressing P. falciparum peptides, was applied to the immobilised GST-tagged ‘bait’ protein 
(green).  Non-binding phage were washed away, while phage that bound because of protein-protein 
interactions (red) were amplified, before being reapplied to the ‘bait’. 
 
2.2.9.2 Identification of Interacting P. falciparum Peptides 
Following biopanning, PCR was performed on individual bacteriophage as described in 
2.2.8.9.  PCR amplicons larger than 300 bp were sequenced by Inqaba Biotec™, South 
Africa.  The identity of the P. falciparum binding peptides was determined by using the 
genomic data available in PlasmoDB (Aurrecoechea et al. 2009). 
 
2.2.10 In vitro Binding Assay 
To confirm the interaction of the identified binding partners with the GST-tagged PfIAP 
proteins, in vitro binding assays were performed with two of the interacting proteins.  The 
recombinant His-tagged PfRhopH3 and PfDOC2 proteins, together with the GST-BIR 
protein, were prepared and eluted as described in 2.2.7.2.  The GST-tagged protein was 
dialysed against three changes of TBS using a Slide-A-Lyzer® MINI Dialysis Unit (10 kDa 
molecular weight cut off) for 30 minutes at room temperature.  The His-tagged proteins were 
likewise dialysed against the His-Binding buffer, before 0.5 μg aliquots of each protein were 
rebound to 5 μL of prepared MagneHis™ particles for 1 hour at 4°C.  Increasing 
concentrations of GST-BIR were then exposed to the bound His proteins in a total volume 
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of 150 μL of TBS for 1 hour at 4°C on an Intelli-mixer.  The unbound supernatant was 
removed, before the particles were washed three times with 1 mL of TBS for 5 minutes at 
room temperature.  The bound protein complex was then assessed using SDS-PAGE as 
described in 2.2.7.3 and analysed using densitometry and the GeneSnap 7.04 and GraphPad 
Prism 6 software.  A heat denatured (15 minutes at 70°C) GST-BIR control aliquot was 
included, as were various concentrations of recombinant GST protein, to account for any 
non-specific binding. 
 
2.2.11 Creation of Transgenic PfIAPbir-GFP P. falciparum 
2.2.11.1 Preparation of the PfIAPbir-GFP Construct 
Plasmodium falciparum transfection requires more than 100 μg of plasmid construct, which 
was prepared as described below.  A 5 mL LB culture (containing 100 μg/mL ampicillin, in 
a   50 mL Erlenmeyer flask) was inoculated with a glycerol scraping of XL10 E. coli cells 
containing the pARL2-GFP_PfIAPbir plasmid construct (see 2.2.6) and incubated at           
250 rpm for 8 hours at 37°C.  Five hundred millilitres of LB medium (containing 100 μg/mL 
ampicillin) was seeded with 1 mL of the initial culture, split into two 250 mL aliquots (in     
1 L Erlenmeyer flasks) and incubated for 16 hours as described above (Thermo Scientific 
Forma incubated/refrigerated floor orbital shaker).  The OD600 of each aliquot was measured 
and when greater than 2 the bacterial cells were centrifuged at 6 000 ×g for 15 minutes at 
4°C (Beckman Coulter Avanti® J-E centrifuge). 
Large-scale plasmid purification was performed using the NucleoBond® Xtra Maxi Plus 
Plasmid Kit according to the manufacturer’s specifications and eluted into 1 mL of the 
provided Tris Buffer (5 mM Tris-HCl; pH 8.5).  A 1:10 dilution of the eluted plasmid 
construct was linearized with FastDigest® BamHI and then quantified by agarose gel 
electrophoresis as described in 2.2.3.1.  An elution volume equivalent to ≥150 μg of plasmid 
construct was purified by adding an equal volume of 1:1 phenol/chloroform.  After mixing, 
the tube was centrifuged at 16 000 ×g for 5 minutes at 4°C and the aqueous phase was 
transferred to a 1.5 mL Eppendorf tube.  One volume of chloroform was added to the tube 
which was mixed and centrifuged again.  The aqueous phase was transferred to a 2 mL 
Eppendorf tube and the plasmid construct was precipitated as described in 2.2.3.  The pellet 
was allowed to air-dry before being resuspended in 30 μL of TE buffer. 
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2.2.11.2 Transfection of Parasite Cultures 
The ~150 μg of purified pARL2-GFP_PfIAPbir construct in 30 μL of TE buffer was added 
to 370 μL of pre-warmed cytomix (37°C; 120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 
mM MgCl2, 10 mM K2HPO4/KH2PO4, 25 mM HEPES; pH 7.6; Wu et al. 1995).  Two 
hundred microlitres of fresh, unwashed, packed RBCs were added to the plasmid construct 
cytomix solution, which was transferred to a 2 mm Bio-Rad Gene Pulser® electroporation 
cuvette.  The mixture was electroporated using a Bio-Rad Gene Pulser Xcell™ 
electroporation system configured to 310 V and 950 µF, with an expected time range for the 
electroporation of        12 to 14 msec.  The contents of the cuvette were then transferred to a 
small culture flask using 5 mL of complete medium, before 50 μL of ~5% ring stage 
parasitised RBCs (pRBCs) were added (final parasitaemia ~1%).  The culture was then 
gassed and incubated at 37°C as described in 2.2.2.2.  The following day the culture medium 
was changed as described in 2.2.2.2, but from 48 hours post-transfection the positive 
selection WR99210 compound was added to the culture medium (10 μM stock in DMSO; 
final concentration of 2 nM).  The pARL2-GFP plasmid contains the human dihydrofolate 
reductase (hdhfr) cassette which confers resistance to the WR99210 compound.  The 
transfected parasite culture was monitored daily and maintained under WR99210 pressure 
for one week.  Subsequently, the culture medium (containing the WR99210 compound) was 
changed three times a week, with the addition of 100 μL of fresh, washed RBCs suspended 
in incomplete medium in a 1:1 ratio once a week.  Daily culturing, with the continued 
pressure of the WR99210 compound, was resumed once transgenic parasites were 
microscopically detectable.  Glycerol stocks of the transfected parasites were created from a 
~4% ring stage parasite culture, as described in 2.2.2.3. 
 
To verify transfection, parasite DNA was extracted from a culture with a parasitaemia 
greater than 4% mixed stage parasites (Tirasophon et al. 1991; Vu et al. 1995).  Three 
millilitres of culture was transferred to a 15 mL centrifuge tube and 1.5 mL of lysis solution 
(34 mM NaCl, 1% (v/v) Triton X-100, 1.2 mM EDTA) added.  The tube was briefly vortexed 
before being centrifuged at 3 000 ×g for 10 minutes at 4°C.  The supernatant was aspirated 
and the parasite pellet was resuspended in 100 μL of Tris buffer (10 mM Tris-HCl, 50 mM 
KCl; pH 8.3) before being transferred to a 1.5 mL Eppendorf tube.  After a brief vortex, the 
tube was centrifuged at 16 000 ×g for 5 minutes at 4°C and the supernatant was aspirated.  
The pellet was again resuspended in 100 μL of Tris buffer, vortexed and centrifuged as 
above.  After the supernatant was aspirated, the pellet was resuspended in 100 μL of boiling 
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buffer (10 mM Tris-HCl, 50 mM KCl, 3 mM MgCl2; pH 8.8) and boiled for 10 minutes.  
Two hundred microlitres of 1:1 phenol/chloroform were added to the tube, mixed briefly 
and centrifuged at 16 000 ×g for 5 minutes at 4°C.  The top aqueous phase was transferred 
to a 1.5 mL Eppendorf tube and one volume of chloroform was added to the tube which was 
briefly vortexed and centrifuged again.  The aqueous phase (~80 μL) was transferred to a 
new 1.5 mL Eppendorf tube and stored at -20°C.  A PCR reaction, using pARL2-GFP 
specific primers (pARL2 Fwd/Rev; available in APPENDIX A), at a Ta of 63°C was carried 
out and the PCR amplicons were visualised by agarose gel electrophoresis. 
 
2.2.11.3 Visualisation of PfIAPbir-GFP in Live Transgenic Parasites 
Three hundred microlitres of synchronised transgenic parasite culture (~5% parasitaemia) 
was removed from its culture flask and added to 700 μL of incomplete medium.  To visualise 
the nucleus either DAPI (5 mg/mL stock in water; final concentration of 0.2 μg/mL) or 
Hoechst 33258 pentahydrate (1 mg/mL stock in water; final concentration of 6 μg/mL) was 
added to the parasite mixture which was incubated for 5 minutes at room temperature or        
2 hours at 37°C, respectively.  The parasite suspension was centrifuged at 600 ×g for                 
3 minutes at 4°C.  The supernatant was aspirated, the pRBC pellet was resuspended in 
incomplete medium and centrifuged at 600 ×g for 3 minutes at 4°C.  The pRBC pellet was 
washed again, before being resuspended in 200 μL of incomplete medium. 
Live parasites were visualised by placing 5 μL of the stained parasite suspension on a 
microscope slide with a cover slip and viewing at 1 000X magnification using an Olympus 
BX41 microscope.  Filters U-MWB2 (emission above 510 nm) and U-MWU2 (emission 
above 410 nm) were used to visualise GFP and stained nucleic material, respectively, while 
images were captured using an Olympus DP72 camera with CellSense Dimensions 1.7 
software. 
 
Induction of RCD.  The effect of fever in malaria patients was mimicked by exposing 
synchronised transgenic parasite cultures (~5% parasitaemia) of both ring and trophozoite 
stages to 41°C for 2 hours, after which time the cultures were returned to 37°C.  Images of 
live, stressed parasite cultures were captured 30 minutes, 2 and 24 hours post heat-shock. 
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2.3 Results 
2.3.1 Characteristics of PfIAP and its Orthologues 
Scrutiny of the PF3D7_0519600 entry in PlasmoDB v9.1 showed that pfiap is a single exon 
gene (Figure 2.3.1) with two identified domains: a C3HC zinc finger-like domain (aa: 50-
168) and a β-sandwich domain (aa: 378-726; although this domain has since been refined to 
amino acid positions: 378-437 – PlasmoDB v34).  SMART was used to identify the location 
of the BIR domain in the PfIAP protein (aa: 53-128), which corresponds to what is now 
identified as an IAP repeat (aa: 52-127) in PlasmoDB v34.  The PF3D7_0519600 protein 
lacks the other domains (e.g. RING domain) found in some members of the BIRC family of 
proteins. 
 
Figure 2.3.1: Domain Structure of PF3D7_0519600 
a) Diagram of the pfiap gene.  Blue = location of the β-sandwich domain (PlasmoDB v34); green = 
location of the β-sandwich domain (PlasmoDB v9.1); orange = location of the BIR domain; purple 
= pfiap gene.  Numbers = nucleotide number. 
b) Diagram of the PfIAP protein.  Blue = location of the β-sandwich domain (PlasmoDB v34); green 
= location of the β-sandwich domain (PlasmoDB v9.1); orange = location of the BIR domain; purple 
= PfIAP protein.  Numbers = amino acid number. 
 
One orthologue of the pfiap gene was found in other Plasmodium species including:                
P. berghei (PBANKA_123440), P. chabaudi (PCHAS_123500), P. knowlesi 
(PKNH_1013500), P. malariae (PmUG01_10025000), P. ovale (PocGH01_00238900),     
P. reichenowi (PRCDC_0518700), P. vivax (PVX_080265) and P. yoelii 
(PY17X_1237800).  The Plasmodium orthologues all contained one conserved BIR domain 
which, along with the iap gene, is not present in other Protozoa (Toxoplasma gondii, 
Trichomonas vaginalis, Leishmania, Entamoeba etc.).  Analysis of the amino acid alignment 
of these eight Plasmodium proteins with PfIAP (Figure 2.3.2) showed that these Plasmodium 
orthologues were 34.8% identical (31.2%-38.1%) and 52.4% similar (50.7%-54.4%) to 
PfIAP.  Plasmodium reichenowi was an outlier with 86.5% identity (and 89.4% similarity) 
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to PfIAP, but this can be explained by that fact these two species are closely related to each 
other.  A high degree of similarity was also observed at the beginning and at the very              
C-terminal end of the proteins.  The green and blue boxes (Figure 2.3.2) show the previous 
(PlasmoDB v9.1) and new (PlasmoDB v34) locations of the predicted β-sandwich domain 
of the P. falciparum protein, which is not predicted for any of the other orthologues.                
β-sandwich domains are composed of two opposing antiparallel β-sheets (Kister et al. 2006).  
Another unique feature of the P. falciparum orthologue is that it is the only protein that has 
a 62 amino acid low complexity region, made up of repeating sequences of the asparagine, 
glutamine and histidine amino acids. 
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Figure 2.3.2: Plasmodium IAP Alignment 
Amino acid alignment of the nine BIR-containing Plasmodium proteins.  Blue box = β-sandwich 
domain (PlasmoDB v34); green box = β-sandwich domain (PlasmoDB v9.1); orange box = BIR 
domain.  * = identical; : = conserved; . = semi-conserved.  
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Each of the nine Plasmodium proteins only has one BIR domain (orange box in Figure 2.3.3), 
that shows 64.7% identity (57.9%-72.4%) and 81.4% similarity (77.6%-88.2%) to PfIAP 
(except for P. reichenowi which shows 98.7% identity).  The four important zinc ion 
chelating amino acid residues are conserved between the nine studied Plasmodium IAP 
proteins and all follow the same sequence layout (green triangles in Figure 2.3.3).  This 
CX2CX23HX3C (C = cysteine; H = histidine; X = any amino acid) sequence of the 
Plasmodium BIR domains is different to the general CX2CX16HX6C sequence of human and 
other species’ BIR domains (green triangles in Figure 2.3.4; Srinivasula and Ashwell 2008).  
Some amino acids are identical between the BIR domain of P. falciparum PF3D7_0519600 
and the BIR domains of members of the human IAP family of proteins (Figure 2.3.4).  The 
PfIAP BIR domain appears to have the highest degree of identity and similarity with the 
third BIR domain of the human NAIP protein (BIRC1c; Table 2.3.1), although the XIAP 
BIR domains are the preferred templates for the PfIAP BIR 3D models (see below). 
 
Figure 2.3.3: The BIR Domains of the Plasmodium IAP Orthologues 
Amino acid alignment of the N-terminal end of the nine Plasmodium orthologues.  Green arrows = 
inferred zinc-chelating residues; orange box = BIR domain. 
 
 
Figure 2.3.4: Human IAP Proteins and PfIAP 
Amino acid alignment of the BIR domains of some of the human IAP proteins and the P. falciparum 
IAP protein.  Green triangles = Zn2+-chelating residues.  a,b,c = the first, second and third BIR 
domains of the given human BIRC protein respectively. 
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Table 2.3.1: Amino Acid Comparison Between PfIAP BIR and Some Human BIR Domains 
a,b,c = the first, second and third BIR domains of the given human BIRC protein respectively. 
IAP Protein and 
BIR Domain 
Identity 
(%) 
Similarity 
(%) 
IAP Protein and 
BIR Domain 
Identity 
(%) 
Similarity 
(%) 
BIRC1b 16.3 31.5 BIRC3c 14.7 23.5 
BIRC1c 25.9 46.9 BIRC4a 21.2 42.5 
BIRC2a 11.9 16.1 BIRC4b 15.8 24.8 
BIRC2b 24.7 36.5 BIRC4c 16.2 24.2 
BIRC2c 14.7 20.2 BIRC7 14.6 25.2 
BIRC3a 11.9 16.1 BIRC8 16.2 24.2 
BIRC3b 24.1 37.3    
 
The consensus of various secondary structure algorithms predicts that the BIR domain of the 
PfIAP protein consists of three α-helices and three β-strands (Figure 2.3.5).  This prediction 
is similar to various predictions for the three BIR domains of the human XIAP protein - three 
α-helices and two/three β-strands.  These structures are present in the predicted 3D structure 
of the PfIAP BIR domain (Figure 2.3.6a) that was modelled on the human XIAP BIR1 
domain (Figure 2.3.6b) using SWISS-MODEL.  These two models look very similar: both 
have two α-helices, an antiparallel β-sheet made up of three β-strands, followed by a third 
α-helix.  A zinc ion (grey dot) is shown to be chelated by four amino acids (blue residues) 
towards the C-terminal end of the XIAP BIR1 domain (Figure 2.3.6b).  The corresponding 
amino acids (green triangles in Figure 2.3.4) in the PfIAP model (blue residues in Figure 
2.3.6a) are in a similar spatial arrangement, but do not form a pocket of the exact same shape.  
This discrepancy can be explained by the inaccuracy of this PfIAP 3D model, with a 
QMEAN score less than -3 (the closer the QMEAN is to 1, the better the prediction).  This 
discrepancy is also evident in the Phyre2 derived model (Figure 2.3.6c) in which only 62% 
of residues are modelled at >90% accuracy, primarily using the BIR3 domain of XIAP (PDB: 
2VSL chain A), with a QMEAN score smaller than -4.  The amino acid residues that were 
not accurately modelled occur after the β-sheet, which explains why the third α-helix of the 
Phyre2 model is longer and more rigid than the helices of the other model and the XIAP 
crystal structure, and has no zinc ion pocket (blue residues in Figure 2.3.6c).  
Notwithstanding the uncertainty associated with these two PfIAP models, they do conform 
to the general 3D structure that is expected in a BIR domain.  The hydrophobic, IBM-binding 
groove of the human BIR domain is created by the conformational arrangement of the last 
strand of the β-sheet and the following α-helix (Herman et al. 2009).  This same location in 
the PfIAP BIR domain contains a number of nonpolar amino acid residues that are similar 
in number and position to those found in the human BIR domain, suggesting that these 
domains may share the same hydrophobic characteristics. 
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Figure 2.3.5: PfIAP BIR Domain Secondary Structure Prediction 
a) Various secondary structure predictions of the PfIAP BIR domain using online tools.  E = β-strand; 
H = α-helix.  Numbers = amino acid number 
b) Diagram showing the average secondary structure prediction of the BIR domain of the PfIAP 
protein.  Gold arrow = β-strand; pink block = α-helix. 
 
 
Figure 2.3.6: 3D Models of the PfIAP BIR Domain 
a) Two views of the predicted 3D structure of the BIR domain of the PfIAP protein by SWISS-
MODEL.  Blue = inferred zinc-chelating residues; gold = β-strand; pink = α-helix.  QMEAN = -3.49. 
b) Visualisation of the crystal structure of the XIAP BIR1 domain (PDB: 4OXC chain A).  Blue = 
zinc-chelating residues; gold = β-strand; grey dot = Zn2+ ion; pink = α-helix. 
c) Two views of the predicted 3D structure of the PfIAP BIR domain by Phyre2.  Blue = inferred 
zinc-chelating residues; gold = β-strand; pink = α-helix.  QMEAN = -4.46. 
 
2.3.2 Cloning and Expression of Recombinant PfIAP Proteins 
2.3.2.1 P. falciparum Genomic DNA Extraction 
Genomic DNA was extracted from P. falciparum 3D7 parasites with a concentration of     
586 ng/μL and subsequently used for PCR.  Spectrophotometric analysis revealed that the 
DNA had an A260:A280 ratio of 1.89, which is indicative of DNA free from RNA or any 
contaminating proteins that tend to lower the absorbance value by absorbing 280 nm light.  
The A260:A230 ratio of 1.94 was greater than the A260:A280 ratio as expected and so is another 
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measure of the DNA purity (NanoDrop 2008).  Agarose gel electrophoresis resolved this 
DNA sample as a single, high molecular weight band with no contaminating bands. 
 
2.3.2.2 Creation of Various PfIAP Constructs 
Three regions of the pfiap gene (BIR, Middle and Terminal; Figure 2.3.7a) were amplified 
by PCR as single bands of the expected size and then inserted into the pGEX-4T-2 vector 
(Figure 2.3.7b).  The predicted β-sandwich domain (PlasmoDB v34) consists of a series of 
amino acids repeats and so this unstructured low complexity region (Aravind et al. 2003) 
was not selected for protein expression.  The BIR region encompasses the area around the 
identified BIR domain, the Middle region covers the part of the gene between the BIR 
domain and the predicted β-sandwich domain, while the Terminal region represents the 3’ 
end of the gene that follows the predicted β-sandwich domain.  The linearized pGEX-4T-2 
plasmid appeared slightly larger than expected, but sequencing did confirm that the GST 
coding sequence of the plasmid was as expected. 
 
Figure 2.3.7: PCR Amplification of Three PfIAP Regions and the pGEX-4T-2 Plasmid 
a) Diagram showing the locations of the three regions of the pfiap gene (BIR, Middle and Terminal) 
amplified by PCR for cloning into the pGEX-4T-2 vector.  Blue = the forward and reverse PCR 
primers; orange = BIR domain; purple = pfiap gene.  Numbers = nucleotide number.  Amplified 
regions: BIR = 1 - 450 bp, Middle = 580 - 1 119 bp and Terminal = 1 297 - 2 259 bp. 
b) Agarose gel (1%) showing three BamHI/XhoI digested PfIAP PCR amplicons and the linearized 
pGEX-4T-2 vector prior to ligation.  ◄ = expected band size. 
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After transformation, bacterial colonies were assessed for the presence of the three PfIAP 
constructs using colony PCR and restriction enzyme digestion of the extracted plasmids 
(Figure 2.3.8).  The expected PCR amplicon sizes and digestion patterns were obtained for 
all three of the PfIAP clones, one sample of each was sent for sequencing.  The sequencing 
results for the Middle and Terminal constructs were as expected, but an error was detected 
in the BIR region sequencing result.  The expected codon sequence TTA was instead CTA 
(Figure 2.3.9), but as this mutation is silent and still allows for the translation of a leucine 
amino acid, the plasmid construct was retained. 
 
  
Figure 2.3.8: Verification of the Insertion of PfIAP Amplicons into the pGEX-4T-2 Vector. 
a) Agarose gel (1%) showing colony PCR of the three PfIAP regions after cloning.  ◄ = expected 
band size. 
b) Agarose gel (1%) of the three pGEX-4T-2 plasmids after digestion with BamHI/XhoI, resulting in 
two bands each.  ◄ = expected band size. 
c) Vector diagrams of the pGEX-4T-2 plasmid and the plasmid containing the PfIAP BIR region 
with BamHI/XhoI cloning restriction sites.  Blue = inserted BIR domain. 
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Figure 2.3.9: Sequencing Chromatogram of the pGEX-4T-2_BIR Plasmid 
a) Extract of the sequencing chromatogram of the PfIAP BIR construct present in the pGEX-4T-
2_BIR vector.  Purple = the identified T→C substitution. 
 
2.3.2.3 Expression and Purification of Recombinant GST-Tagged PfIAP 
Rosetta™ 2 (DE3) E. coli, transformed with the different pGEX-4T-2 constructs, were 
grown in Overnight Express™ Instant TB Media to induce the expression of GST-tagged 
PfIAP proteins.  It was not possible to purify the PfIAP Middle region (referred to as GST-
Middle) as, in six different experiments, it only expressed as an insoluble protein when 
compared to uninduced E. coli (Figure 2.3.10), as predicted using the PROSO II and SOLpro 
online tools (solubility probabilities of 35% and 24% respectively).  The protein appeared 
slightly smaller than expected, but this cannot be accurately judged as the induced fractions 
have not travelled the same distance through the polyacrylamide gel as the ladder (the dye 
front is not at the same level across the gel).  Virtually no purified, GST-Middle protein was 
detected by Western blot (data not shown). 
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Figure 2.3.10: Expression of the Insoluble GST-Tagged PfIAP Middle Region 
Coomassie-stained SDS-polyacrylamide gel (12%) of induced and uninduced GST-Middle aliquots 
(2.5 μL of 1.5 mL).  Ladder = human red cell membrane ladder.  ◄ GST-Middle: predicted size = 
48 kDa; observed size = ~42 kDa. 
 
Although some of the PfIAP BIR region (GST-BIR) expressed as insoluble protein 
(insoluble fraction; Figure 2.3.11a), sufficient amounts of soluble GST-tagged protein was 
purified using MagneGST™ particles.  At least 8 μg of eluted protein was obtained per         
20 mL E. coli culture.  As seen in the SDS-polyacrylamide gel and the anti-GST Western 
Blot (Figure 2.3.11) the purified protein was of the expected size of 44 kDa, although other 
smaller bands were detected.  One of these bands is the same size as the GST positive control 
protein (Figure 2.3.11b) and may be endogenous E. coli GST.  It is assumed that the             
<44 kDa, GST-positive bands are recombinant proteins that suffered premature mRNA 
termination during translation.  Two elutions were performed using 500 mM glutathione and 
500 mM NaCl, but this was not sufficient to remove all of the GST-tagged protein from the 
MagneGST™ particles (beads fraction in Figure 2.3.11; elution 2 not shown). 
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Figure 2.3.11: Expression and Purification of GST-Tagged PfIAP BIR Domain 
a) Coomassie-stained SDS-polyacrylamide gel (12%) of the purification of GST-BIR.  Total, soluble 
and insoluble E. coli lysates, unbound = 1.0 μL of 1.5 mL; elution 1, protein remaining on beads = 
10.0 μL of 50 μL; wash 1 = 15.0 μL of 1.5 mL.  Ladder = human red cell membrane ladder.  ◄ GST-
BIR: predicted/observed size = 44 kDa. 
b) Anti-GST western blot of the purification of GST-BIR.  Soluble and insoluble E. coli lysates, 
unbound = 2.5 μL of 1.5 mL; wash 1 = 5.0 μL of 1.5 mL; elution 1 = 10.0 μL of 100 μL; protein 
remaining on beads = 5.0 μL of 100 μL.  ◄ GST-BIR: predicted/observed size = 44 kDa; GST: 
known size = 26 kDa. 
 
The GST-Terminal protein (PfIAP Terminal region), which was predicted to have a 50% to 
80% chance of being insoluble by PROSO II and SOLpro, expressed as both soluble and 
insoluble proteins and was successfully purified.  When analysed on a SDS-polyacrylamide 
gel the GST-tagged protein appeared to have a larger molecular mass than expected           
(~74 kDa vs 65 kDa; Figure 2.3.12a).  This discrepancy in the expected migration pattern 
has previously been documented for proteins characterised by regions of low complexity, a 
number of which are present in the expressed region (Figure 2.3.13; Tompa 2003).  Other 
bands are present in the eluates but are not visible on the Western Blot (Figure 2.3.12b), 
implying that these bands are not truncated forms of the protein but rather other E. coli 
proteins.  For each 20 ml E. coli grow ~10 μg of soluble GST-Terminal protein was obtained, 
but more than this remained bound to the magnetic beads despite using a high salt 
concentration elution buffer (500 mM glutathione + 500 mM NaCl; beads fraction; Figure 
2.3.12a). 
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Figure 2.3.12: Expression and Purification of GST-Tagged PfIAP Terminal Region 
a) Coomassie-stained SDS-polyacrylamide gel (12%) of the purification of GST-Terminal.  Total, 
soluble and insoluble E. coli lysates, unbound = 2.5 μL of 1.5 mL; wash 1 = 5.0 μL of 1.5 mL; elution 
1, elution 2, protein remaining on beads =   10.0 μL of 50 μL.  Ladder = human red cell membrane 
ladder.  ◄ GST-Terminal: predicted size = 65 kDa; observed size = ~74 kDa; GST = 26 kDa. 
b) Anti-GST western blot of the purified GST-Terminal.  Elution 1 = 10.0 μL of 100 μL.  ◄ GST-
Terminal: predicted size = 65 kDa; observed size = ~74 kDa; GST: known size = 26 kDa. 
 
 
Figure 2.3.13: Low Complexity Regions of PfIAP 
Diagram showing regions of low complexity in the PfIAP protein.  Blue = the regions expressed as 
GST-tagged proteins; purple = PfIAP protein.  Numbers = amino acid number.  Adapted from 
PlasmoDB (Aurrecoechea et al. 2009). 
 
2.3.3 P. falciparum Phage Display Library Creation 
2.3.3.1 P. falciparum mRNA Isolation 
The combined amount of total RNA extracted from ten 35 mL, mixed stage P. falciparum 
culture flasks was 923 μg.  The A260:A280 ratio of the various RNA extractions ranged from 
1.45 to 2.13.  Since the expected value for pure RNA is >2 (NanoDrop 2008) this indicates 
that some of the total RNA samples were contaminated, most likely with the protein 
containing phase of the TRI Reagent®.  Agarose gel electrophoresis showed the 
predominant 28S and 18S and the small 5S rRNA subunits as expected (Figure 2.3.14).  
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Dynabeads® were used to isolate 9 μg of mRNA or 1% of the total available RNA, which 
is acceptable as a typical eukaryotic cell has between 1-5% mRNA (Lodish et al. 2000). 
 
Figure 2.3.14: Extracted P. falciparum RNA 
Agarose gel (1%) showing a sample of total RNA extracted from P. falciparum parasites. 
 
2.3.3.2 P. falciparum Phage Display Library Construction 
The isolated mRNA was reverse transcribed, before EcoRI/HindIII Directional Linkers were 
ligated to the P. falciparum cDNA.  The average size of the DNA fragments present was 
determined by visualising an aliquot of the sample by agarose gel electrophoresis (~300 bp 
– ~800 bp; data not shown).  These fragments were then inserted into the T7 vector arms 
containing the biotin cassette and packaged.  A plaque assay was performed to determine the 
number of recombinant T7 bacteriophage generated by the packaging reaction (Table 2.3.2).  
Using 0.5 μg of vector DNA for the 0.3 mL packaging reaction resulted in the creation of 
7.32 × 105 bacteriophage (or plaque forming units). 
Table 2.3.2: Biotin-Tagged P. falciparum Phage Display Library Numbers 
Phage Titre (pfu/ml) Library Size (pfu) Packaging Efficiency (pfu/µg) 
2.44 × 106 7.32 × 105 1.46 × 106 
 
A plate amplification step was used to amplify the number of bacteriophage present in the 
library as less than 5 × 106 phage were present in the library.  The titre of the phage display 
library increased to 6.49 × 1011 pfu/mL after plate amplification.  PCR amplification of 
randomly selected plaques from the library showed a range of sizes from 237 bp (an empty 
cassette) to 550 bp (Figure 2.3.15). 
 
63 
Chapter 2: The Characterisation of PfIAP 
 
Figure 2.3.15: PCR Amplification of Random Plaques from the Biotin-Tagged P. falciparum 
Phage Display Library 
Agarose gel (1%) showing the PCR products of a random selection of bacteriophage taken after plate 
amplification of the initial library. 
 
Streptavidin magnetic particles were used to select bacteriophage from the newly created 
phage display library expressing the biotinylated protein and therefore in-frame                         
P. falciparum peptides.  Phage were applied to these particles so that a multiplicity of 
infection of 5 was achieved (5 bacteriophage representing each unique P. falciparum insert).  
Following streptavidin isolation, the biotin phage were amplified to a titre of 1.86 × 1010 
pfu/mL. 
 
2.3.4 Identification of Novel PfIAP Binding Partners 
The P. falciparum phage display library was biopanned against both the GST-BIR and GST-
Terminal recombinant proteins.  After four rounds of biopanning, a plaque lift using an anti-
biotin antibody was performed (Figure 2.3.16).  Biotin-positive plaques were then selected 
for PCR using primers specific to the T7 phage arms (Figure 2.3.17).  A range of differently 
sized PCR amplicons over 300 bp in size were obtained.  The presence of multiple, similarly 
sized bands (not shown) suggests enrichment and amplification of the same specific phage 
which is what is expected after four rounds of biopanning.  A number of the larger phage 
inserts were sequenced (see APPENDIX C for an example) and the P. falciparum inserts 
were then translated to their amino acid sequences.  The identity of these perspective binding 
partners was determined by using search and alignment facilities of PlasmoDB (Table 2.3.3).  
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Figure 2.3.16: Plaque Lift Detecting Bacteriophage Expressing Biotin 
A plaque lift using an anti-biotin antibody on a 10-6 dilution plaque assay plate of the phage display 
library after streptavidin screening. 
 
 
Figure 2.3.17: PCR of Three Selected Plaques after Four Rounds of Biopanning 
Agarose gel (1%) showing the PCR products of some of the bacteriophage plaques after biopanning 
that were selected for sequencing. 
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Table 2.3.3: GST-Tagged PfIAP Binding Partners* 
PlasmoDB Name Gene I.D. Peptide Length (aa) 
GST-BIR 
High molecular weight rhoptry protein 3 (RhopH3) PF3D7_0905400 101 
60S ribosomal protein L24, putative PF3D7_1309100 50 
Double C2-like domain-containing protein (DOC2) PF3D7_1243900 49 
LisH domain-containing protein, putative (LisH) PF3D7_1303400 34 
GST-Terminal 
Chromodomain-helicase-DNA-binding protein 1 
homolog, putative (CHD1) 
PF3D7_1023900 65 
Mature parasite-infected erythrocyte surface 
antigen (MESA) 
PF3D7_0500800 63 
*Additional details are available in APPENDIX D. 
 
Four unique binding partners were identified for the GST-BIR domain, while GST-Terminal 
had two unique binding partners (Figure 2.3.18).  PfRhopH3 is in the family of proteins that 
includes PfRhopH1/Clag and PfRhopH2, while PF3D7_1309100 is the L24 component of 
the 60S ribosomal subunit.  PfDOC2 contains two C2 domains that act as Ca2+ binding motifs 
and one Lissencephaly type-1-like homology (LisH) motif is present at the N-terminal end 
of PF3D7_1303400.  PfCHD1 has a helicase domain and motifs that are involved in 
chromatin organization, while the C-terminal end of PfMESA contains a DnaJ molecular 
chaperone homology domain. 
 
Figure 2.3.18: The PfIAP Binding Partners Identified Using a Phage Display Library 
Diagram showing the gene coding sequence (purple) and the region that bound to the GST-PfIAP 
proteins (green).  Red = known gene domains.  Numbers = nucleotide number. 
a) The pfrhoph3 (PF3D7_0905400) gene. d) The pflish (PF3D7_1303400) gene. 
b) The pfl24 (PF3D7_1309100) gene.  e) The pfchd1 (PF3D7_1023900) gene. 
c) The pfdoc2 (PF3D7_1243900) gene.  f) The pfmesa (PF3D7_0500800) gene. 
 
66 
Chapter 2: The Characterisation of PfIAP 
No common binding motif was present across the binding regions of the four GST-BIR 
partners, nor across the two GST-Terminal binding partners (Figure 2.3.19a).  Analysis of 
the amino acid composition of these binding regions revealed that the five charged amino 
acids (D, E, H, K and R) made up 52 – 63% of the total amino acids present in these peptides 
(except for PfRhopH3 with 35%; Figure 2.3.19b and Table 2.3.4).  The GST-BIR and GST-
Terminal proteins only contain 33 – 34% charged amino acids, with a fairly equal 
distribution of positive and negative residues. 
 
 
Figure 2.3.19: Amino Acid Alignment of the Binding Regions of the PfIAP Partner Proteins 
Amino acid alignment of the six PfIAP binding regions. 
a) BLOSUM62 colour scheme.  Percentage identity across all the sequences determines the shade of 
blue. 
b) Zappo colour scheme.  Blue = positive; green = hydrophilic; magenta = conformationally special; 
pink = aliphatic/hydrophobic; red = negative; yellow = aromatic. 
 
Table 2.3.4: Percentage of Charged Amino Acids Present in Each Binding Peptide 
Binding Partner 
Basic Residues (%) Acidic Residues (%) Total Charged 
Residues (%) Arg His Lys Asp Glu 
GST-BIR 
PfDOC2 12.2 0.0 22.5 4.1 24.5 63.3 
PfLisH 2.9 0.0 47.1 2.9 8.8 61.7 
PfL24 0.0 4.0 38.0 8.0 4.0 54.0 
PfRhopH3 0.0 0.0 11.9 6.9 16.8 35.6 
GST-Terminal 
PfMESA 1.6 0.0 28.6 6.3 19.0 55.5 
PfCHD1 10.8 0.0 15.4 10.8 15.4 52.4 
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The secondary structures of the recombinant PfIAP proteins revealed that α-helices are the 
predominantly predicted structure with only some β-strands predicted to be present (Figure 
2.3.20 and Figure 2.3.21).  The same observation is true when looking at the secondary 
structures of the six binding regions (Figure 2.3.20 and Figure 2.3.21).  Across both groups 
of proteins the charged amino acids are evenly distributed, with most of the α-helices 
containing both positive and negative residues (Figure 2.3.20 and Figure 2.3.21).  
Biopanning occurred at a pH of 7.5, which means that both GST-tagged PfIAP proteins were 
predicted to be negatively charged, while the binding peptides are positively charged at this 
pH (except for PfCHD1 which is neutral and PfRhopH3 which is negative).  However, these 
predicted charges do not take into account the 3D conformation of the peptides, which could 
alter the overall charge.  The lack of binding motif and the predominant presence of charged 
basic and acidic residues imply that these interactions occurred via ionic bonds between the 
α-helices of the respective proteins. 
 
Figure 2.3.20: Secondary Structures of GST-BIR and the Binding Regions of its Partners 
Diagrams showing the predicted secondary structure of GST-BIR and its binding partners.  Gold 
arrow = β-strand; pink block = α-helix; gold/pink shapes = both α-helix and β-strand predictions.  
Blue = positive amino acids; red = negative amino acids. 
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Figure 2.3.21: Secondary Structures of GST-Terminal and the Binding Regions of its Partners 
Diagrams showing the predicted secondary structure of GST-Terminal and its binding partners.  Gold 
arrow = β-strand; pink block = α-helix; gold/pink shapes = both α-helix and β-strand predictions.  
Blue = positive amino acids; red = negative amino acids. 
 
2.3.5 Cloning and Expression of Recombinant Binding Partners 
2.3.5.1 Cloning of His-Tagged Binding Partners 
Since the BIR domain is the principal PfIAP region, it was important to verify the novel 
protein interactions with this domain.  Three of the interesting GST-BIR binding partners 
(PfDOC2, PfLisH and PfRhopH3) were selected and cloned into the pET-15b plasmid.  They 
were expressed as N-terminal His-tagged recombinant proteins, but sufficient amounts of 
purified PfLisH could not be obtained to perform a binding assay, so only the other two 
binding partners selected for further investigation. 
 
pfdoc2 consists of six exons and the sequence that was selected for PCR amplification is 
towards the 3’ end of the gene and includes the identified binding region.  Almost all of the 
last exon (out of seven) of the pfrhoph3 gene, which contains the binding region, was 
selected for PCR amplification (Figure 2.3.22). 
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Figure 2.3.22: Binding Partners of PfIAP BIR 
Diagram showing the location of the PCR primers on either side of the binding region identified from 
the phage display library.  Blue = the forward and reverse PCR primers; green = the binding region; 
purple = gene coding sequence.  Numbers = nucleotide number. 
a) The pfdoc2 (PF3D7_1243900) gene.  Red = the location of the C2 domains.  Amplified region = 
4 210 - 5 193 bp. 
b) The pfrhoph3 (PF3D7_0905400) gene.  Amplified region = 2 209 - 2 694 bp. 
 
The two binding regions were PCR-amplified as single bands of the expected size (Figure 
2.3.23), cloned into the pET-15b vector and used to transform DH5α E. coli cells. 
  
 
Figure 2.3.23: PCR Amplicons of the Binding Partners and pET-15b Plasmid prior to Ligation 
Agarose gel (1%) showing PCR amplicons after digestion with BamHI/NdeI and the linearized pET-
15b vector.  ◄ = expected band size. 
 
Colony PCR, using pET-15b specific primers which result in amplicons larger than the initial 
cloned region, was used to confirm the presence of the inserts after transformation (Figure 
2.3.24a), as was digestion of the new pET-15b constructs with EcoRV (Figure 2.3.24b) that 
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resulted in the expected digestion patterns.  Sequencing of one sample of each insert verified 
that the cloning was error-free.  These verified plasmids were used to transform Rosetta™ 2 
(DE3) E. coli, which allowed for expression of the recombinant binding proteins. 
 
Figure 2.3.24: Verification of the Insertion of Binding Amplicons into the pET-15b Vector. 
a) Agarose gel (1%) showing colony PCR of the two binding partners after cloning.  ◄ = expected 
band size. 
b) Agarose gel (1%) of the two pET-15b plasmids after digestion with EcoRV.  ◄ = expected band 
size. 
c) Vector diagrams of the pET-15b plasmid and the two plasmids containing the binding partners 
with BamHI/NdeI and EcoRV restriction sites.  Blue = inserted binding regions. 
 
2.3.5.2 Expression of Recombinant His-Tagged Binding Partners 
Overnight Express™ Instant TB Media was used to induce the expression of the His-tagged 
binding proteins.  His-DOC expressed easily as a soluble protein, as predicted by the online 
tool SOLpro (85%), while PROSO II predicted that the protein would only have a 48% 
chance of being soluble.  The protein was larger than the expected molecular size of 44 kDa 
(Figure 2.3.25a), which could be explained by the presence of low complexity regions in the 
expressed region (Figure 2.3.26).  Slightly truncated His-DOC was also purified, as verified 
by the anti-His western blot (Figure 2.3.25b).  Approximately 25 μg of the His-tagged 
protein was obtained per 20 mL E. coli culture. 
 
71 
Chapter 2: The Characterisation of PfIAP 
 
Figure 2.3.25: Expression and Purification of His-Tagged PfDOC2 Binding Region 
a) Coomassie-stained SDS-polyacrylamide gel (12%) of the purification of His-DOC.  Total, soluble 
and insoluble E. coli lysates, unbound = 1.5 μL of 1.5 mL; wash 1, wash 2 = 15.0 μL of 1.5mL; 
elution 1, elution 2, protein remaining on beads = 10.0 μL of 100 μL.  Ladder = human red cell 
membrane ladder.  ◄ His-DOC: predicted size = 44 kDa; observed size = ~50 kDa. 
b) Anti-His western blot of the purification of His-DOC.  Total, soluble and insoluble E. coli lysates, 
unbound = 1.0 μL of 1.5 mL; wash 1 = 15.0 μL of 1.5 mL; elution 1, protein remaining on beads = 
10.0 μL of 100 μL.  ◄ His-DOC: predicted size = 44 kDa; observed size = ~50 kDa. 
 
 
 
Figure 2.3.26: Low Complexity Regions of PfDOC2 
Diagram showing regions of low complexity in the PfDOC2 protein.  Blue = the region expressed as 
a His-tagged protein; purple = PfDOC2 protein.  Numbers = amino acid number.  Adapted from 
PlasmoDB (Aurrecoechea et al. 2009). 
 
As seen when comparing the soluble and insoluble fractions of His-Rhop (Figure 2.3.27a), 
the protein is soluble (as predicted by both online tools) but resolved at a higher molecular 
weight on the SDS-polyacrylamide gel than was expected likely due to the presence of two 
regions of low complexity (Figure 2.3.28).  At least 15 μg of eluted protein was obtained per 
20 mL E. coli grow.  An anti-His western blot confirmed that this protein, and the slightly 
smaller truncated proteins, were His-tagged proteins (Figure 2.3.27b). 
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Figure 2.3.27: Expression and Purification of His-Tagged PfRhopH3 Binding Region 
a) Coomassie-stained SDS-polyacrylamide gel (12%) of the purification of His-Rhop.  Total, soluble 
and insoluble E. coli lysates, unbound = 1.0 μL of 1.5 mL; wash1, wash 2 = 15.0 μL of 1.5mL; 
elution 1, protein remaining on beads = 10.0 μL of 100 μL.  Ladder = human red cell membrane 
ladder.  ◄ His-Rhop: predicted size = 21 kDa; observed size = ~30 kDa. 
b) Anti-His western blot of the purification of His-Rhop.  Total, soluble and insoluble E. coli lysates, 
unbound = 1.0 μL of 1.5 mL; wash 1 = 15.0 μL of 1.5 mL; elution 1 = 10.0 μL of 100 μL.  ◄ His-
Rhop: predicted size = 21 kDa; observed size = ~30 kDa. 
 
 
Figure 2.3.28: Low Complexity Regions of PfRhopH3 
Diagram showing regions of low complexity in the PfRhopH3 protein.  Blue = the region expressed 
as a His-tagged protein; purple = PfRhopH3 protein.  Numbers = amino acid number.  Adapted from 
PlasmoDB (Aurrecoechea et al. 2009). 
 
2.3.6 In vitro Binding Assays between GST-BIR and its Binding Partners 
As a means of verifying the biopanning results and to eliminate the possibility of having 
identified a false binding partner, two and three in vitro binding assays were performed using 
the His-Rhop and His-DOC proteins respectively.  A constant amount of both of the His-
tagged binding partners was immobilised on MagneHis™ particles, before being subjected 
to increasing amounts of the GST-BIR protein.  As seen in the representative SDS-
polyacrylamide gels and verified graphically (Figure 2.3.29 and Figure 2.3.30), there was a 
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dose-dependent association between the proteins that reached saturation, with PfIAP binding 
PfDOC2 and PfRhopH3 with a stoichiometry of approximately 1:3 and 1:5 respectively. 
Controls ensured the specificity of these binding results.  Heat denatured GST-BIR showed 
substantially reduced binding to both the immobilized binding partners (the last lane in both 
Figure 2.3.29a and Figure 2.3.30a), while free GST showed minimal interaction with the 
His-tagged proteins (not shown). 
 
Figure 2.3.29: Binding Assay between GST-BIR and His-DOC Binding Partner 
a) Coomassie-stained SDS-polyacrylamide gel (12%) of the in vitro binding assay between GST-
BIR and His-DOC.  Lane 2 = ~0.5 μg free GST-BIR; lane 3 = ~0.5 μg free His-DOC; lanes 4-8 = 
0.5 μg immobilised His-DOC/0.2 – 1.0 μg GST-BIR; lane 9 = 0.5 μg immobilised His-DOC/0.5 μg 
denatured GST-BIR.  Ladder = human red cell membrane ladder.  ◄ GST-BIR: observed size =      
~44 kDa; His-DOC: observed size = ~50 kDa. 
b) Graphs showing the dose-dependent binding of GST-BIR to immobilised His-DOC, following 
densitometry of the SDS-polyacrylamide gel. 
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Figure 2.3.30: Binding Assay between GST-BIR and His-Rhop Binding Partner 
a) Coomassie-stained SDS-polyacrylamide gel (12%) of the in vitro binding assay between GST-
BIR and His-Rhop.  Lane 2 = ~0.5 μg free GST-BIR; lane 3 = ~0.5 μg free His-Rhop; lanes 4-8 = 
0.5 μg immobilised His-Rhop/0.25 – 1.5 μg GST-BIR; lane 9 = 0.5 μg immobilised His-Rhop/0.5 μg 
denatured GST-BIR.  Ladder = human red cell membrane ladder.  ◄ GST-BIR: observed size =      
~44 kDa; His-Rhop: observed size = ~30 kDa. 
b) Graphs showing the dose-dependent binding of GST-BIR to immobilised His-Rhop, following 
densitometry of the SDS-polyacrylamide gel. 
 
2.3.7 Episomal Expression of PfIAPbir-GFP 
2.3.7.1 Creation of the pARL2-GFP_PfIAPbir Vector 
Determining the localisation of the PfIAP protein in the P. falciparum parasite is an 
important step in the characterisation of the protein.  The 5’ region of the pfiap gene 
containing the BIR domain (Figure 2.3.31a) was amplified by PCR, without a STOP codon, 
as a single band of the expected size and prepared for ligation into the pARL2-GFP vector 
(Figure 2.3.31b). 
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Figure 2.3.31: The pARL2-GFP Plasmid and PfIAPbir PCR Amplicon 
a) Diagram showing the location of the region of the pfiap gene amplified by PCR for cloning into 
the pARL2-GFP vector.  Blue = the forward and reverse PCR primers; orange = BIR domain; purple 
= pfiap gene.  Numbers = nucleotide number. 
b) Agarose gel (1%) showing the AvrII/XhoI digested pARL2-GFP vector and PfIAPbir PCR 
amplicon prior to ligation.  ◄ = expected band size. 
 
After E. coli transformation, the pARL2-GFP_PfIAPbir construct was verified by colony 
PCR and restriction enzyme digestion.  PCR was performed using pARL2-GFP specific 
primers, which generate an amplicon larger than the initial cloned region, and resulted in a 
strong band around 600 bp (Figure 2.3.32a).  Digestion analysis of the new pARL2-
GFP_PfIAPbir vector, using EcoRI, showed two bands at the expected sizes (Figure 
2.3.32b).  DNA sequencing of the insert indicated that the PfIAPbir sequence was error-free 
and suitable for P. falciparum transfection. 
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Figure 2.3.32: Verification of the Insertion of PfIAPbir into the pARL2-GFP Vector. 
a) Agarose gel (1%) showing colony PCR of PfIAPbir after cloning into the pARL2-GFP vector.                 
◄ = expected band size. 
b) Agarose gel (1%) of the pARL2-GFP_IAPbir plasmid following cloning, after digestion with 
EcoRI.  ◄ = expected band size. 
c) Vector diagrams of the pARL2-GFP plasmid and the plasmid containing the PfIAPbir insert with 
AvrII/XhoI and EcoRI restriction sites.  Blue = inserted BIR domain. 
 
2.3.7.2 Generation of PfIAPbir-GFP P. falciparum Transgenic Parasites 
The pARL2-GFP_PfIAPbir construct (Figure 2.3.33) was used to transfect ring stage             
P. falciparum 3D7 parasites and transgenic parasites were detected 32 days after 
electroporation.  The GFP-tagged protein expressed in parasites containing the pARL2-
GFP_PfIAPbir plasmid will be referred to as PfIAPbir-GFP.  A control P. falciparum 
pARL2-GFP transgenic line was donated by Dr Belinda Bezuidenhout and only expressed 
the GFP protein. 
 
Figure 2.3.33: The pARL2-GFP_IAPbir Vector prior to Parasite Transfection 
Agarose gel (1%) showing the BamHI-linearized pARL2-GFP_PfIAPbir plasmid before parasite 
transfection.  ◄ = expected band size. 
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DNA was extracted from both the pARL2-GFP and pARL2-GFP_PfIAPbir transgenic 
parasites.  PCR analysis, using the pARL2-GFP specific primers, was used to verify the 
presence of the episomal vectors in each of the transgenic lines (Figure 2.3.34).  DNA was 
also extracted from wild type P. falciparum 3D7 parasites as a control, but as expected this 
did not produce a PCR amplicon (data not shown). 
 
Figure 2.3.34: PCR Verification of the PfIAPbir-GFP Parasite Line 
Agarose gel (1%) showing the presence of the pARL2-GFP_PfIAPbir plasmid by PCR using 
pARL2-GFP specific primers after parasite transfection.  ◄ = expected band size. 
 
2.3.7.3 Visualisation of Episomally Expressed PfIAPbir-GFP 
Fluorescent images of live P. falciparum 3D7 pARL2-GFP transgenic parasites only 
expressing the GFP protein were captured.  Across all three stages of the asexual life cycle 
the GFP protein was visible, as its expression was being driven by the crt promoter.  As 
expected, the GFP protein displayed a cytoplasmic localisation (Figure 2.3.35; VanWye and 
Haldar 1997).  Similarly, transgenic P. falciparum pARL2-PfIAPbir-GFP parasites 
expressed PfIAPbir-GFP in the cytoplasm of ring, trophozoite and schizont parasites, 
although the appearance of the signal was more punctate (Figure 2.3.36).  
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Figure 2.3.35: Fluorescence Microscopy Images of Live P. falciparum Transgenic Parasites 
Expressing the pARL2-GFP Protein 
Localisation of the GFP protein in asexual P. falciparum transgenic parasites.  Hoechst dye was used 
to stain ring stage nucleic acid, while DAPI was used to stain trophozoite and schizont nuclei. 
 
 
Figure 2.3.36: Fluorescence Microscopy Images of Live PfIAPbir-GFP P. falciparum 
Transgenic Parasites 
Localisation of the fluorescent PfIAPbir-GFP protein in asexual P. falciparum transgenic parasites.  
Hoechst dye and DAPI were used to stain ring stage and trophozoite/schizont nuclei respectively.  
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2.3.7.4 The Effect of Heat-Shock on the Localisation of PfIAPbir-GFP 
Febrile illness is the most recognisable symptom of malaria infection and has documented 
consequences for the malaria parasite, including differential gene expression and the 
induction of various RCD-like phenotypes (Oakley et al. 2007; Engelbrecht and Coetzer 
2013).  Synchronised ring and trophozoite transgenic parasite cultures were subjected to 
41°C for 2 hours in order to simulate the effects of RCD on the parasites (Engelbrecht and 
Coetzer 2013).  The localisation of both the GFP and PfIAPbir-GFP fluorescent proteins 
remained unchanged at various time points after heat-shock (Figure 2.3.37, Figure 2.3.38 
and Figure 2.3.39).  A large percentage of dead parasites (those lacking any intracellular 
movement) was observed 24 hours after heat-shock and those surviving parasites displayed 
retarded development as they remained in their initial life stage for at least 24 hours before 
progressing (as previously noted by Engelbrecht and Coetzer 2013). 
 
Figure 2.3.37: Fluorescence Microscopy Images of Heat-Shocked P. falciparum Transgenic 
Schizont Parasites Expressing the pARL2-GFP Protein 
Heat-shock (41°C, 2 hours) had no effect on the localisation of the GFP protein in live, asexual           
P. falciparum transgenic parasites.  DAPI was used to stain schizont nuclei. 
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Figure 2.3.38: Fluorescence Microscopy Images of Heat-Shocked PfIAPbir-GFP P. falciparum 
Transgenic Ring Stage Parasites 
The localisation of PfIAPbir-GFP in live, ring stage P. falciparum transgenic parasites after heat-
shock (41°C, 2 hours) was unchanged.  Hoechst dye was used to stain ring stage nucleic acid. 
 
 
Figure 2.3.39: Fluorescence Microscopy Images of Heat-Shocked PfIAPbir-GFP P. falciparum 
Transgenic Trophozoite Parasites 
Heat-shock (41°C, 2 hours) had no effect on the localisation of PfIAPbir-GFP in live, trophozoite 
stage P. falciparum transgenic parasites.  DAPI was used to stain late stage nuclei. 
 
2.4 Discussion 
In light of the growing P. falciparum drug resistance (Dondorp et al. 2017), there is a need 
to identify novel drug targets.  Characterising the ~50% hypothetical P. falciparum genes 
(Webster and McFadden 2014) is an important step in this process.  PF3D7_0519600 is 
currently annotated in PlasmoDB as a putative zinc finger protein, but in this study is referred 
to as a P. falciparum IAP protein, following the identification of an N-terminal BIR domain.  
Biopanning experiments with recombinant PfIAP regions and a newly created biotin-tagged, 
P. falciparum cDNA phage display library have resulted in the identification of six novel 
PfIAP binding partners. 
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2.4.1 Recombinant Expression of PfIAP and Other P. falciparum Proteins 
Five protein regions were expressed during the course of this study as recombinant proteins, 
using E. coli as the expression host.  A bacterial protein expression system is a common and 
convenient tool but is not without challenges, especially when trying to express                         
P. falciparum proteins.  This is primarily a consequence of the fact that E. coli is a 
prokaryotic organism, while P. falciparum is eukaryotic.  Differences between these two cell 
types include how proteins are synthesised: eukaryotic protein synthesis occurs in the 
cytoplasm, while protein synthesis in prokaryotes is initiated even before mRNA 
transcription is complete and is referred to as transcription–translation coupling 
(Gowrishankar and Harinarayanan 2004). 
 
Another hazard is codon bias that occurs when the frequency of specific codons in the 
foreign DNA is different to the codons normally used by the host organism.  The range of 
tRNAs available in a cell closely reflects the codon bias of its mRNA (Sahdev et al. 2007; 
Rosano and Ceccarelli 2014).  A consequence of this is that during synthesis of a 
recombinant protein these low-abundant tRNA become depleted, resulting in either the 
misincorporation of an amino acid or the truncation of the peptide (Rosano and Ceccarelli 
2014).  Three of the proteins expressed in this study (GST-BIR, His-DOC and His-Rhop) 
were purified as both whole and truncated proteins, something that is not uncommon when 
expressing P. falciparum proteins using an E. coli system (Flick et al. 2004; Mehlin et al. 
2006).  Some of the identified rare codons (Sahdev et al. 2007), particularly those coding for 
arginine and isoleucine, are present in these proteins.  As a way of limiting the effect of 
codon bias, Rosetta™ 2 (DE3) E. coli cells containing the pRARE plasmid were used for 
recombinant protein expression.  This plasmid provides tRNAs for the amino acids alanine 
(CUA), arginine (AGA, AGG and CGG), cysteine (CCC), glycine (GGA) and isoleucine 
(AUA).  Apart from codon bias, another contributing factor to protein truncation could be 
the fact that these P. falciparum proteins contain short stretches of the same amino acid 
(particularly lysine).  This repetition could cause the bacterial translation machinery to stall 
for a moment, resulting in the production of a truncated recombinant protein.  The predicted 
β-sandwich domain (PlasmoDB v34) consists of asparagine, glutamine and histidine amino 
acid repeats and was not expressed as a recombinant protein.  This series of amino acids 
repeats could create a situation where the supply of the required tRNAs is simply exhausted 
in the bacterial host, leading to the incomplete translation of the recombinant domain. 
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Plasmodium falciparum proteins often aggregate and form insoluble inclusion bodies (Flick 
et al. 2004).  All of the proteins expressed in the study had some level of protein detectable 
in the insoluble fraction, although GST-Middle was wholly insoluble.  The factors affecting 
the solubility of expressed proteins include the size of the protein and its pI, although these 
factors cannot be compiled into a rule that can be universally applied to all proteins (Mehlin 
et al. 2006).  For example, although proteins with a pI between 6 and 8 are favoured for 
protein expression (Mehlin et al. 2006), GST-Middle has a pI of 6.33 and was the only 
insoluble protein in this study, while the other proteins all had pI values outside of the given 
range.  The predicted 48 kDa size of GST-Middle was between that of the other two soluble 
GST-tagged proteins, inferring that perhaps there is something else about this protein that 
resulted in it expressing as an insoluble protein.  An easy to employ technique that often 
improves the solubility of expressed proteins is to grow the bacterial cells at a lower 
temperature.  The hydrophobic interactions involved in inclusion body formation are 
temperature dependent and so a low temperature helps with the correct folding and increased 
stability of the protein (Sahdev et al. 2007).  In this study, all protein expression cultures 
were incubated at room temperature, but it did not aid in the expression of soluble GST-
Middle protein.  Other approaches that can result in improved protein solubility include the 
use of different affinity tags (haemagglutinin (HA), maltose binding protein, thioredoxin 
etc.) or a different expression system, such as the yeast S. cerevisiae or insect cells (Birkholtz 
et al. 2008).  Since the Middle region does not contain a recognisable domain, no further 
experiments were conducted with this protein. 
 
For three of the four purified proteins in this study (GST-Terminal, His-DOC and His-Rhop), 
the expected molecular weights of the proteins were different to the molecular weights 
calculated from the SDS-polyacrylamide gels.  This can be attributed to the regions of low 
complexity present in these recombinant proteins.  Low complexity regions are characterised 
by one or a few amino acid repeat sequences and are present in more than 90% of                      
P. falciparum proteins, including highly conserved housekeeping genes (Pizzi and Frontali 
2001; Aravind et al. 2003).  As a consequence of their unusual amino acid composition, 
intrinsically unstructured proteins bind less SDS than would be expected and so they migrate 
slower through the SDS-polyacrylamide gel, resulting in apparent molecular weights up to 
1.8 times higher than calculated (Tompa 2003).  The observed molecular weights of the three 
affected recombinant proteins in this study were 1.1-1.4 times higher than their calculated 
molecular weights.  These unstructured soluble low complexity regions tend to be located 
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on the external surface of the folded protein and do not appear to interfere with the 
functioning of the rest of the protein (Aravind et al. 2003). Although no function has been 
assigned to low complexity regions, it is thought that they may be involved in antigen 
diversification (Ferreira et al. 2003; Cortes et al. 2005) or used as a means of eliciting an 
ineffective immune response (Anders 1986). 
 
2.4.2 The Pros and Cons of Using a Phage Display Library 
Most cellular proteins interact with other proteins, forming networks that facilitate the 
functioning of a cell (Berggård et al. 2007).  From amongst the protein techniques available 
to detect these PPIs, this study utilised a newly constructed phage display library to identify 
novel binding partners for the BIR-containing PfIAP.  Phage display libraries are easy to 
use, allow for the simultaneous expression of many different peptides and can be applied to 
a diverse range of targets (Lanzillotti and Coetzer 2008).  Plasmodium falciparum phage 
display libraries were first successfully created in the Coetzer laboratory (Lauterbach et al. 
2003) and used to identify P. falciparum interactions with the erythrocyte proteins spectrin 
and protein 4.1 (Lauterbach et al. 2003; Lanzillotti and Coetzer 2004). 
 
The binding partners that are identified do not necessarily represent all of the bait protein’s 
PPIs.  Although the cDNA library created in this study was sourced from mixed stage, 
asexual P. falciparum cultures, the mRNA that was extracted may not represent all of the 
proteins that are expressed by the parasite during this life stage.  During early and late 
trophozoite development the parasite synthesises many new proteins, leading to a drastic 
increase in the amount of mRNA present.  The parasite cultures used in this study were 
biased towards late stage parasites as this helped facilitate the isolation of a sufficient amount 
of mRNA.  Taken together, these factors mean that ring stage specific mRNA is likely to be 
present at a lower concentration then trophozoite mRNA and therefore could be under 
represented.  Even at each discreet time point of the P. falciparum life cycle, some mRNAs 
are only transcribed at a low copy number and so they could easily be lost amongst the more 
abundant transcripts.  Plasmodium parasites undergo many phenotypic changes during their 
life cycle, each of which is brought about by a different transcriptome.  A phage display 
library constructed from only asexual P. falciparum parasites will inherently not be able to 
facilitate the identification of PPIs from other points of the parasite’s development, such as 
the sexual gametocytes and mosquito stages.  Therefore it is important to remember that the 
protein network constructed as part of this study is not the complete PfIAP interactome. 
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The oligo (dT)25 beads that were used to isolate the parasite mRNA, rely on the 3’ poly(A) 
tail of the mRNA.  The complication that arises is that the P. falciparum genome is very AT-
rich (~80%; Gardner et al. 2002) so any noncoding or ribosomal sequences that contain a 
series of adenosine repeats would also be isolated.  The consequence of this Plasmodium 
quirk is the unfortunate presentation of short peptides that would not normally be present    
in vivo but that could still bind to the bait PfIAP protein (Lanzillotti and Coetzer 2008).  In 
this study, bacteriophage expressing short sequences of unnatural lysine amino acids (codons 
AAA and AAG) were frequently detected.   
 
A different consideration when using phage display libraries is the bait which is used during 
the biopanning experiments.  A potential consequence of using a recombinant protein, 
expressed in bacterial cells, is that the protein may not have folded correctly (Sahdev et al. 
2007), which could hamper the protein-binding ability of the bait.  Since the natural 
conformation of the PfIAP protein is unknown, it was not possible to verify that the 
recombinant domains were correctly folded.  A related issue is that peptides that are 
expressed on the surface of the bacteriophage may not be presented in their native 
conformation.  This study investigated two regions of PfIAP, which were expressed as two 
separate recombinant proteins.  While there is no reason that these individual regions would 
not interact with other proteins, particularly the BIR domain, it is also feasible that the whole 
protein may be required for certain protein interactions.  Unfortunately it was not practical 
to express the whole PfIAP protein in this study, nor was it possible to use natively expressed 
PfIAP protein, isolated from P. falciparum parasites, due to the lack of PfIAP-specific 
antibodies required for protein isolation. 
 
The actual biopanning procedure itself also requires some thought.  The immobilisation of 
the recombinant PfIAP regions on magnetic beads, or the actual GST tag itself, could 
physically hinder binding of the phage peptides to the bait protein.  The bacteriophage could 
also bind the GST tag, although this concern is diminished by the fact that the library 
underwent initial pre-screening using only the GST protein.  The stringency of the wash 
steps following bait/phage library binding could inadvertently dislodge binding partners that 
form weak or transient connections.  Between each successive round of biopanning, the 
bound bacteriophage are amplified.  This provides opportunity for some phage (practically 
those with smaller inserts) to replicate at a faster rate than others, and so be in a position to 
outcompete them during the next round of biopanning (Ansuini et al. 2002).  This event was 
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observed during this study.  Of the bacteriophage plaques that were amplified by PCR, the 
number of amplicons that were >400 bp in size were vastly outnumbered by the amplicons 
of ~300 bp (each of which codes for a peptide about 20 amino acids in length).  Since 
biopanning experiments are performed in vitro, peptides that would not normally bind to the 
bait protein in vivo now have the opportunity to interact, which can lead to false positives. 
 
The validity of any newly identified binding partner needs to be confirmed using another 
biological technique.  This study made use of an in vitro binding assay as its means of 
binding partner validation, although other techniques such as surface plasmon resonance 
may be used (Berggård et al. 2007).  Heat denatured GST-BIR and free GST protein were 
employed as controls during the in vitro binding assays.  The dose-dependent interactions 
that reached saturation between GST-BIR and the immobilised binding partner proteins were 
truly as a result of the increasing amounts of GST-BIR that were applied, since the  
recombinant GST and the heat-denatured BIR proteins showed only minimal and 
substantially reduced binding respectively. 
 
2.4.3 The PfIAP BIR Domain Localises to the Cytoplasm 
Expressing a protein of interest with a fluorescent tag from an episomal plasmid construct is 
a useful method for determining the subcellular localisation of the protein within a cell.  In 
this study the N-terminal region of the PfIAP protein, containing the BIR domain, was 
expressed with a GFP tag in live, transgenic P. falciparum parasites.  PfIAPbir-GFP was 
observed to have a cytoplasmic pattern that was dispersed throughout the parasite during all 
three stages of asexual development.  The pARL2-GFP vector uses the crt promoter to drive 
the expression of the GFP-tagged protein, therefore the persistent expression of PfIAPbir-
GFP is not unexpected.  Given that pfiap mRNA is detected during many stages of the 
parasite’s life cycle, prominently during the ring and trophozoite stages (Figure 2.4.1a), and 
that the PfIAP protein is detected throughout the asexual life cycle (Figure 2.4.1b), the use 
of an episomal plasmid with the crt promotor that allows for ubiquitous protein expression 
was appropriate. 
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Figure 2.4.1: PfIAP mRNA and Protein Expression Levels (PlasmoDB) 
Adapted from PlasmoDB (Aurrecoechea et al. 2009). 
a) RNA was collected from synchronised P. falciparum parasites at seven different life stages           
(x-axis) and sequenced (López-Barragán et al. 2011).  Transcript levels are indicated as fragments 
per kilo-base of exon model per million mapped reads (FPKM; y-axis). 
b) Protein was harvested from synchronised P. falciparum parasites at three asexual life stages          
(x-axis) and quantified (Pease et al. 2013).  Protein abundance percentile values (y-axis). 
 
The various human anti-apoptotic, BIR-containing proteins have been shown to localise to 
a range of cellular components.  cIAP1 (BIRC2) is a nuclear protein, while cIAP2 (BIRC3) 
is both cytoplasmic and nuclear (Samuel et al. 2005).  The mitochondrial and cytoplasmic 
fractions of survivin (BIRC5) are thought to function as an apoptotic suppressor, while the 
nuclear pool of the protein is believed to regulate cell division (Garg et al. 2016).  Full length 
livin (BIRC7) is exclusively found in the cytoplasm (Nachmias et al. 2007), as is the 
prominent anti-apoptotic XIAP (BIRC4; Liston et al. 2001).  PlasmoDB (Aurrecoechea et 
al. 2009) indicates that the cellular compartment of PfIAP is the nucleus, therefore the 
observed cytoplasmic pattern of PfIAPbir-GFP may not be representative of the true 
subcellular localisation of the PfIAP protein.  Numerous attempts were made to clone the 
whole pfiap gene into the pARL2-GFP vector, but none of the expected banding patterns 
were observed after restriction enzyme digestion. 
 
It should be possible through single-crossover homologous recombination to insert a GFP 
coding sequence at the 3’ end of the iap gene, allowing for the endogenous expression of 
GFP-tagged, full-length PfIAP protein.  This will allow for the monitoring of the 
spatiotemporal expression of the whole PfIAP protein, either by direct fluorescence or 
through immunofluorescence assays (using an anti-GFP antibody).  A GFP-tagged PfIAP 
would also allow for co-immunoprecipitation to be performed in live transgenic parasite 
cultures, followed by mass spectrometry, which would provide another method of 
identifying PfIAP binding partners.  Co-localisation and co-immunoprecipitation studies 
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could also be performed on wild type parasites using anti-PfIAP antibodies, generated in 
mice or rabbits by immunisation with the recombinant PfIAP proteins. 
 
PfIAPbir is a truncated form of the whole protein and could therefore be missing a trafficking 
motif that is necessary for the correct localisation of the protein.  An example of this is 
provided by the cytoplasmic XIAP, which mainly localised in the nucleus when the                
C-terminal RING domain was removed (Cao et al. 2014).  The nuclear localisation of cIAP1 
on the other hand is dependent on its BIR domains (Samuel et al. 2005), while caspase-
mediated cleavage of the cytoplasmic livin results in translocation of the truncated protein 
to the Golgi apparatus (Nachmias et al. 2007). 
 
2.4.4 Heat Shock Does Not Affect the Localisation of PfIAPbir 
The activation of RCD is a stressful event and results in biochemical changes within a cell.  
In human cells, the use of cytotoxic drugs to induce apoptosis results in the redistribution of 
XIAP from the cytoplasm into nuclear inclusions (Nowak et al. 2004).  Also the nuclear 
XIAP-associated factor 1 binds to and inhibits XIAP by sequestering it in the nucleus, 
allowing apoptosis to proceed (Liston et al. 2001).  RCD in P. falciparum caused the 
temporary translocation of PfSWIB from the cytoplasm to the nucleus, before the protein 
returned to the cytoplasm (Vieira and Coetzer 2016).  In the current study RCD was 
stimulated by incubating parasites at 41°C for 2 hours, mimicking the high temperatures 
associated with febrile malaria illness (Engelbrecht and Coetzer 2013).  The cytoplasmic 
localisation of PfIAPbir-GFP remained unchanged at various time points after heat-shock, 
irrespective of whether ring or trophozoite stage parasites had been exposed to heat-shock.  
This could be because the truncated protein lacks the signal sequence necessary for it to 
respond to heat stress, or it could be that the cytoplasmic localisation of the PfIAP BIR 
domain is already where the domain is required to be upon RCD activation.  
 
2.4.5 Plasmodium IAP Proteins are Similar but PfIAP has Distinctive 
Structural Features 
Each of the Plasmodium IAP proteins contain one BIR domain, which all follow the same 
general amino acid sequence, and a C-terminal end that is conserved across the Plasmodium 
genus.  When compared to the human BIRC family of proteins, possessing one BIR domain 
is not uncommon, although some of the human IAP proteins contain three domains.  None 
of the Plasmodium IAP proteins contain any of the recognisable C-terminal domains (RING 
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or UBC domains for example) that are associated with metazoan IAP proteins.  This means 
that the Plasmodium IAPs cannot be classed as ubiquitin ligases, unlike some of the human 
IAP proteins (Feltham et al. 2012) and so makes it unlikely that PfIAP would be able to 
ubiquitinate other proteins without the help of an interacting partner. 
 
PfIAP is the only Plasmodium species that contains what has been identified as a β-sandwich 
domain (Aurrecoechea et al. 2009), which is not present in any of the human BIRC proteins.  
These domains are common in proteins and have the characteristic structure of two opposing 
antiparallel β-sheets (Kister et al. 2006).  The refined location of this β-sandwich domain 
(PlasmoDB v34) corresponds to a 62 residue, low complexity region of repeating amino 
acids: NQNQ(NQHQ)56NQ (H = histidine; N = asparagine; Q = glutamine).  Structural 
predictions of this β-sandwich region failed to produce any meaningful results (data not 
shown), which is not unexpected as low complexity regions are regarded as unstructured 
(Aravind et al. 2003).  This implies that the identification of this region by PlasmoDB as a 
β-sandwich domain using the Hidden Markov Model SUPERFAMILY library (Gough et al. 
2001) may not be correct.  This low complexity region is unique to P. falciparum and is not 
even present in the primate P. reichenowi IAP orthologue, which is by far the most similar 
(89.4%) of all the Plasmodium PfIAP orthologues.  Why such a stretch of amino acids would 
be present in the P. falciparum protein is uncertain given the conserved nature of the rest of 
this gene throughout the Plasmodium genus.  It could be required as a binding motif or 
structural component of the PfIAP protein for some function that none of the other 
Plasmodium IAP proteins participate in, perhaps something related to P. falciparum RCD.  
Or this stretch of amino acids could act as a decoy against the host’s immune system (Anders 
1986), reflecting the importance of the PfIAP protein when compared to the other 
Plasmodium species. 
 
2.4.6 The Plasmodium iap Gene is Unique amongst Apicomplexa, Limiting 
what can be Suggested about the Protein 
The iap gene was not identified in other members of the Apicomplexa phylum or the wider 
protozoan group of unicellular eukaryotic organisms.  Protozoa like Leishmania or 
Trypanosoma experience cell death (Proto et al. 2012), but a BLAST search was unable to 
identify any BIR-containing proteins within these genomes.  This implies that either these 
organisms undergo RCD in a way that does not need the participation of an IAP protein or 
the Plasmodium BIRC proteins have been adapted to the parasite’s life cycle in its vertebrate 
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and non-vertebrate hosts.  Alternatively the Plasmodium IAP proteins may have a role in the 
parasite that is not related to RCD (whether solely or in addition to its RCD function) and so 
is needed by all Plasmodium species during the course of normal cellular functioning.  Such 
an uncharacteristic role is not unprecedented.  There are numerous examples of human 
proteins (including IAP proteins) that are involved in regulating RCD, but also have non-
apoptotic functions (Galluzzi et al. 2012).  This introduces the question about the 
evolutionary origin of the BIR domain as it is present in metazoans where RCD is a hallmark 
of multi-cellularity, but not in the unicellular organisms that are more closely related to 
Plasmodium.  Did Plasmodium acquire the iap gene from its human host or was the gene 
present in the last common ancestor of the Apicomplexa and the other protozoa simply lost 
the gene as there was no selective pressure to keep a protein that was not being used? 
 
2.4.7 Why is iap Present in Numerous Plasmodium Species? 
It is currently unclear why all five of the human Plasmodium species, one species infecting 
primates and three species infecting rodents possess the proposed anti-apoptotic IAP protein 
given the intraerythrocytic differences between the species, which means that each species 
experiences a different population density pressure and need for RCD.  Plasmodium 
falciparum sexual gametocytes mature over the course of 10-12 days (Meibalan and Marti 
2017), while asexual reproduction involves a merozoite invading an erythrocyte and 
developing for 48 hours, before releasing up to 32 merozoites to repeat the cycle (Josling 
and Llinás 2015).  A consequence of this exponential asexual reproduction is likely the 
premature death of the human host before the sexual gametocytes have had enough time to 
develop and so the use of RCD by P. falciparum to control its population number makes 
sense. 
 
For the other Plasmodium species infecting humans the population pressures during the 
intraerythrocytic stages are not as severe and sexual development is much quicker than for 
P. falciparum, so the need for RCD is less clear.  Plasmodium malariae parasites produce 
fewer merozoites per cycle and require 72 hours for asexual development so the parasitaemia 
experienced by patients is usually lower than that of P. falciparum infections (Collins and 
Jeffery 2007; Kerlin and Gatton 2013).  Plasmodium vivax and P. ovale both only invade 
immature red blood cells, reticulocytes, which is the likely reason why these infections are 
characterised by low parasitaemia and low pathogenicity, as compared to P. falciparum.  The 
asexual cycles of P. vivax and P. ovale both take about two days to complete with fewer than 
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20 merozoites being released per schizont and only 48-49 hours are required for gametocyte 
development (McKenzie et al. 2002; Collins and Jeffery 2005).  Although the red blood cell 
preference of P. knowlesi is currently unknown (Kerlin and Gatton 2013), the release of up 
to 16 merozoites every 24 hours (the shortest asexual cycle of any human and non-human 
primate species) means that there is the potential for a very rapid increase in parasitaemia to 
the detriment of the infected human, but this is offset by the short time period of 48-49 hours 
needed for gametocytes to develop (Collins 2012).  The rodent P. berghei and P. yoelii 
parasites, with asexual cycles of less than one day, produce gametocytes in the very short 
time of 24-27 hours (Meibalan and Marti 2017). 
 
Available transcriptomic data (Figure 2.4.2) show that the P. berghei and P. vivax IAP 
orthologues have very similar expression profiles to PfIAP (with peak expression during the 
trophozoite stage).  Despite this, it is evident that the differences in the intraerythrocytic 
parasite stages between the various Plasmodium species means that each Plasmodium 
species experiences a different population pressure and has different RCD requirements, yet 
all of the Plasmodium species possess the iap gene.  The invertebrate Plasmodium life stage 
involves the development of ookinetes and their transformation into oocysts in the mosquito 
vector.   It is during this ookinete stage that apoptosis-like cell death has been detected in 
both P. berghei and P. falciparum (Al-Olayan et al. 2002; Arambage et al. 2009; Ali et al. 
2010).  Available data show that both P. berghei and P. falciparum iap mRNA is detected 
during this time.  The existence of the conserved IAP protein across the Plasmodium genus 
could be because, irrespective of their individual needs for intraerythrocytic RCD, IAP is 
required by all the Plasmodium species for RCD during the mosquito stage, or the protein 
might play another unrelated role in the parasite. 
 
Figure 2.4.2: mRNA Expression Levels of Plasmodium IAP Orthologues (PlasmoDB) 
Adapted from PlasmoDB (Aurrecoechea et al. 2009).  RNA was collected from Plasmodium 
parasites at different time points (x-axis) and sequenced.  Transcript levels are indicated as fragments 
per kilo-base of exon model per million mapped reads (FPKM; y-axis). 
a) P. berghei IAP orthologue (PBANKA_1234400; Otto et al. 2014).   
b) P. vivax IAP orthologue (PVX_080265; Zhu et al. 2016). 
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2.4.8 Could PfIAP Perform the Same Functions as the Human IAP Proteins?  
Each of the Plasmodium IAP proteins is currently annotated in PlasmoDB as putative zinc 
finger (ZF) proteins.  In eukaryotic genomes, ZFs are amongst the largest transcription factor 
families but in addition to their DNA binding roles, zinc fingers have been shown to 
participate in protein assembly, lipid binding, RNA packaging and the regulation of 
apoptosis (Laity et al. 2001).  Human BIR motifs use the CCHC (C = cysteine; H = histidine) 
motif to coordinate zinc and structurally resemble the classical C2H2 zinc finger (Laity et al. 
2001).  Although the conserved  CX2CX23HX3C (X = any amino acid) pattern of the 
Plasmodium BIR domains is slightly longer than the sequence attributed to human BIR 
domains (CX2CX16HX6C), the predicted Plasmodium BIR domain structure is in keeping 
with the known structures of the various human BIR domains.  Visualising the conserved 
zinc-chelating residues in the PfIAP 3D models, makes it possible to locate the important 
hydrophobic pocket in this Plasmodium domain (see Figure 2.3.6). 
 
Given the structural similarities between the human and P. falciparum BIR domains, it is 
possible that this domain is involved in biological functions analogous to those performed 
by the human BIR domains – perhaps inhibiting the caspase-like metacaspase proteins 
present in P. falciparum  (Meslin et al. 2007; no caspases are present in Plasmodium).  
However, the following examples show that the various human IAP proteins also have non-
apoptotic roles and are involved in other cellular processes.  The BIR3 domain of XIAP can 
promote cellular copper retention by binding COMMD1 (copper metabolism gene MURR1 
domain containing 1), a protein involved in copper efflux to ensure proper homeostasis, 
triggering its ubiquitination and degradation.  XIAP is also able to bind free copper itself, 
resulting in a conformational change in the protein that alters its ability to successfully inhibit 
caspase-3, an effector caspase (Burstein et al. 2004; Mufti et al. 2007).  In addition to anti-
apoptotic functions, survivin is known to play an essential role in cell division by forming a 
chromosomal passenger complex with other proteins, mediated through its BIR domain 
(Kelly et al. 2010; Wang et al. 2010; Yamagishi et al. 2010).  Although NAIP has been 
shown to attenuate apoptosis, its main role is emerging to be in the regulation of innate 
immune signalling (Finlay et al. 2017).  Likewise, the cIAP1 and cIAP2 proteins are 
important constituents of the tumor necrosis factor receptor pathway and play a role in NF-
κB signalling (Kocab and Duckett 2016).   
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Given the various functions each of the human IAP homologues can perform, and the fact 
that some of these roles are not directly transferrable from the human system to that of the 
Plasmodium parasite, the function of the PfIAP protein cannot be inferred from its structure 
alone.  
 
2.4.9 Building a PfIAP Protein-Protein Network to Potentially Ascertain its 
Function 
Using the results of the biopanning experiments in this study it is possible to create a protein-
protein network centred on PfIAP.  This is likely to only be a partial protein network, since 
the phage display library used is not representative of the full P. falciparum transcriptome 
(see 2.4.2).  Previous high throughput yeast two-hybrid experiments failed to identify any 
binding partners for PfIAP (LaCount et al. 2005). 
 
2.4.9.1 Binding Partners of the PfIAP BIR Domain 
In the current study the PfIAP BIR region bound four P. falciparum proteins (Figure 2.4.3). 
 
Figure 2.4.3: Primary PfIAP BIR Domain Protein Network 
Diagram showing the PfIAP BIR domain interactions as determined by biopanning in this study.  
Numbers = PlasmoDB gene identifiers.  Colours = Gene Ontology biological process available on 
PlasmoDB (Ashburner et al. 2000; Aurrecoechea et al. 2009).  Detailed protein information can be 
found in APPENDIX D. 
 
The LisH Protein.  The phage peptide that bound GST-BIR is located in the middle of 
PF3D7_1303400 which has one N-terminal LisH motif and no other identified domains.  
The eukaryotic LisH motif plays a role in regulating transcription (Wei et al. 2003).  
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Bioinformatic analysis has identified 114 intracellular eukaryotic proteins that contain this 
domain, with many of these proteins also possessing other, unrelated C-terminal domains 
(Emes 2001).  This group of proteins has many functions, including being involved in 
protein-protein interactions (Gerlitz et al. 2005; Mikolajka et al. 2006).  Bioinformatics 
strongly predicts that PfLisH localises to the P. falciparum nucleus (Vieira and Coetzer 
2016), which correlates with a role in transcription.  Through phage display and binding 
studies PfLisH has been verified as a binding partner of PfMDM2, although the biological 
function of this interaction is uncertain as PfMDM2 localises to the P. falciparum 
mitochondria (Vieira and Coetzer 2016).  The mRNA and protein expression profiles of 
PfIAP and PfLisH are similar (Figure 2.4.1 and Figure 2.4.4), with mRNA being detected 
for both proteins during asexual, gametocyte and ookinete life stages.   Both PfIAP and 
PfLisH are more prevalent during the ring and trophozoite stages, but are still present during 
the schizont life stage.  If PfLisH has a similar regulatory role as it eukaryotic counterparts, 
its interaction with PfIAP is feasible, given that both proteins are predicted to localise to the 
nucleus.  This could provide a mechanism by which PfIAP can influence the expression of 
other proteins, either by up- or down-regulating proteins involved in RCD or perhaps 
proteins involved in other cellular processes that are unknown at this time. 
 
Figure 2.4.4: PfLisH mRNA and Protein Expression Levels (PlasmoDB) 
Adapted from PlasmoDB (Aurrecoechea et al. 2009). 
a) RNA was collected from synchronised P. falciparum parasites at seven different life stages           
(x-axis) and sequenced (López-Barragán et al. 2011).  Transcript levels are indicated as fragments 
per kilo-base of exon model per million mapped reads (FPKM; y-axis). 
b) Protein was harvested from synchronised P. falciparum parasites at three asexual life stages          
(x-axis) and quantified (Pease et al. 2013).  Protein abundance percentile values (y-axis). 
 
The Protein Synthesis Component.  PfL24 (PF3D7_1309100) is only mentioned in the 
literature with respect to the P. falciparum 80S ribosome, where it is a constituent of the 
Pf60S subunit (Wong et al. 2014).  This protein is located in the cytoplasm and is present 
throughout the P. falciparum asexual life cycle (Figure 2.4.5), particularly during the ring 
and trophozoite stages.  This makes sense as it is during these life stages that the parasite is 
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growing rapidly and requires the synthesis of many proteins.  While there is currently no 
indication that PfIAP is directly involved in protein synthesis, PfIAP could be present with 
PfL24 as part of a larger protein complex, one that perhaps controls which/when proteins are 
synthesised.  The interaction of the cytoplasmic PfL24 with the nuclear PfIAP might be 
inconsistent, but the PlasmoDB prediction is based on the fact that this protein is currently 
listed as a zinc finger protein.  While these types of proteins, which includes the IAP family, 
can be nuclear proteins, many of them do have additional roles outside of the nucleus (Laity 
et al. 2001).  As noted previously (see 2.4.3), the human BIRC proteins are distributed to 
various locations throughout the cell and as such PfIAP may localise to more than one area 
of the parasite or may translocate to the cytoplasm under stress conditions. 
 
Figure 2.4.5: PfL24 mRNA and Protein Expression Levels (PlasmoDB) 
Adapted from PlasmoDB (Aurrecoechea et al. 2009). 
a) RNA was collected from synchronised P. falciparum parasites at seven different life stages           
(x-axis) and sequenced (López-Barragán et al. 2011).  Transcript levels are indicated as fragments 
per kilo-base of exon model per million mapped reads (FPKM; y-axis). 
b) Protein was harvested from synchronised P. falciparum parasites at three asexual life stages          
(x-axis) and quantified (Pease et al. 2013).  Protein abundance percentile values (y-axis). 
 
The Invasion Conspirators - PfDOC2 and PfRhopH3.  The Ca2+-triggered release of cellular 
components (such as neurotransmitters) is regulated by a range of different proteins, 
including those with double calcium lipid-binding domains, DOC2 proteins (Friedrich et al. 
2010).  Egress of merozoites from erythrocytes and the subsequent release of invasion 
proteins are important P. falciparum exocytotic events.  PfDOC2 (PF3D7_1243900) has two 
calcium binding sites and is conserved across the Apicomplexa phylum (Farrell et al. 2012).  
Only when this protein is associated with membranous structures will calcium bind to it, 
which is consistent with other double C2 domains (Jean et al. 2014).  PfDOC2 displayed a 
punctate staining pattern throughout the cytoplasm in schizont stage parasites (Jean et al. 
2014).  Conditional knockdown of the PfDOC2 protein had no effect on the asexual 
development or egress of the parasite, but did negatively affect RBC invasion as a 
consequence of incomplete microneme discharge (Farrell et al. 2012).  This adds to a body 
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of evidence showing that, although both merozoite egress and the release of invasion 
proteins from the micronemes are calcium-dependent processes, they utilise different 
mechanisms (Soni et al. 2017).  The PfDOC2 protein has been detected at the same level in 
all three asexual life stages (Jean et al. 2014).  While PfDOC2 is involved in red blood cell 
invasion, it could have other cellular functions and as such could have the opportunity to 
interact with PfIAP.  
 
PfRhopH3 (PF3D7_0905400) plays a role in both erythrocyte invasion and parasite growth 
and is part of the high molecular weight, multi-protein RhopH complex (Cooper et al. 1988).  
It is released from the rhoptry during erythrocyte invasion and contributes to merozoite 
invasion either through interaction with red blood cell receptors (such as the anion exchanger 
band 3; Baldwin et al. 2014) and/or by helping with parasite internalization (Ito et al. 2017).  
Following invasion, the multi-protein PfRhopH complex is introduced into the 
parasitophorous vacuole and then possibly uses the Plasmodium translocon of exported 
proteins (PTEX) complex to move to the erythrocyte cytosol.  From here the complex is 
inserted into the RBC membrane where it is involved in the formation of the plasmodial 
surface anion channel (PSAC; Ito et al. 2017), which is an ion and nutrient channel in the 
host cell membrane and is part of the new permeability pathways that are created following 
merozoite invasion.  The single copy pfrhoph3 gene is essential for P. falciparum survival 
(Ito et al. 2017) and conditional truncation of PfRhopH3 results in parasites with a reduced 
invasive capacity and altered growth as a consequence of defective nutrient import (Sherling 
et al. 2017).  pfrhoph3 mRNA is prominent during the late trophozoite and schizont life 
stages (Figure 2.4.6a) which correlates with its role in invasion, but the PfRhopH3 protein 
is present throughout the asexual stages (Figure 2.4.6b), in line with the protein being present 
in the PSAC.  It is unlikely that PfIAP would interact with PfRhopH3 while the protein is 
being stored in the rhoptry, but PfIAP could interact with PfRhopH3 after invasion, before 
it is exported out of the parasite to the host cell membrane.  The other members of the RhopH 
complex are the multi-gene family PfRhopH1/Clag (PfCLAG2, 3.1, 3.2, 8 and 9) and the 
single gene pfrhoph2.  When PfCLAG3 is knocked out, growth defects consistent with poor 
nutrient uptake are observed (Comeaux et al. 2011), which is expected since PfCLAG3 has 
been implicated with the PSAC (Nguitragool et al. 2011).  PfRhopH2 is also involved in 
PSAC formation, is essential for P. falciparum survival (Ito et al. 2017) and alters parasite 
growth if its expression is knocked down using a glmS riboswitch (Counihan et al. 2017). 
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Figure 2.4.6: PfRhopH3 mRNA and Protein Expression Levels (PlasmoDB) 
Adapted from PlasmoDB (Aurrecoechea et al. 2009). 
a) RNA was collected from synchronised P. falciparum parasites at seven different life stages           
(x-axis) and sequenced (López-Barragán et al. 2011).  Transcript levels are indicated as fragments 
per kilo-base of exon model per million mapped reads (FPKM; y-axis). 
b) Protein was harvested from synchronised P. falciparum parasites at three asexual life stages          
(x-axis) and quantified (Pease et al. 2013).  Protein abundance percentile values (y-axis). 
 
2.4.9.2 The C-Terminal Binding Partners of PfIAP 
The recombinant Terminal region of PfIAP bound two P. falciparum proteins (Figure 2.4.7). 
 
 
Figure 2.4.7: Primary PfIAP C-Terminal Protein Network 
Diagram showing the C-terminal PfIAP interactions as determined by biopanning in this study.  
Numbers = PlasmoDB gene identifiers.  Colours = Gene Ontology biological process available on 
PlasmoDB (Ashburner et al. 2000; Aurrecoechea et al. 2009).  Detailed protein information can be 
found in APPENDIX D. 
 
The Transcription Participant.  One of the proteins that bound to the Terminal region of 
PfIAP is the P. falciparum chromodomain-helicase-DNA-binding protein 1 
(PF3D7_1023900).  A common role of the human CHD proteins is in ATP-dependent 
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chromatin remodelling (Hall and Georgel 2007).  Human CHD1 in particular is involved in 
transcriptional repression and RNA splicing (Tai et al. 2003), keeping the double-stranded 
DNA helix open and transcriptionally active, and is critical to the pluripotency of embryonic 
stem cells (Gaspar-Maia et al. 2009).  Experimental evidence showed that P. falciparum 
CHD1 is found in the parasite nucleus (Volz et al. 2010) and its expression profiles show 
that the most protein is present during the trophozoite life stage (Figure 2.4.8), which is 
understandable as this is when the P. falciparum parasite is undergoing rapid growth that 
requires transcription and synthesis of new proteins.  As with the PfLisH protein, the 
interaction of PfIAP with a protein that is likely to be involved in transcription means that 
PfIAP may be able to use this interaction to influence the expression of other proteins, 
possibly ones involved in parasite RCD. 
 
Figure 2.4.8: PfCHD1 mRNA and Protein Expression Levels (PlasmoDB) 
Adapted from PlasmoDB (Aurrecoechea et al. 2009). 
a) RNA was collected from synchronised P. falciparum parasites at seven different life stages           
(x-axis) and sequenced (López-Barragán et al. 2011).  Transcript levels are indicated as fragments 
per kilo-base of exon model per million mapped reads (FPKM; y-axis). 
b) Protein was harvested from synchronised P. falciparum parasites at three asexual life stages          
(x-axis) and quantified (Pease et al. 2013).  Protein abundance percentile values (y-axis). 
 
The Red Cell Membrane Connection.  The P. falciparum mature parasite-infected 
erythrocyte surface antigen (PfMESA; PF3D7_0500800) is the first P. falciparum protein to 
have its cytoskeleton-binding partner identified (Lustigman et al. 1990).  MESA interacts 
with the N-terminal 30 kDa domain of the phosphorylated form of protein 4.1, competing 
with the cellular protein p55 (Waller et al. 2003).  This interaction occurs adjacent to the 
PEXEL/HT motif, which is how PfMESA is exported to the RBC cytosol (Black et al. 2008).  
This protein is expressed during the intraerythrocytic trophozoite stage (Figure 2.4.2) and 
colocalises with the knobs that develop on the erythrocyte surface, but is not required for the 
formation of these knobs nor is it involved in their associated cytoadherence (Petersen et al. 
1989).  There is no indication that PfIAP travels to the host cell membrane, therefore PfIAP 
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would have to interact with PfMESA prior to its export from the parasite, although it is 
currently unclear what function PfIAP would perform binding to PfMESA. 
 
Figure 2.4.9: PfMESA mRNA and Protein Expression Levels (PlasmoDB) 
Adapted from PlasmoDB (Aurrecoechea et al. 2009). 
a) RNA was collected from synchronised P. falciparum parasites at seven different life stages           
(x-axis) and sequenced (López-Barragán et al. 2011).  Transcript levels are indicated as fragments 
per kilo-base of exon model per million mapped reads (FPKM; y-axis). 
b) Protein was harvested from synchronised P. falciparum parasites at three asexual life stages          
(x-axis) and quantified (Pease et al. 2013).  Protein abundance percentile values (y-axis). 
 
2.4.9.3 Expanding the PfIAP Protein Network 
The PfCHD1, PfL24, PfMESA and PfRhopH3 binding partners all interact with other 
proteins as identified by yeast two-hybrid studies (LaCount et al. 2005).  By incorporating 
these new proteins it is possible to expand the PfIAP protein-protein network (Figure 2.4.10) 
to include proteins involved in various biological processes, ranging from metabolism to 
pathogenesis.  A number of these proteins are interacting partners of more than one of the 
PfIAP binding proteins, pointing to PfIAP being involved in a network of highly 
interconnected P. falciparum proteins.  The wide range of Gene Ontology  annotations 
(Ashburner et al. 2000) that can be applied to proteins identified in both biopanning and 
yeast two-hybrid experiments is an indication of alternative functions of both PfIAP and its 
binding partners (LaCount et al. 2005). 
 
The interaction of PfIAP with any of its primary partners could indicate that this binding has 
a biological function.  Alternatively these binding partners could form complexes with PfIAP 
and their own interacting proteins, providing PfIAP with the opportunity to interact with 
other proteins.  For example, one of the PfL24 binding partners is the putative autophagy-
related protein 23 (PfATG23) which is required for selective P. falciparum autophagy 
(Navale et al. 2014) and is an RCD protein that PfIAP would conceivably interact with.  The 
cell death participants in P. falciparum are currently unknown, therefore any of these 
secondary proteins with undefined functions could have RCD-related roles and be of 
significance to the functioning of PfIAP.  At this stage it is not possible to say whether these 
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primary and secondary interactions are stable or transient protein-protein connections.  It is 
also not clear whether these interactions represent the action of PfIAP on these binding 
partners or if it is these associated proteins that influencing PfIAP.  Further biochemical and 
molecular biology experiments involving PfIAP and its binding partners are required before 
these interactions can be truly elucidated. 
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Figure 2.4.10: The Expanded PfIAP Protein Network 
Diagram showing the PfIAP protein (dashed outline), its partner proteins (dark outline) and their associated binding partners as determined by yeast two-hybrid 
experiments (LaCount et al. 2005).  * = PfMDM2 binds PfLisH (Vieira and Coetzer 2016).  Numbers = PlasmoDB gene identifiers.  Dashed lines = Proteins 
that appear multiple times.  Colours = Gene Ontology biological process available on PlasmoDB (Ashburner et al. 2000; Aurrecoechea et al. 2009).  Detailed 
protein information can be found in APPENDIX D. 
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Given the previously described need for RCD in P. falciparum, the BIR-containing PfIAP 
protein may be expected to have an anti-apoptotic function in the parasite – that is, function 
in such a way as to prevent an excessive number of P. falciparum parasites from dying after 
the activation of RCD in response to population pressure during gametocyte development.  
This could involve binding to and inhibiting the actions of the available metacaspases or 
other cell death proteins.  Metacaspase proteins would thus have been expected amongst the 
identified binding partners, although technical reasons for this lack of association might 
apply (see 2.4.2).  Other reasons could be that these two protein families do not interact and 
that PfIAP is involved in the regulation of P. falciparum RCD via a different 
pathway/proteins.  In addition to this role, or perhaps as its sole function, the PfIAP protein 
could be involved with everyday processes in the parasite, since its binding partners are 
involved in DNA transcription, RBC invasion and other functions. 
 
Identifying the binding partners of a protein of interest and elucidating its protein-protein 
network is only a piece of the PfIAP puzzle.  Another question of primary concern when 
characterising an unknown protein is whether it is important in the cell and if the gene is 
essential for survival of the parasite. 
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CHAPTER 3: Manipulation of the P. falciparum Genome 
3.  
3.1 Introduction 
The whole P. falciparum genome is distributed between 14 nuclear chromosomes, a 35 kb 
apicoplast genome and a 6 kb mitochondrial genome (Gardner et al. 2002).  At the time of 
publication of the P. falciparum genome ~60% of predicted genes were hypothetical, more 
than a decade later that number has only decreased to ~50% (Webster and McFadden 2014).  
When investigating the function of an unknown gene/protein many different approaches can 
be employed.  Conditional disruption of a gene locus can for example be achieved using 
either the Cre-loxP or FLP–frt systems that utilise a recombinase enzyme to trigger a 
recombination event between two sequence specific regions (DeKoning-Ward et al. 2015).  
If the protein has many different roles in the cell though, then simply removing the gene will 
mean that only the earliest non-redundant downstream function of the protein will be 
observed (Webster and McFadden 2014).  As a way to circumvent this it is possible to affect 
the transcriptional activation of a gene, interfere with the produced mRNA or influence the 
protein itself.  RNA interference (RNAi) is a popular method of gene silencing, but unlike 
in mammalian systems, Plasmodium species seem to lack the necessary machinery for RNAi 
to be an effective means of regulating mRNA levels (Baum et al. 2009).  A technique that 
has been shown to work in P. falciparum involves inserting the glmS ribozyme sequence at 
the 3’ of the gene of interest (GOI).  The addition of exogenous glucosamine triggers 
ribozyme self-cleavage and the conditional knockdown of the associated mRNA.  The 
stability of the synthesised protein can also be disrupted using tools such as the destabilizing 
domain (DD) system.  The FK506-binding protein is fused to the C-terminal end of the 
protein of interest and will cause this protein to be degraded if the synthetic Shield-1 ligand 
is not present to stabilise the DD (Webster and McFadden 2014; DeKoning-Ward et al. 
2015). 
 
Deleting a GOI and observing the phenotypic effects is an important step in characterising 
an unknown gene. Performing such a genetic manipulation can be achieved quicker and 
more precisely using one of the gene editing tools that have been developed recently. 
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3.1.1 Engineered Genome Editing Techniques 
Genome editing methods modify GOIs by using site-specific DNA nucleases to cleave the 
genome, triggering the activation of cellular repair machinery which can then be directed to 
‘fix’ the genome in a number of different ways, such as introducing a mutation into the 
sequence or deleting a whole gene (Lee and Fidock 2014). 
 
A potentially hazardous event for any cell is the occurrence of a double-strand break (DSB) 
in a chromosome.  This can be a consequence of normal cellular processes, such as the action 
of reactive oxygen species for example, or it can be experimentally induced using ionizing 
radiation, chemical mutagens and DNA nucleases (Lee et al. 2014).  A single DSB can lead 
to genetic instability, for example chromosome translocation or even cell death, and as such 
organisms have developed DNA repair machinery.  DSBs though can also have benefits, 
like immune response diversification, and thus the fidelity of DSB repair need not be perfect 
(Lee et al. 2014).  One of these mechanisms is non-homologous end joining (NHEJ) and is 
the potentially “error-prone” pathway.  It simply ligates the broken DNA ends together, 
without the use of a homologous template, which means that the process can introduce indels 
(insertions or deletions) into the DNA sequence.  An alternative is the “error-free” 
homologous recombination (HR) pathway which utilizes a homologous template, whether 
present on the homologous chromosome or a donor plasmid, to repair the broken DNA strand 
(Lee and Fidock 2014; Lee et al. 2014).  No Plasmodium canonical NHEJ homologues have 
been identified (Straimer et al. 2012), although T. gondii does make use of a functional NHEJ 
pathway (Fox et al. 2009).  Given the close evolutionary relationship between the two 
Apicomplexa this suggests that Plasmodium has lost its NHEJ machinery (Lee et al. 2014), 
similar to other eukaryotic pathogens such as Encephalitozoon cuniculi (Gill and Fast 2007) 
and Giardia lamblia (Manning et al. 2011). 
 
3.1.1.1 Zinc Finger Nucleases and TALENs 
A zinc finger nuclease (ZFN) is a metalloenzyme that is able to bind to and cleave DNA 
(Figure 3.1.1a).  Each ZF is about 30 amino acids in size and generally binds three base 
pairs.  Therefore 3-6 ZF units are generally combined together to produce a DNA-binding 
array with 9-18 base pairs of specificity.  This is joined to a DNA-cleaving module in the 
form of the restriction endonuclease FokI.  Dimerization of two FokI domains is required 
for cleavage of double-stranded DNA and so two ZFNs must be simultaneously employed, 
one for each DNA strand.  This increases the specificity of the ZFN binding as not only are 
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two DNA-binding events required, but the ZFNs also need to be in the correct orientation 
(Carlson et al. 2012; Gaj et al. 2013).  ZFNs were the first customised nucleases to be widely 
employed for genome editing in various organisms, including P. falciparum (Straimer et al. 
2012; McNamara et al. 2013), P. vivax (Moraes Barros et al. 2015) and P. berghei (Singer 
et al. 2015).  They have also been used in the mosquito Aedes aegypti to disrupt pathways 
and behaviours as part of dengue control measures (Reegan et al. 2016). 
 
Figure 3.1.1: The Architecture of ZFNs and TALENs 
Adapted from Carlson et al. (2012). 
a) Schematic representation of a zinc-finger nuclease (ZFN).  Each zinc finger (ZF) is able to bind 
three base pairs (coloured triangles).  These units are combined to form a DNA-binding array, which 
is attached to the FokI restriction endonuclease (red arrow). 
b) Schematic representation of a transcription activator-like effector nuclease (TALEN).  The TALE 
polypeptide consists of DNA-binding monomers (coloured triangles), which are composed of a 
conserved amino acid sequence.  The 12th and 13th repeat variable diresidue (RVD; orange) dictates 
which DNA base the monomer will bind to.  A TALEN is formed through the fusing of the TALE 
with a FokI restriction endonuclease (red arrow). 
 
Transcription activator-like effectors (TALEs) are DNA-binding domains, derived from the 
plant pathogen Xanthomonas, which are composed of a series of conserved 33-35 amino 
acid repeats (Figure 3.1.1b).  These monomers only differ at the 12th and 13th positions, 
referred to as the repeat variable diresidue (RVD).  There is a simple relationship between 
each RVD combination and its target DNA base, and this is how the TALE is able to identify 
a specific DNA sequence.  TALE nucleases (TALENs) have been engineered by fusing the 
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FokI restriction endonuclease to the DNA-binding domain and like ZFNs, the binding of two 
TALEN units is required for a double-stranded break to occur (Gaj et al. 2013; Guha et al. 
2017).  No experimental data has been published involving Plasmodium and TALENs, but 
in silico work has resulted in the design of TALENs that would target the Plasmepsin V gene 
of P. falciparum (Cermak et al. 2011).  Work in dengue and malaria control on Ae. aegypti 
and Anopheles gambiae mosquitoes respectively has been performed using TALENs 
(Reegan et al. 2016). 
 
3.1.2 CRISPR-Cas9 
Clustered regulatory interspaced short palindromic repeats (CRISPRs) were first discovered 
in E. coli (Ishino et al. 1987) and together with the CRISPR-associated protein (Cas) form 
the only known prokaryotic adaptive immune system (Hille and Charpentier 2016).  This 
RNA-based, defensive mechanism involves a group of Cas genes, that encode the Cas 
proteins, which are located near the CRISPR locus.  This locus acts as the immunological 
memory and contains short repetitive sequences (repeats) that are separated by hypervariable 
sequences (protospacers), which have been obtained from previously invading pathogens 
(viruses and plasmids; Amitai and Sorek 2016).  The molecular defence mechanism of the 
CRISPR-Cas system can be divided into three stages: adaptation, expression and maturation, 
and interference (Figure 3.1.2).  During the adaptation stage, foreign DNA is recognised and 
Cas proteins acquire a new protospacer sequence, that is inserted into the CRISPR locus.   
Expression and maturation refer to the transcription of the CRISPR array into noncoding, 
precursor RNAs which are then processed into smaller CRISPR RNAs (crRNAs).  Each 
crRNA, containing a single protospacer and part of the repeat sequence, then forms a 
complex with a Cas protein.  The interference phase involves the Cas-crRNA recognising 
specific invading DNA, due to complementary base-pairing between the crRNA and the 
target, and cleaving it to produce a double-stranded break (Amitai and Sorek 2016; Cui and 
Yu 2016; Hille and Charpentier 2016). 
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Figure 3.1.2: The Process of Type II CRISPR-Derived Immunity in Bacteria (Cui and Yu 2016) 
The CRISPR locus consists of protospacers (coloured blocks) separated by repeat sequences (black 
diamond), with the Cas genes nearby.  During the adaptation phase foreign DNA is fragmented and 
a new protospacer (purple square) is inserted into the CRISPR locus.  The expression stage involves 
the transcription and processing of protospacers and repeats into mature CRISPR RNAs (crRNAs).  
During the interference phase the Cas-crRNA complex targets and cleaves invading DNA by 
recognising the nucleotides complementary to the protospacer sequence. 
 
In recent years CRISPR has been adapted for use as a gene editing tool in a variety of 
different organisms including bacteria, Drosophila and human cells.  CRISPR-Cas type II 
has become the prominent system that is employed and makes use of the well characterised 
Cas9 endonuclease from Streptococcus pyogenes.  This protein contains two active domains, 
the HNH and RuvC domains, which cleave the target and non-target DNA strands 
respectively.  The Cas9 protein forms a complex with two RNA sequences: the trans-
activating crRNA (tracrRNA) and the crRNA (Figure 3.1.3). The tracrRNA is a scaffold 
sequence that binds the Cas9 protein, while the crRNA contains the ~20 nucleotide “user-
designed” guide RNA (gRNA) sequence which targets the complex to a specific gene locus.  
In engineered systems, these two RNA sequences are expressed as a single guide RNA 
(sgRNA) construct.  The specificity of this system is due to the fact that the gRNA needs to 
be located upstream of a protospacer adjacent motif (PAM) sequence that is specific for each 
of the bacterial Cas9 proteins, in the case of S. pyogenes Cas9 it is NGG.  Upon base-pairing 
between the gRNA and the target, the Cas9 nuclease creates a double-stranded break in the 
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DNA 3 bp upstream of the PAM sequence.  The domains of the Cas9 protein can be mutated 
to produce “dead” Cas9 (dCas9), which is nuclease-deficient but still retains its DNA-
binding characteristics.  Fusing effector domains, such as the negative transcriptional KRAB 
(Krüppel-associated box) domain, with the dCas9 protein can allow for silencing or 
activation of the targeted gene, as opposed to cleavage (Doetschman and Georgieva 2017; 
Guha et al. 2017; Singh et al. 2017). 
 
Figure 3.1.3: The CRISPR-Cas9 Gene Targeting System 
Diagram showing the binding of the CRISPR-Cas9 complex to a target gene locus.  The Cas9 protein 
(purple) forms a complex with the engineered single guide RNA (sgRNA; green), which is composed 
of the CRISPR RNA (crRNA) and the trans-activating crRNA (tracrRNA).  The guide RNA (gRNA) 
targets the CRISP-Cas9 complex by binding to the genomic target sequence (blue), immediately 
upstream of the NGG protospacer adjacent motif (PAM) sequence.  The Cas9 nuclease then cleaves 
the DNA (red scissors), creating a double-stranded break upstream of the PAM sequence.  Adapted 
from Ceasar et al. (2016). 
 
3.1.2.1 CRISPR-Cas9 and Malaria 
CRISPR-Cas9 in P. falciparum. The CRISPR-Cas9 technology has recently been adapted 
for use in Plasmodium.  In the first description of CRISPR-Cas9 in P. falciparum, Ghorbal 
et al. (2014) expressed the Cas9 nuclease and the sgRNA off separate plasmids using the U6 
small nuclear RNA (snRNA) regulatory elements to recruit RNA polymerase III.  These 
plasmids contained positive and negative drug selection cassettes, while the sgRNA plasmid 
also had the DNA templates for HR.  Two non-essential genes, an integrated GFP gene and 
the knob-associated, histidine-rich protein (KAHRP) gene, were successfully disrupted in 
three weeks by the insertion of a selectable marker within their sequences (Ghorbal et al. 
2014).  Modifications to the coding sequences of the putative gene silencing orc1 and 
artemisinin resistance kelch propeller domain were also obtained.  Whole-genome 
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sequencing of parental and mutant lines did not reveal any off-target activity. In silico 
analysis of the P. falciparum genome predicted that there is a CRISPR-Cas9 target site on 
average every 35 base pairs, meaning virtually any gene locus could be targeted by CRISPR-
Cas9 (Ghorbal et al. 2014).  Two plasmids with drug selection cassettes, one containing the 
Cas9 nuclease and the sgRNA (each controlled using separate T7 promotors) and the other 
with the donor template and the T7 RNA polymerase, were used to disrupt the P. falciparum 
KAHRP and erythrocyte binding antigen 175 genes within ~4-6 weeks (Wagner et al. 2014). 
 
CRISPR-Cas9 has been used in subsequent studies investigating P. falciparum drug 
resistance.  It was shown that mutations in the cyclic amine resistance locus are sufficient to 
cause resistance to the imidazolopiperazine class of antimalarial compounds (LaMonte et al. 
2016).  The CRISPR-Cas9 system has confirmed that point mutations in the multidrug 
resistance-1 gene mediate resistance to the piperazine-containing compound ACT-451840 
(Ng et al. 2016) and verified the mutations in the cleavage and polyadenylation specificity 
factor subunit 3 gene that are responsible for resistance to the benzoxaborole compound 
AN3661 (Sonoiki et al. 2017).  This system has been used to introduce a bulky gatekeeper 
residue into the P. falciparum calcium-dependent protein kinase 1 in order to assess the 
activity of the protein (Bansal et al. 2016).  CRISPR-Cas9 methods involving deletion of the 
P. falciparum var2csa intron have shown that, while the var intron may play a role in in the 
regulation and switching of the members of the var gene family, it is not required for 
silencing or activation of the var2csa gene (Bryant et al. 2017). 
 
Modifications have been made to the P. falciparum CRISPR-Cas9 system allowing for 
“marker-free” gene editing (Lu et al. 2016; Mogollon et al. 2016).  This technology is also 
being incorporated with other gene editing tools like the Cre-loxP recombination system 
(Knuepfer et al. 2017).  A plasmid-free method, which involves transfecting P. falciparum 
parasites with the Cas9 protein, the guide RNA and the repair template, has also been 
developed (Crawford et al. 2017). 
 
CRISPR-Cas9 in P. yoelii.  Gene deletion, reporter knock-in and nucleotide replacement was 
performed in P. yoelii using a single plasmid. It contained the HR templates, the sgRNA and 
expressed off the same promotor the positive drug selection cassette and Cas9 protein, 
separated by the viral “ribosome skip” 2A peptide (Zhang et al. 2014).  Genes important for 
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P. yoelii ookinete motility have been sequentially disrupted using a CRISPR-Cas9 mediated 
system (Zhang et al. 2017).   
 
CRISPR-Cas9 in Anopheles.  CRISPR-Cas9 has been used to manipulate An. gambiae and 
An. stephensi mosquitoes with the goal, for example, of controlling their population number 
or generating mosquitoes that are not able to transmit the malaria parasite (McLean and 
Jacobs-Lorena 2016; Reegan et al. 2016). 
 
The studies described above indicate that gene editing is a useful technique to manipulate 
the P. falciparum genome and so CRISPR-Cas9 was used in this study to delete the pfiap 
gene. 
 
3.1.3 Objectives 
The objective of this chapter was to: 
- Use CRISPR-Cas9 to facilitate knockout experiments to determine if the pfiap gene is 
essential for P. falciparum parasite survival 
 
3.2 Materials and Methods 
The preparation of the vector constructs described in this section follows the general protocol 
described in 2.2.4 - 2.2.6 with respect to the PCR amplification of gene regions, insertion of 
these amplicons into plasmids, bacterial transformation and the treatment of the resultant    
E. coli colonies. 
 
3.2.1 CRISPR-Cas9 Plasmid Preparation 
Two CRISPR-Cas9 vectors were adapted for use in P. falciparum by Ghorbal et al. (2014). 
The pUF1-Cas9 plasmid (Figure 3.2.1a) contains an engineered S. pyogenes Cas9 
endonuclease (with a nuclear localisation signal) under the control of plasmodial regulatory 
heat shock protein elements.  Resistance to DSM1, a P. falciparum dihydroorotate 
dehydrogenase (PfDHODH) inhibitor, is achieved through the presence of the drug-
selectable marker ydhodh.  The pL6-GOI plasmid (Figure 3.2.1b) makes use of P. falciparum 
U6 snRNA regulatory elements for the transcription of the sgRNA, for which there is a 
cloning site.  Multiple cloning sites are present on either side of the positive selection hdhfr 
cassette to facilitate the insertion of the donor DNA templates.  The vector also contains the 
suicide-gene yeast cytosine deaminase/uracil phosphoribosyl transferase (yfcu) which allows 
for the removal of parasites that contain the pL6-GOI plasmid.  Cytosine deaminase (CD) 
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converts a harmless 5-fluorocytosine metabolite into 5-fluorouracil, which inhibits RNA 
synthesis and the enzyme thymidylate synthase (TS).  Uracil phosphoribosyl transferase 
efficiently converts 5-fluorouracil into further metabolites that also inhibit RNA synthesis 
and TS.  This suicide gene codes for a bifunctional chimeric protein that is 1 000-fold more 
potent than CD itself (Maier et al. 2006). 
  
 
Figure 3.2.1: Plasmid Maps of the pUF1-Cas9 and pL6-GOI Vectors 
a) A basic vector map of the pUF1-Cas9 plasmid, details are available in APPENDIX B. 
b) A basic vector map of the pL6-GOI plasmid, details are available in APPENDIX B. 
 
The pUF1-Cas9 and pL6-GOI plasmids were kindly donated by Dr Ghorbal and used to 
transform in-house, chemically competent XL10 E. coli cells (provided by Dr Sonja 
Lauterbach).  A 50 μL aliquot of E. coli cells was incubated with either 25 ng of the pUF1-
Cas9 vector or 25 ng of the pL6-GOI vector for 30 minutes on ice, before being heat-shocked 
at 42°C for 90 seconds.  After transforming E. coli with the two samples, glycerol stocks of 
the plasmids were created from the resulting colonies. 
 
3.2.2 Deletion of the pfiap Gene 
3.2.2.1 Construction of the pL6-DEL Vector 
Knockout of the pfiap gene required the creation of the intermediate pL6-DEL vector which 
involved the insertion of pfiap homologous arms into the pL6-GOI plasmid (Figure 3.2.2). 
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Figure 3.2.2: Diagram of the Steps in the Creation of the pL6-DEL Plasmid 
Diagram showing the process followed to generate the pL6-DEL vector.  Grey = left/right pfiap 
homologous arms (HA_L/R); pink = human dihydrofolate reductase cassette (hdhfr). 
 
The 5’ and 3’ untranslated regions (UTRs) of the pfiap gene were amplified by PCR using 
DreamTaq Green PCR Master Mix (Figure 3.2.3) to create the left and right homologous 
arms (HA_L/R) respectively.  The PCR amplicons were created with the appropriate 
restriction sites (DEL_L Fwd – AscI, DEL_L Rev – SpeI, DEL_R Fwd – EcoRI, DEL_R 
Rev – NcoI) to allow for the sequential insertion of the homologous arms, on either side of 
the hdhfr cassette.  Detailed primer sequences are available in APPENDIX A. 
 
  
Figure 3.2.3: Location of the Knockout Homologous Arms of the pfiap Gene 
Diagram showing the two pfiap UTRs amplified by PCR as homologous arms.  Blue = the forward 
and reverse PCR primers; grey = pfiap UTRs; purple = pfiap gene.  Numbers = nucleotide number. 
 
Table 3.2.1: PCR Parameters for the Amplification of pfiap Homologous Arms 
Region Name Vector 
P. falciparum 
Specific Ta (°C) 
Full Length 
Primer Ta (°C) 
PCR Product 
(bp) 
DEL_R pL6-GOI 45.0 56.0 396 
DEL_L pL6-DEL_R 47.0 59.0 376 
 
The pL6-GOI vector was extracted from XL10 E. coli and together with the DEL_R 
amplicon, was prepared for cloning by digestion with FastDigest® EcoRI and NcoI 
restriction enzymes, before being ligated together.  A 100 μL aliquot of in-house competent 
XL10 E. coli cells were transformed, after which successful transformation was verified 
using the FastDigest® XbaI restriction enzyme and sequencing of the new pL6-DEL_R 
plasmid construct.  The DEL_L PCR amplicon was then cloned into the pL6-DEL_R vector 
using FastDigest® AscI and SpeI restriction enzymes, followed by restriction enzyme 
digestion (FastDigest® BamHI) and sequencing to verify the new pL6-DEL plasmid 
construct. 
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3.2.2.2 Creation of the pL7-DEL Vector 
The second step in creating the knockout vector involved inserting the selected gRNA into 
the pL6-DEL plasmid (Figure 3.2.4). 
 
  
Figure 3.2.4: Diagram of the Steps in the Creation of the pL7-DEL Plasmid 
Diagram showing the generation the pL7-DEL vector.  Blue = guide RNA; grey = left/right pfiap 
homologous arms (HA_L/R); pink = human dihydrofolate reductase cassette (hdhfr). 
 
The Cas9 endonuclease will only bind to the target DNA if the unique ~20 bp guide sequence 
is immediately upstream of a three nucleotide PAM site.  The PAM sequence (GGG) used 
for the knockout of the pfiap gene is on the antisense strand towards the end of the BIR 
domain (Figure 3.2.5a).  The 20 bp preceding the PAM site were selected (Figure 3.2.5b) 
and synthesised by Integrated DNA Technologies, USA as complementary 5’→3’ and 
3’→5’ oligonucleotides (DEL (+)/DEL (-); available in APPENDIX A).  A G nucleotide 
was included at the 5’ end of the selected sequence (this is the preferred initiation nucleic 
acid and so increases the transcription efficiency of the U6 promoter; Ma et al. 2014), while 
15 bp homologous to the pL6-DEL vector were included on both the 5’ and 3’ ends of the 
sequence (Figure 3.2.5c and d).  Even though these oligonucleotides are DNA they will be 
referred to as the guide RNA, as the sequence will ultimately be transcribed as part of the 
sgRNA. 
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Figure 3.2.5: The pfiap Knockout Guide RNA 
a) Diagram showing the pfiap knockout PAM site.  Grey = pfiap UTRs; purple = pfiap gene; red = 
the location of the PAM site.  Numbers = number of nucleotides. 
b) Diagram showing the PAM site and the selected guide RNA used for pfiap knockout.  Green = 
the selected guide sequence; red = the location of the PAM site.  Numbers = nucleotide number. 
c) Diagram showing the complementary guide RNA sequences annealed together.  Green = the 
selected guide sequence; grey = 15 bp pL6-GOI homologous regions. 
d) Diagram showing the pL7-DEL plasmid with the inserted guide RNA sequence and the 15 bp 
pL6-DEL homologous regions synthesised as part of the (+)/(-) oligonucleotides. 
 
 
  
These guide oligonucleotides were resuspended to a final concentration of 100 μM using 
nuclease-free water, before they were annealed by means of a step-down PCR program 
(Ghorbal et al. 2014). 
Table 3.2.2: Guide RNA Reaction Set-Up 
Component Volume Final Concentration Manufacturer 
10X NEBuffer 2 2.22 μL 1X New England Biolabs 
DEL (+) 10.00 μL 45 μM - 
DEL (-) 10.00 μL 45 μM - 
Total 22.22 μL   
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Figure 3.2.6: Guide RNA PCR Annealing Program 
Diagram showing PCR reaction conditions used during the guide RNA annealing reaction. 
 
The annealed guide RNA was stored on ice and then diluted to 0.5 μM with ice-cold 5 mM 
Tris-HCl; pH 8.  The pL6-DEL vector was extracted from XL10 E. coli and digested using 
BtgZI for 2 hours at 60°C before being purified using the NucleoSpin® Gel and PCR Clean-
Up Kit as per the manufacturer’s instructions and eluted in 10 μL of nuclease-free water.  
The guide RNA was cloned into the digested pL6-DEL vector (which had been quantified 
by agarose gel electrophoresis) using Gibson Assembly as per the manufacturer’s 
instructions (Gibson et al. 2009).  The Gibson Assembly Master Mix contains a 5’ 
exonuclease which removes some of the exposed 5’ nucleotides from all of the fragments.  
The homologous regions of the fragments anneal and a DNA polymerase extends the 3’ 
ends, before a DNA ligase seals the exposed nicks (Figure 3.2.7).  Cloning using Gibson 
Assembly has the advantage that only the vector, but not the insert, needs to be digested 
prior to cloning and can be used to assemble multiple fragments in one reaction. 
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Figure 3.2.7: Insertion of the Guide RNA into the pL6-DEL Vector 
a) Diagram showing the digestion of the pL6-DEL vector with the BtgZI restriction enzyme.  Red 
underlined = the BtgZI recognition sites; red cut = the BtgZI cleavage sites 
b) Diagram showing the creation the pL7-DEL plasmid using Gibson Assembly.  A 5’ exonuclease 
removes base pairs from the 5’ ends, which allows the homologous regions to anneal before the 
missing base pairs are replaced using a DNA polymerase to extend the 3’ ends and a DNA ligase to 
seal the nicks (Gibson et al. 2009).  Green = the selected guide sequence; orange = pL6-DEL plasmid; 
grey = 15 bp pL6-DEL homologous regions. 
 
Table 3.2.3: Gibson Assembly Reaction Set-Up 
Component Volume Final Concentration Manufacturer 
2X Gibson Assembly Master Mix 5.0 μL 1X New England Biolabs 
Annealed Guide RNA 1.5 μL 75 nM - 
Digested pL6-DEL Vector x μL 110 ng - 
Nuclease-Free Water y μL - - 
Total 10.0 μL   
 
The Gibson Assembly reaction was incubated for 30 minutes at 50°C, after which 5 μL of 
the reaction mixture was used to transform a 100 μL aliquot of in-house XL10 E. coli cells 
(see 3.2.2.1).  Successful transformation and creation of the pL7-DEL vector construct was 
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verified using the FastDigest® XbaI restriction enzyme, followed by plasmid sequencing to 
ensure the construct was error-free. 
 
3.2.2.3 Transfection of P. falciparum Parasite Cultures 
The pL7-DEL and pUF1-Cas9 plasmid constructs were prepared as described in 2.2.11.1, 
except that the constructs were prepared from one litre LB cultures (four 250 mL aliquots) 
and quantified after linearization with FastDigest® EcoRI.  Elution volumes equivalent to 
150 μg of pL7-DEL and pUF1-Cas9 plasmid were purified and the plasmids were each 
resuspended in 15 μL of TE buffer.  The two plasmid solutions were combined and added to 
370 μL of pre-warmed cytomix, before being used to transfect a P. falciparum culture (see 
2.2.11.2).  This transfection experiment was performed three times, each time the transfected 
culture was maintained under 2 nM WR99210 selection pressure for more than two months. 
 
3.3 Results 
3.3.1 Knocking Out the pfiap Gene 
3.3.1.1 Creation of the pL7-DEL Plasmid Construct 
The 396 bp 3’ UTR of the pfiap gene was cloned into the EcoRI/NcoI site of the pL6-GOI 
vector (Figure 3.3.1). 
 
Figure 3.3.1: DEL_R PCR Amplicon and pL6-GOI Plasmid prior to Ligation 
Agarose gel (1%) showing the EcoRI/NcoI-digested DEL_R PCR amplicon and pL6-GOI vector.                
◄ = expected band size. 
 
Digestion of the newly created pL6-DEL_R plasmid using XbaI resulted in the expected 
banding pattern on the agarose gel (Figure 3.3.2a).  Sequence analysis of one sample 
confirmed that the expected DEL_R arm was present in the pL6-DEL_R vector, but did 
reveal that two nucleotides (AT) were absent from the middle of the insert (Figure 3.3.3).  
The DEL_R fragment was generated by PCR using the DreamTaq DNA polymerase which 
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is a low fidelity enzyme that does not have any proofreading ability (3’→5’ exonuclease 
activity).  It is therefore understandable why there are errors in this fragment, particularly in 
a stretch of DNA that contains repeating AT nucleotides.  The DreamTaq enzyme was used 
because PCR of the DEL _R arm using various high fidelity polymerase enzymes was 
unsuccessful.  Since this deletion occurred in the pfiap 3’ UTR homologous arm and 
represented less than 0.5% of the nucleotides in the UTR, it was decided that the effect of 
these mutations would be negligible and that the recombination event would still be able to 
occur. 
 
Figure 3.3.2: Verification of the Insertion of DEL_R into the pL6-GOI Vector 
a) Agarose gel (1%) of the pL6-DEL_R plasmid following cloning, after digestion with XbaI.                        
◄ = expected band size. 
b) Vector diagrams of the pL6-GOI plasmid and the plasmid containing the 3’UTR DEL_R insert 
with EcoRI/NcoI and XbaI restriction sites.  Grey = the 3’ URT homologous insert. 
 
 
Figure 3.3.3: Sequencing Chromatogram of the pL6-DEL_R Plasmid 
Extract of the sequencing chromatogram of the DEL_R insert present in the pL6-DEL_R vector.  
Purple = the location of the missing AT nucleotides. 
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The 5’ UTR of the pfiap gene (DEL_L) was PCR-amplified as a single amplicon, digested 
with AscI and SpeI and inserted into the prepared pL6-DEL_R plasmid to create the pL6-
DEL construct (Figure 3.3.4). 
 
Figure 3.3.4: Digested DEL_L PCR Amplicon and pL6-DEL_R Plasmid 
Agarose gel (1%) showing the DEL_L PCR amplicon and pL6-DEL_R vector, digested with 
AscI/SpeI, prior to ligation.  ◄ = expected band size. 
 
Following E. coli transformation, digestion of the pL6-DEL plasmid with BamHI and EcoRI 
showed the expected banding pattern (Figure 3.3.5a)  Digestion of the initial pL6-DEL_R 
plasmid would have resulted in a band of expected size 1 247 bp as opposed to the observed 
band of size 1 563 bp.  Two mutations were identified after sequencing one sample insert: 
an AT nucleotide pair were missing, and an A had been replaced by a G (Figure 3.3.6).  The 
use of the DreamTaq enzyme could explain the discrepancies between the expected and 
achieved sequences, but as these minor mutations should not interfere with the homologous 
recombination event the pL6-DEL plasmid was taken forward. 
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Figure 3.3.5: Verification of the Insertion of DEL_L into the pL6-DEL_R Vector 
a) Agarose gel (1%) of the pL6-DEL plasmid after digestion with BamHI/EcoRV.  ◄ = expected 
band size. 
b) Vector diagrams of the pL6-DEL_R plasmid and the pL6-DEL plasmid containing both DEL_R 
& DEL_L inserts with AscI/SpeI and BamHI/EcoRV restriction sites.  Grey = the 5’ & 3’ URT 
homologous inserts. 
 
 
Figure 3.3.6: Sequencing Chromatogram of the pL6-DEL Plasmid 
a) Extract of the sequencing chromatogram of the DEL_L construct present in the pL6-DEL vector.  
Purple = the identified A→G substitution. 
b) Extract of the sequencing chromatogram of the DEL_L insert present in the pL6-DEL vector.  
Purple = the location of the missing AT nucleotides. 
 
120 
Chapter 3: Manipulation of the P. falciparum Genome 
The pL6-DEL vector was digested with BtgZI and placed in a Gibson Assembly reaction 
with the annealed DEL guide RNA oligonucleotides to create the pL7-DEL vector.  
Following E. coli transformation, digestion of the newly created plasmid with XbaI resulted 
in what was assumed to be the expected banding pattern (Figure 3.3.7a).  It was not possible 
to detect a 20 bp insert in the 5 539 bp largest band, but sequencing of one sample of the 
pL7-DEL vector verified that the guide RNA was present and error-free. 
  
 
Figure 3.3.7: Verification of the Insertion of the DEL gRNA into the pL6-DEL Vector 
a) Agarose gel (1%) of the pL7-DEL plasmid with XbaI.  ◄ = expected band size. 
b) Vector diagrams of the pL6-DEL plasmid and the plasmid containing the DEL gRNA insert with 
BtgZI and XbaI restriction sites.  Blue = the guide RNA insert; grey = the URT homologous inserts. 
 
3.3.1.2 Knocking Out pfiap by Transfecting P. falciparum with pL7-DEL 
The circular pL7-Del and pUF1-Cas9 plasmids (quantified in Figure 3.3.8) were used to 
transfect ring stage P. falciparum 3D7 parasites, with constant 2 nM WR99210 pressure 
after 48 hours, on three different occasions.  After more than 60 days of monitoring, no 
parasites were detected in any of the transfected culture flasks. 
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Figure 3.3.8: Linearized pL7-DEL and pUF1-Cas9 prior to Parasite Transfection 
Agarose gel (1%) showing the EcoRI-linearized pL7-DEL and pUF1-Cas9 plasmids before parasite 
transfection.  Expected sizes: pL7-DEL = 9 955 bp; pUF1-Cas9 = 11 096 bp. 
 
3.4 Discussion 
A key part of characterising an unknown protein is determining if the protein plays a critical 
role in the cell, during the life stage under investigation.  To this end, the CRISPR-Cas9 
genome editing tool was utilised in this study in attempts to disrupt the pfiap gene, as a 
means of gathering more information about the PfIAP protein. 
 
3.4.1 Genome Editing in Plasmodium and the Advantage of CRISPR-Cas9 
Following the introduction of transfection techniques in the mid-1990s and their 
implementation in the analysis of the P. falciparum genome, electroporation has emerged as 
a tool that provides consistent transfection reliability.  The trade-off is that transfection 
experiments require large amounts of the plasmid to be transfected and the timeframe for 
recovery is variable (up to three months in some cases), with the need for constant 
monitoring for the re-emergence of drug-resistant parasites (Lee et al. 2014; Webster and 
McFadden 2014).  Although there has been movement in the development of genetic tools 
for the investigation of Plasmodium genes, difficulties exist and these hinder progress.  One 
problem is the study of genes that are critical to the parasite’s survival, as the disturbance of 
such genes is lethal.  Another is the low transfection efficiency that is experienced and how 
this limits the high-throughput screening of multiple genes.  A third is the scarceness of 
positive selectable markers, which restricts the number of consecutive genetic operations 
that can be performed on the same parasites (Webster and McFadden 2014; DeKoning-Ward 
et al. 2015). 
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The primary reason for the long delay between transfection of a P. falciparum culture and 
the appearance of genetically modified parasites is the fact that traditional gene manipulation 
techniques rely on randomly occurring, stochastic HR events to introduce the modification 
into the GOI.  The benefit of employing an engineered gene editing tool is that HR is no 
longer a rare event as the selected nuclease actively creates a DSB at the target location.  
This forces the cell to repair the damaged DNA, thereby facilitating the introduction of the 
desired change into the genome at an accelerated rate (Lee and Fidock 2014; DeKoning-
Ward et al. 2015). 
 
Several tools have been developed to improve the efficiency of genomic manipulation 
experiments, including ZFNs and TALENs.  Although the specificity associated with ZFN 
binding is quite high, a hindrance to its use is the arduous process of engineering the user-
defined ZF arrays which are context-dependent and this impacts the reproducibility and scale 
to which they can be used (Sander and Joung 2014; Eid and Mahfouz 2016).  The simple, 
modular design is a benefit to using the TALEN system, but the highly repetitive 
composition of the multiple domain sequences and the size of the nuclease can ultimately 
lead to difficulties (Sander and Joung 2014; Ceasar et al. 2016).  The CRISPR-Cas9 system 
is comparatively simpler to use, not requiring a new protein to be engineered for each GOI.  
The targeting gRNA constructs are easy to make, the system is cost-effective and can be 
used to edit multiple genes simultaneously (DeKoning-Ward et al. 2015; Ceasar et al. 2016; 
Eid and Mahfouz 2016).  Caution though must be employed when using the CRISPR-Cas9 
system as off-target effects have been noted.  It is likely that this unintended Cas9 binding 
to DNA can be mediated by the perfect complementation of only the ten guide nucleotides 
proximal to the PAM site, out of the twenty total gRNA bases (Kuscu et al. 2014).  In              
P. falciparum CRISPR-Cas9 has been used to realise genome modifications within three to 
six weeks (Ghorbal et al. 2014; Wagner et al. 2014). 
 
3.4.2 The pfiap Gene may be Essential 
Three separate P. falciparum cultures were each co-transfected with the pL7-DEL and 
pUF1-Cas9 plasmid constructs and maintained under positive selection pressure for more 
than two months.  No parasites were detected in any of these transfected cultures which 
would mean that a homologous recombination event had occurred, replacing the pfiap gene 
with the hdhfr cassette that provides resistance to WR99210, but that the lack of the pfiap 
gene and the subsequent absence of the PfIAP protein was detrimental to the survival of the 
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P. falciparum parasite.  This implies that the pfiap gene is essential in P. falciparum asexual 
parasites.  In mice models iap deletion has resulted in various phenotypes including being 
embryonically lethal when survivin or Apollon (BIRC6), for example, were knocked out 
(Silke and Vaux 2015), so it is not unexpected that the deletion of pfiap has a detrimental 
effect on the parasite. 
 
By itself, the absence of evidence is not sufficient to prove a negative result, so alternative 
options to account for the lack of viable P. falciparum parasites may also be considered.  
Technical reasons could include that electroporation of the RBCs with the plasmid 
containing the hdhfr cassette was not successful, and that the subsequent application of the 
WR99210 compound simply killed all of the parasites, or that any viable parasites died as a 
result of suboptimal culturing.  These explanations are unlikely as P. falciparum parasites 
have been successfully transfected with a pARL2-GFP vector (see 2.3.7) and it is not likely 
that a parasite culturing error would have occurred on three separate occasions.  Performing 
a transfection using a CRISPR-Cas9 vector designed to target an established, non-essential 
gene (such as PfEBA175) could act as a culturing and transfection technique control. 
 
Transfected parasites were maintained in culture for more than 60 days, therefore viable 
pfiap knockout parasites should have been detected since the CRISPR-Cas9 system should 
reduce the time for transfected parasites to re-emerge when compared to conventional 
methods (Ghorbal et al. 2014).  During this time there was only selection pressure for the 
pL7-DEL plasmid, not for the pUF1-Cas9 vector in the form of the PfDHODH inhibitor 
DSM1, which means that the transfected parasites would eventually lose the pUF1-Cas9 
plasmid.  This transient expression of the Cas9 protein though should still be sufficient to 
induce a DSB as cleavage and repair of a target sequence has been shown to occur within 
the first few growth cycles following transfection (Ghorbal et al. 2014). 
 
Not all PAM sites and guide RNAs function with the same level of efficiency (Doench et al. 
2014) and so it is possible that the guide RNA used during these experiments was not 
optimal.  pfiap deletion experiments can be attempted after identifying other PAM sites 
within the BIR domain and cloning their associated gRNA into the pL6-DEL vector.  These 
new targeting sequences might be more effective than the gRNA used in this study, but while 
a suboptimal gRNA might have decreased the chances that the Cas9 nuclease would bind 
the target site and create a DSB, it does not mean that the recombinant knockout event could 
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not occur.  The only difference between the pL6-GOI vector used in this study and the     
pCC-1 vector, which is the vector that has traditionally been used in knockout experiments 
and relies solely on spontaneous recombination events, is that the pL6-GOI plasmid contains 
the sgRNA sequence and its associated promotor.  This means that the pL7-DEL vector with 
the pfiap homologous arms, which is always present due to the constant positive drug 
pressure, would still be able to participate in a spontaneously occurring recombination event 
and replace the pfiap gene with the hdhfr cassette.  This point also covers any scenario in 
which some of the P. falciparum parasites might only have been transfected with the         
pL7-DEL plasmid and not successfully co-transfected with both pL7-DEL and PUF1-Cas9 
vectors. 
 
3.4.3 Alternative Approaches for Manipulating pfiap 
The absence of P. falciparum parasites following pfiap knockout transfection does not 
conclusively prove that pfiap is essential for P. falciparum intraerythrocytic development.  
Unfortunately there is no ideal strategy that can be followed to investigate and interfere with 
an essential asexual gene and there is not a globally accepted number of attempts that should 
be undertaken before it is concluded that the GOI is indispensable (Webster and McFadden 
2014). 
 
As part of building a case that a GOI is essential, experiments can be done to show that the 
gene is targetable.  This can involve single-crossover homologous recombination to, for 
example, insert a HA coding sequence at the 5’ start of the GOI or a GFP sequence at the 3’ 
end of the gene to produce HA- and GFP-tagged proteins respectively, that can be used in 
subsequent molecular experiments.  Once pfiap has been shown to be targetable with no 
loss-of-function, then a single-crossover modification of the coding region could be 
performed to show that it is the disruption of the gene itself that results in no viable parasites.  
An additional step may involve the complementation system (Sultan et al. 2001).  It should 
be possible to knock out the genomic pfiap gene in an established transgenic P. falciparum 
line with an episomal plasmid that expresses the PfIAP protein.  Once the gene deletion has 
been confirmed in viable parasites, then negative selection can be used to remove the 
episomal plasmid.  If any parasites survive this step, then it means that pfiap is not an 
essential gene as no copies of the gene would be present in the P. falciparum culture. 
 
Approaches not focusing on the removal of pfiap can also be employed in the quest to obtain 
information about the function of PfIAP.  Examples of these techniques include conditional 
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inactivation of pfiap transcription, mRNA knockdown or the fusion of the Shield-controlling 
destabilizing domain to the PfIAP protein (Webster and McFadden 2014).  Future in vivo 
work employing any number of molecular techniques should be able to provide more 
information about the function of this putative P. falciparum inhibitor of apoptosis protein. 
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CHAPTER 4: Concluding Remarks 
4.  
While the willingness of a unicellular organism to commit suicide is hard to comprehend, 
the need for a P. falciparum population to be able to control its number by sacrificing some 
individual parasites is easier to understand.  The exponential, asexual growth of the parasite 
during its 48 hour intraerythrocytic life stage is capable of killing the human host before the 
12 days required for sexual gametocyte development have passed.  Various studies have 
shown that some form of RCD occurs in P. falciparum, but there is a lack of consensus about 
the phenotype of this cell death.  No RCD protein network has been elucidated, but a few 
possible participants, such as the metacaspase family of proteins, have been investigated.  
This study adds to the pool of available Plasmodium cell death knowledge by investigating 
a putative P. falciparum IAP protein. 
 
Metazoan IAP proteins are primarily known as anti-apoptotic proteins as they are able to 
interact with and inhibit various pro-apoptotic caspases, although they also perform other 
cellular roles.  The PfIAP protein contains one N-terminal BIR domain, the characteristic 
domain of its metazoan IAP homologues.  This P. falciparum domain contains the conserved 
amino acids required for zinc ion binding and is structurally similar to human BIR domains, 
containing the expected α-helices and β-sheet conformations.  This suggests that PfIAP 
could have the same function as the human IAP proteins, but given the wide range of their 
roles in the cell nothing definite can be extrapolated to the function of PfIAP.  One 
orthologue of PfIAP is present in various other Plasmodium species, including all the human 
parasites.  Given the intraerythrocytic differences and the reduced population pressure in 
these other species, it is unclear why they would need this proposed anti-apoptotic IAP 
protein to be expressed during the RBC life stage, unless IAP plays other roles in the parasite 
that pertain to normal cellular functioning. 
 
These non-apoptotic roles of PfIAP, suggested by both the human proteins and the 
Plasmodium orthologues, are supported by the wide spectrum of PfIAP binding partners that 
were identified during the biopanning experiments.  The functions of these proteins range 
from invasion to transcription, nutrient intake to protein synthesis and they localise to 
various sites in the parasite, some are even exported to the host cell membrane.  The in vivo 
relevance of these interactions still needs to be confirmed experimentally, as does the 
localisation of the full length PfIAP protein.  Of the PfIAP binding partners and their 
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associated interacting partners, PfATG23 is the only protein that has an obvious connection 
to RCD, although there are many unknown proteins in this protein-protein network. 
 
The inference of the CRISPR-Cas9 knockout experiments is that the pfiap gene could be 
essential for P. falciparum survival during the intraerythrocytic life stage.  This effect is 
conceivable given the expansive PfIAP centred protein-protein network and the fact that it 
covers numerous biological functions.  To build a more complete picture of the role of the 
pfiap gene additional genomic manipulation, such as tagging the gene, is required.  At the 
same time further information could be obtained about the PfIAP protein by generating, for 
example, a parasite line in which the PfIAP protein can be conditionally knocked down.  
 
The findings of this study strongly suggest that PfIAP has a non-apoptotic role in                      
P. falciparum, as well as a potential RCD function that is currently undefined.  Future work 
investigating PfIAP and the various components of its protein-protein network is needed 
before a true role can be assigned to PfIAP. 
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APPENDIX A: Primers 
 
Table A 1: PCR Cycling Protocols 
 
DreamTaq PCR Master 
Mix / High Fidelity PCR 
Enzyme Mix 
Phusion Flash PCR 
Master Mix 
 
Step 
Temperature 
(°C) 
Time 
Temperature 
(°C) 
Time 
Number of 
Cycles 
Initial Denaturation 94/95 3 min 98 10 sec 1 
Denaturation 94/95 30 sec 98 1 sec 
5 Annealing 
P. falciparum 
Specific Ta 
30 sec 
P. falciparum 
Specific Ta 
5 sec 
Extension 68 1 min/kb 72 15 sec/kb 
Denaturation 94/95 30 sec 98 1 sec 
25 Annealing 
Full Length 
Primer Ta 
30 sec 
Full Length 
Primer Ta 
5 sec 
Extension 68 1 min/kb 72 15 sec/kb 
Final Extension 68 5-10 min 72 1 min 1 
 
Table A 2: PCR Primers for P. falciparum Specific Region Amplification 
Protein Region Vector Primer Name 
Primer Sequence 
(5’ - 3’)* 
PCR Product 
(bp) 
PfIAP 
BIR 
Domain 
pGEX-
4T-2 
IAP1 Fwd 
TTTGGATCCATGAGCGAATC
AAGTGCCT 
471 
IAP1 Rev 
TTTCTCGAGTTATTCTTTAAG
TAATTCTTCTTTTGT 
pARL2-
GFP 
BIR Fwd 
TTTCTCGAGATGAGCGAATC
AAGTGCCTTGAGT 
468 
BIR Rev 
TTTCCTAGGTTCTTTAAGTAA
TTCTTCTTTTGTT 
Middle 
Region 
pGEX-
4T-2 
IAP2 Fwd 
TTTGGATCCTTTAGCATTTTT
GATCATTATGT 
561 
IAP2 Rev 
TTTCTCGAGTTATTTCCTTTG
TTCTAATAAGATGT 
Terminal 
Region 
pGEX-
4T-2 
IAP3 Fwd 
AAAGGATCCCAACATCAAAA
TCAAAAGGATAC 
984 
IAP3 Rev 
TTTCTCGAGTCATACATATTT
TCTTTCAAATTCCA 
5’ UTR pL7-DEL 
DEL_L Fwd 
GTCTAAGGCGCGCCATATAA
TTCAACATATCTGTC 
376 
DEL_L Rev 
GTCGACACTAGTCCTTCATTT
GAATATTAAAAAAGG 
3’ UTR pL7-DEL 
DEL_R Fwd 
GACGTCGAATTCAATAAAAA
AAATAAAAGCAATCA 
396 
DEL_R Fwd 
GACATACCATGGGAAAATTT
GCTACATATTTTCT 
PfDOC2 
Binding 
Region 
pET-15b 
DOC2 Fwd 
TCTGTTGCGCATATGCAATTT
CAAAAGGAAAAAATTCGT 
1 011 
DOC2 Rev 
TTTGGATCCTTACTTTGAATA
AATTTGATTCAAATCT 
PfRhopH3 
Binding 
Region 
pET-15b 
RhopH3 Fwd 
TCTGTTGCGCATATGTATGAA
GAAACTGTAGATGAAGA 
510 
RhopH3 Rev 
TTTGGATCCTTACAATTCATT
TTCAGAAGTAAAGGT 
* Bold = STOP codon; bold & underlined = intentional mutation to PCR product; italics = 
overlapping region; italics and underlined = extra nucleotides for restriction enzyme efficiency; 
underlined = restriction enzyme site 
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Table A 3: PCR Primers for Vector Specific Region Amplification 
Vector Primer Name Primer Sequence (5’ - 3’) PCR Product (bp) 
pARL2-
GFP 
pARL2 Fwd CCGTTAATAATAAATACACGCAG  
165 
pARL2 Rev CCATCTAATTCAACAAGAATTGGGACAAC 
pET-15b 
T7 Promoter Fwd TAATACGACTCACTATAGGG 
224 
T7 Terminator Rev GCTAGTTATTGCTCAGCGGT 
T7 Phage 
Arms 
T7SelectUP2 Fwd GCTAACTTCCAAGCGGACCA 
237 
T7SelectDOWN Rev GCTAGTTATTGCTCAGCGGT 
 
Table A 4: CRISPR-Cas9 Targeting Sequences 
Vector Sequence Name Targeting Sequence (5’ - 3’)* 
pL7-DEL 
DEL (+) 
TAAGTATATAATATTGCCATAAGATT
ATTTCTCCATGTTTTAGAGCTAGAA 
DEL (-) 
TTCTAGCTCTAAAACATGGAGAAATA
ATCTTATGGCAATATTATATACTTA 
* Italics = overlapping region; italics & underlined = addition ‘G’ base 
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APPENDIX B: Vector Maps 
 
  
  
 
Figure B 1: pGEX-4T-2 Vector Map 
A vector map of the pGEX-4T-2 plasmid with various restriction enzymes digestion sites marked.  
AmpR = confers resistance to ampicillin and related antibiotics; GST = glutathione S-transferase N-
terminal tag; lacI = lac repressor that binds to the lac operator to inhibit transcription, but can be 
relieved; ori = origin of replication. 
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Figure B 2: pET-15b Vector Map 
A vector map of the pET-15b plasmid with various restriction enzymes digestion sites marked.  
AmpR = confers resistance to ampicillin and related antibiotics; His = 6× His amino acid N-terminal 
tag; lacI = lac repressor that binds to the lac operator to inhibit transcription, but can be relieved; ori 
= origin of replication. 
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Figure B 3: T7Select®10-3b (Novagen) Bacteriophage Vector Map 
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Figure B 4: pARL2-GFP Vector Map 
A vector map of the pARL2-GFP plasmid with various restriction enzymes digestion sites marked.  
AmpR = confers resistance to ampicillin and related antibiotics; GFP = green fluorescent N-terminal 
tag; hdhfr = human dihydrofolate reductase cassette which confers resistance to the WR99210 
compound; ori = origin of replication. 
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Figure B 5: pUF1-Cas9 Vector Map 
A vector map of the pUF1-Cas9 plasmid with the EcoRI restriction enzyme digestion site marked.  
AmpR = confers resistance to ampicillin and related antibiotics; Cas9 = engineered S. pyogenes Cas9 
endonuclease under the control of plasmodial regulatory elements; ori = origin of replication; ydhodh 
= drug-selectable marker which gives resistance to a P. falciparum dihydroorotate dehydrogenase 
(PfDHODH) inhibitor, DSM. 
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Figure B 6: pL6-GOI Vector Map 
A vector map of the pL6-GOI plasmid with various restriction enzymes digestion sites marked.  
AmpR = confers resistance to ampicillin and related antibiotics; hdhfr = human dihydrofolate 
reductase cassette which confers resistance to the WR99210 compound; ori = origin of replication; 
U6 = P. falciparum small nuclear RNA regulatory elements that allow for the transcription of the 
sgRNA; sgRNA = single guide RNA that is made of the trans-activating crRNA (tracrRNA) that 
binds to the Cas9 endonuclease and the CRISPR RNA (crRNA) which contains the 20 bp guide 
RNA; yfcu = the suicide-gene cassette, yeast cytosine deaminase/uracil phosphoribosyl transferase, 
results in the conversion of harmless 5-fluorocytosine into 5-fluorouracil which kills the parasite. 
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Figure C 1: Identification of a PfIAP BIR Domain Binding Partner 
The sequencing chromatogram of the identified PF3D7_1303400 binding partner.  Orange = the        
P. falciparum peptide insert; purple = the AviTag™ biotin cassette; red = restriction enzyme sites 
used during the creation of the phage display library. 
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Table D 1: PfIAP Binding Partner Details 
PlasmoDB 
Name 
60S ribosomal protein 
L24, putative 
Chromodomain-helicase-
DNA-binding protein 1 
homolog, putative 
(CHD1) 
Double C2-like domain-
containing protein 
(DOC2) 
Gene I.D. PF3D7_1309100 PF3D7_1023900 PF3D7_1243900 
Intron/Exon 2 introns/3 exons 0 introns/1 exon 5 introns/6 exons 
Gene Size 489 bp 9 987 bp 5 541 bp 
Protein Size 162 aa 3 328 aa 1 846 aa 
Binding Region 
(aa positions) 
113 – 162 2 891 – 2 955 1 606 – 1 654 
Binding 
Sequence 
AKFGTKEKEDKKKTK
DDKKKNLVHFQQKKD
FTKSKMLNMAKSKMH
KMMKK 
DEESGECDKEEETGKR
KRRRNSRYYKSSNKYI
KDNEMLDITSVGAND
EYKYEDGDNLERKKR
SSK 
QKMREEEKIREEEQM
KREKKMRREEKKKRV
QEPIKIDEIQVYDIIKNE
K 
 
PlasmoDB 
Name 
High molecular weight 
rhoptry protein 3 
(RhopH3) 
LisH domain-containing 
protein, putative (LisH) 
Mature parasite-infected 
erythrocyte surface 
antigen (MESA) 
Gene I.D. PF3D7_0905400 PF3D7_1303400 PF3D7_0500800 
Intron/Exon 6 introns/7 exons 0 introns/1 exon 1 intron/2 exons 
Gene Size 2 694 bp 3 069 bp 4 305 bp 
Protein Size 897 aa 1 022 aa 1 434 aa 
Binding Region 
(aa positions) 
760 – 860 505 – 538 814 – 876 
Binding 
Sequence 
AIAEKDILEEKTKDQD
LEIELYKYMGPLKEQS
KSTSAASTSDEISGSEG
PSTESTSTGNQGEDKT
TDNTYKEMEELEEAE
GTSNLKKGLEFYKSSL
KLDQL 
KKKKKKEQTNEGKKS
VKGINKKDKKRNSKV
ESKK 
IEKQVEEGIKENDTES
KDKVIGQEVIKGDVNE
EGPENKDKVTKQEKV
KEVKKEVKKKVKKRV
K 
 
Table D 2: The expanded PfIAP protein network combining biopanning data from this study 
and available yeast two-hybrid data (LaCount et al. 2005). 
Numbers = PlasmoDB gene identifiers.  Classification = Consensus of the Gene Ontology biological 
processes available on PlasmoDB (Ashburner et al. 2000; Aurrecoechea et al. 2009). 
PlasmoDB I.D. PlasmoDB Name Classification 
GST-BIR 
PF3D7_0905400 High Molecular Weight Rhoptry Protein 3 (RhopH3) Erythrocyte Invasion 
 PF3D7_0930300 Merozoite Surface Protein 1 (MSP1) Erythrocyte Invasion 
 PF3D7_0108000 Proteasome Subunit Beta Type-3, Putative Protein Metabolism 
 PF3D7_0625200 Conserved Plasmodium Protein, Unknown Function 
Unknown Function  PF3D7_0813400 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1227600 Conserved Plasmodium Protein, Unknown Function 
PF3D7_1243900 Double C2-Like Domain-Containing Protein (DOC2) Erythrocyte Invasion 
PF3D7_1303400 LisH Domain-Containing Protein, Putative (LisH) Unknown Function 
PF3D7_1309100 60S Ribosomal Protein L24, Putative Protein Synthesis 
 PF3D7_1203700 Nucleosome Assembly Protein (NAPL) DNA/RNA 
 PF3D7_0936800 Plasmodium Exported Protein (PHISTc), Unknown Function Exported Protein 
 PF3D7_1126700 Autophagy-Related Protein 23, Putative (ATG23) RCD 
 PF3D7_1236100 Clustered-Asparagine-Rich Protein (CARP) Unknown Function 
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GST-Terminal 
PF3D7_0500800 Mature Parasite-Infected Erythrocyte Surface Antigen (MESA) Pathogenesis 
 PF3D7_0303300 
DNA-Directed RNA Polymerases I, II, And III Subunit RPABC2, 
Putative (RPB6) 
DNA/RNA 
 PF3D7_0803100 U3 Small Nucleolar RNA-Associated Protein 14, Putative (UTP14) 
 PF3D7_1014600 Transcriptional Coactivator ADA2 (ADA2) 
 PF3D7_1216900 DNA-Binding Chaperone, Putative 
 PF3D7_1321700 Splicing Factor 1 (SF1) 
 PF3D7_1428100 WW Domain-Binding Protein 11, Putative 
 PF3D7_0620400 Merozoite Surface Protein 10 (MSP10) 
Erythrocyte Invasion 
 PF3D7_0929400 High Molecular Weight Rhoptry Protein 2 (RhopH2) 
 PF3D7_0930300 Merozoite Surface Protein 1 (MSP1) 
 PF3D7_1228600 Merozoite Surface Protein 9 (MSP9) 
 PF3D7_1401200 Plasmodium Exported Protein, Unknown Function Exported Protein 
 PF3D7_0935600 Gametocytogenesis-Implicated Protein (GIG) Gametocytogenesis 
 PF3D7_0702900 Centrin, Putative 
Metabolism  PF3D7_1434500 Dynein-Related AAA-Type ATPase, Putative 
 PF3D7_1462800 Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) 
 PF3D7_0207600 Serine Repeat Antigen 5 (SERA5) 
Pathogenesis 
 PF3D7_0302500 Cytoadherence Linked Asexual Protein 3.1 (CLAG3.1) 
 PF3D7_1221000 
Histone-Lysine N-Methyltransferase, H3 Lysine-4 Specific 
(SET10) 
 PF3D7_0302100 Serine/Threonine Protein Kinase (SRPK1) 
Protein Metabolism 
 PF3D7_0501300 Skeleton-Binding Protein 1 (SBP1) 
 PF3D7_1129200 26S Proteasome Regulatory Subunit RPN7, Putative (RPN7) 
 PF3D7_1145400 Dynamin-Like Protein (DYN1) 
 PF3D7_1355500 Serine/Threonine Protein Phosphatase 5 (PP5) 
 PF3D7_0710600 60S Ribosomal Protein L34 (RPL34) 
Protein Synthesis 
 PF3D7_0828500 Translation Initiation Factor eIF-2B Subunit Alpha, Putative 
 PF3D7_0730900 EMP1-Trafficking Protein (PTP4) 
Unknown Function 
 PF3D7_0813400 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_0825500 Protein KRI1, Putative (KRI1) 
 PF3D7_0903600 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1325800 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1433400 Conserved Plasmodium Membrane Protein, Unknown Function 
PF3D7_1023900 
Chromodomain-Helicase-DNA-Binding Protein 1 Homolog, 
Putative (CHD1) 
DNA/RNA 
 PF3D7_0603800 Centrosomal Protein CEP76, Putative (CEP76) 
DNA/RNA 
 PF3D7_0623100 
Nuclear Polyadenylated RNA-Binding Protein NAB2, Putative 
(NAB2) 
 PF3D7_0802100 Transcription Factor With AP2 Domain(s) (ApiAP2) 
 PF3D7_1207100 Small Subunit rRNA Processing Factor, Putative 
 PF3D7_1216900 DNA-Binding Chaperone, Putative 
 PF3D7_1235300 CCR4-NOT Transcription Complex Subunit 4, Putative (NOT4) 
 PF3D7_0930300 Merozoite Surface Protein 1 (MSP1) 
Erythrocyte Invasion  PF3D7_1228600 Merozoite Surface Protein 9 (MSP9) 
 PF3D7_1335100 Merozoite Surface Protein 7 (MSP7) 
 PF3D7_0702100 
Plasmodium Exported Protein (PHISTb), Unknown Function, 
Pseudogene 
Exported Protein 
 PF3D7_0935500 Plasmodium Exported Protein, Unknown Function (GEXP22) 
 PF3D7_1148800 Plasmodium Exported Protein (hyp11), Unknown Function 
 PF3D7_0419900 Phosphatidylinositol 4-Kinase, Putative 
Metabolism  PF3D7_1017400 Phosphomannomutase, Putative (PMM) 
 PF3D7_1449400 Crossover Junction Endonuclease MUS81, Putative (MUS81) 
 PF3D7_0207600 Serine Repeat Antigen 5 (SERA5) 
Pathogenesis 
 PF3D7_1149000 Antigen 332, DBL-Like Protein (Pf332) 
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 PF3D7_0608500 Proteasome Subunit Alpha Type-2, Putative 
Protein Metabolism 
 PF3D7_0728600 RING Zinc Finger Protein, Putative 
 PF3D7_0803700 Tubulin Gamma Chain (g-tub) 
 PF3D7_0810500 Protein Phosphatase PPM7, Putative (PPM7) 
 PF3D7_0826100 E3 Ubiquitin-Protein Ligase, Putative 
 PF3D7_1118500 Nucleolar Protein 56, Putative (NOP56) 
Protein Synthesis  PF3D7_1302700 ATP-Dependent RNA Helicase DHR1, Putative 
 PF3D7_1342000 40S Ribosomal Protein S6 
 PF3D7_0202500 Early Transcribed Membrane Protein 2 (ETRAMP2) 
Unknown Function 
 PF3D7_0317300 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_0407700 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_0410000 Erythrocyte Vesicle Protein 1 (EVP1) 
 PF3D7_0418300 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_0510100 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_0532100 Early Transcribed Membrane Protein 5 (ETRAMP5) 
 PF3D7_0617200 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_0619000 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_0721000 Conserved Plasmodium Membrane Protein, Unknown Function 
 PF3D7_0725300 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_0910200 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1013400 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1014900 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1021700 Conserved Plasmodium Membrane Protein, Unknown Function 
 PF3D7_1029900 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1112100 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1138700 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1140200 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1238500 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1338600 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1359600 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1406200 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1446500 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1451200 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1452400 Conserved Plasmodium Protein, Unknown Function 
 PF3D7_1467600 Conserved Plasmodium Protein, Unknown Function 
 
Table D 3: The expanded PfIAP protein network with Gene Ontology classifications. 
Numbers = PlasmoDB gene identifiers.  Biological Process/Molecular Function/Location = Gene 
Ontology labels available on PlasmoDB (Ashburner et al. 2000; Aurrecoechea et al. 2009). 
PlasmoDB I.D. PlasmoDB Name Biological Process Molecular Function Location 
GST-BIR 
PF3D7_0905400 
High Molecular Weight Rhoptry Protein 3 
(RhopH3) 
Erythrocyte 
Invasion 
Protein Binding Organelle 
 PF3D7_0108000 Proteasome Subunit Beta Type-3, Putative Protein Degradation Protein Activity 
Cytoplasm 
Nucleus 
 PF3D7_0625200 Conserved Plasmodium Protein, Unknown Function DNA/RNA Nucleotide Binding Organelle 
 PF3D7_0813400 Conserved Plasmodium Protein, Unknown Function Unknown Function Nucleotide Binding Nucleus 
 PF3D7_0930300 Merozoite Surface Protein 1 (MSP1) Erythrocyte Invasion Protein Binding Membrane 
 PF3D7_1227600 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Unknown 
PF3D7_1243900 
Double C2-Like Domain-Containing Protein 
(DOC2) 
Erythrocyte 
Invasion 
Protein Binding Host Membrane 
PF3D7_1303400 LisH Domain-Containing Protein, Putative (LisH) Unknown Function Protein Binding Unknown 
PF3D7_1309100 60S Ribosomal Protein L24, Putative Protein Synthesis Structure Cytoplasm 
 PF3D7_0936800 
Plasmodium Exported Protein (PHISTc), Unknown 
Function 
Unknown Function Unknown Function 
Exported 
Host Cytoplasm 
Host Membrane 
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 PF3D7_1126700 Autophagy-Related Protein 23, Putative (ATG23) RCD Unknown Function Unknown 
 PF3D7_1203700 Nucleosome Assembly Protein (NAPL) DNA/RNA 
Nucleotide Binding 
Protein Binding 
Cytoplasm 
Nucleus 
 PF3D7_1236100 Clustered-Asparagine-Rich Protein (CARP) Unknown Function 
Nucleotide Binding 
Protein Binding 
Unknown 
GST-Terminal 
PF3D7_0500800 
Mature Parasite-Infected Erythrocyte Surface 
Antigen (MESA) 
Pathogenesis Protein Binding Host Membrane 
 PF3D7_0207600 Serine Repeat Antigen 5 (SERA5) Pathogenesis 
Protein Activity 
Protein Binding 
Host Cytoplasm 
 PF3D7_0302100 Serine/Threonine Protein Kinase (SRPK1) Protein Modification Protein Activity 
Cytoplasm 
Nucleus 
 PF3D7_0302500 
Cytoadherence Linked Asexual Protein 3.1 
(CLAG3.1) 
Pathogenesis Protein Binding 
Host Membrane 
Organelle 
 PF3D7_0303300 
DNA-Directed RNA Polymerases I, II, And III 
Subunit RPABC2, Putative (RPB6) 
DNA/RNA Nucleotide Binding Nucleus 
 PF3D7_0501300 Skeleton-Binding Protein 1 (SBP1) Protein Transport Protein Binding Membrane 
 PF3D7_0620400 Merozoite Surface Protein 10 (MSP10) Erythrocyte Invasion Protein Binding Host Membrane 
 PF3D7_0702900 Centrin, Putative Metabolism Substrate Binding Cytoplasm 
 PF3D7_0710600 60S Ribosomal Protein L34 (RPL34) Protein Synthesis Structure Cytoplasm 
 PF3D7_0730900 EMP1-Trafficking Protein (PTP4) Unknown Function Unknown Function Unknown 
 PF3D7_0803100 
U3 Small Nucleolar RNA-Associated Protein 14, 
Putative (UTP14) 
DNA/RNA Unknown Function Unknown 
 PF3D7_0813400 Conserved Plasmodium Protein, Unknown Function Unknown Function Nucleotide Binding Nucleus 
 PF3D7_0825500 Protein KRI1, Putative (KRI1) Unknown Function Substrate Binding Unknown 
 PF3D7_0828500 
Translation Initiation Factor eIF-2B Subunit Alpha, 
Putative 
Protein Synthesis Nucleotide Binding Nucleus 
 PF3D7_0903600 Conserved Plasmodium Protein, Unknown Function Unknown Function 
Protein Activity 
Protein Binding 
Cytoplasm 
 PF3D7_0929400 High Molecular Weight Rhoptry Protein 2 (RhopH2) Erythrocyte Invasion Protein Binding 
Host Membrane 
Organelle 
 PF3D7_0930300 Merozoite Surface Protein 1 (MSP1) Erythrocyte Invasion Protein Binding Host Membrane 
 PF3D7_0935600 Gametocytogenesis-Implicated Protein (GIG) Gametocytogenesis Unknown Function Unknown 
 PF3D7_1014600 Transcriptional Coactivator ADA2 (ADA2) DNA/RNA Nucleotide Binding Membrane 
 PF3D7_1129200 
26S Proteasome Regulatory Subunit RPN7, Putative 
(RPN7) 
Protein Degradation 
Protein Activity 
Protein Binding 
Cytoplasm 
Nucleus 
 PF3D7_1145400 Dynamin-Like Protein (DYN1) Protein Transport Protein Activity 
Cytoplasm 
Host Cytoplasm 
Host Membrane 
Membrane 
Organelle 
 PF3D7_1216900 DNA-Binding Chaperone, Putative DNA/RNA Nucleotide Binding Unknown 
 PF3D7_1221000 
Histone-Lysine N-Methyltransferase, H3 Lysine-4 
Specific (SET10) 
Pathogenesis 
Protein Activity 
Protein Binding 
Nucleus 
 PF3D7_1228600 Merozoite Surface Protein 9 (MSP9) Erythrocyte Invasion Unknown Function 
Host Cytoplasm 
Membrane 
 PF3D7_1321700 Splicing Factor 1 (SF1) DNA/RNA Nucleotide Binding Nucleus 
 PF3D7_1325800 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Unknown 
 PF3D7_1355500 Serine/Threonine Protein Phosphatase 5 (PP5) Protein Modification Protein Activity 
Cytoplasm 
Nucleus 
 PF3D7_1401200 Plasmodium Exported Protein, Unknown Function Unknown Function Unknown Function Exported 
 PF3D7_1428100 WW Domain-Binding Protein 11, Putative DNA/RNA Unknown Function 
Cytoplasm 
Membrane 
 PF3D7_1433400 
Conserved Plasmodium Membrane Protein, Unknown 
Function 
Unknown Function Protein Binding 
Cytoplasm 
Membrane 
 
141 
Appendix D 
PlasmoDB I.D. PlasmoDB Name Biological Process Molecular Function Location 
 PF3D7_1434500 Dynein-Related AAA-Type ATPase, Putative Metabolism Protein Activity Membrane 
 PF3D7_1462800 
Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) 
Metabolism Protein Binding 
Cytoplasm 
Membrane 
PF3D7_1023900 
Chromodomain-Helicase-DNA-Binding Protein 1 
Homolog, Putative (CHD1) 
DNA/RNA Nucleotide Binding Nucleus 
 PF3D7_0202500 Early Transcribed Membrane Protein 2 (ETRAMP2) Unknown Function Unknown Function Host Membrane 
 PF3D7_0207600 Serine Repeat Antigen 5 (SERA5) Pathogenesis 
Protein Activity 
Protein Binding 
Host Cytoplasm 
 PF3D7_0317300 Conserved Plasmodium Protein, Unknown Function Unknown Function 
Protein Activity 
Protein Binding 
Cytoplasm 
 PF3D7_0407700 Conserved Plasmodium Protein, Unknown Function Transcription Unknown Function Nucleus 
 PF3D7_0410000 Erythrocyte Vesicle Protein 1 (EVP1) Unknown Function Unknown Function Host Cytoplasm 
 PF3D7_0418300 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Unknown 
 PF3D7_0419900 Phosphatidylinositol 4-Kinase, Putative Metabolism Protein Activity Unknown 
 PF3D7_0510100 Conserved Plasmodium Protein, Unknown Function Unknown Function RNA Binding Unknown 
 PF3D7_0532100 Early Transcribed Membrane Protein 5 (ETRAMP5) Unknown Function Protein Binding Host Membrane 
 PF3D7_0603800 Centrosomal Protein CEP76, Putative (CEP76) DNA/RNA Protein Binding Organelle 
 PF3D7_0608500 Proteasome Subunit Alpha Type-2, Putative Protein Degradation Endopeptidase Activity 
Cytoplasm 
Nucleus 
 PF3D7_0617200 Conserved Plasmodium Protein, Unknown Function Unknown Function 
Protein Activity 
Protein Binding 
Cytoplasm 
 PF3D7_0619000 Conserved Plasmodium Protein, Unknown Function Metabolism Protein Binding Cytoplasm 
 PF3D7_0623100 
Nuclear Polyadenylated RNA-Binding Protein NAB2, 
Putative (NAB2) 
DNA/RNA Nucleotide Binding Unknown 
 PF3D7_0702100 
Plasmodium Exported Protein (PHISTb), Unknown 
Function, Pseudogene 
Unknown Function Metal Ion Binding Exported 
 PF3D7_0721000 
Conserved Plasmodium Membrane Protein, Unknown 
Function 
Unknown Function Unknown Function Unknown 
 PF3D7_0725300 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Cytoplasm 
 PF3D7_0728600 RING Zinc Finger Protein, Putative Protein Degradation Protein Binding Unknown 
 PF3D7_0802100 Transcription Factor With AP2 Domain(s) (ApiAP2) DNA/RNA Nucleotide Binding Unknown 
 PF3D7_0803700 Tubulin Gamma Chain (g-tub) Protein Transport Protein Binding Organelle 
 PF3D7_0810500 Protein Phosphatase PPM7, Putative (PPM7) Protein Modification Protein Activity 
Cytoplasm 
Nucleus 
 PF3D7_0826100 E3 Ubiquitin-Protein Ligase, Putative Protein Degradation Protein Activity Unknown 
 PF3D7_0910200 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Nucleus 
 PF3D7_0930300 Merozoite Surface Protein 1 (MSP1) Erythrocyte Invasion Protein Binding Host Membrane 
 PF3D7_0935500 
Plasmodium Exported Protein, Unknown Function 
(GEXP22) 
Unknown Function Substrate Binding Unknown 
 PF3D7_1013400 Conserved Plasmodium Protein, Unknown Function Unknown Function Substrate Binding Cytoplasm 
 PF3D7_1014900 Conserved Plasmodium Protein, Unknown Function Unknown Function 
Protein Activity 
Protein Binding 
Cytoplasm 
 PF3D7_1017400 Phosphomannomutase, Putative (PMM) Metabolism Protein Activity Cytoplasm 
 PF3D7_1021700 
Conserved Plasmodium Membrane Protein, Unknown 
Function 
Metabolism Protein Activity Organelle 
 PF3D7_1029900 Conserved Plasmodium Protein, Unknown Function DNA/RNA Nucleotide Binding Nucleus 
 PF3D7_1112100 Conserved Plasmodium Protein, Unknown Function Protein Modification Protein Activity 
Cytoplasm 
Membrane 
Nucleus 
 PF3D7_1118500 Nucleolar Protein 56, Putative (NOP56) Protein Synthesis Unknown Function Nucleus 
 PF3D7_1138700 Conserved Plasmodium Protein, Unknown Function Unknown Function 
Protein Activity 
Protein Binding 
Cytoplasm 
 
142 
Appendix D 
PlasmoDB I.D. PlasmoDB Name Biological Process Molecular Function Location 
 PF3D7_1140200 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Unknown 
 PF3D7_1148800 
Plasmodium Exported Protein (hyp11), Unknown 
Function 
Unknown Function Unknown Function Unknown 
 PF3D7_1149000 Antigen 332, DBL-Like Protein (Pf332) Pathogenesis Protein Binding 
Exported 
Host Membrane 
 PF3D7_1207100 Small Subunit rRNA Processing Factor, Putative DNA/RNA Nucleotide Binding 
Cytoplasm 
Nucleus 
 PF3D7_1216900 DNA-Binding Chaperone, Putative DNA/RNA Nucleotide Binding Unknown 
 PF3D7_1228600 Merozoite Surface Protein 9 (MSP9) Erythrocyte Invasion Unknown Function 
Host Cytoplasm 
Membrane 
 PF3D7_1235300 
CCR4-NOT Transcription Complex Subunit 4, 
Putative (NOT4) 
DNA/RNA 
Nucleotide Binding 
Protein Binding 
Unknown 
 PF3D7_1238500 Conserved Plasmodium Protein, Unknown Function Unknown Function 
Protein Activity 
Protein Binding 
Cytoplasm 
 PF3D7_1302700 ATP-Dependent RNA Helicase DHR1, Putative Protein Synthesis Nucleotide Binding Nucleus 
 PF3D7_1335100 Merozoite Surface Protein 7 (MSP7) Erythrocyte Invasion Protein Binding Host Membrane 
 PF3D7_1338600 Conserved Plasmodium Protein, Unknown Function Protein Synthesis Unknown Function Membrane 
 PF3D7_1342000 40S Ribosomal Protein S6 Protein Synthesis Structure Cytoplasm 
 PF3D7_1359600 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Cytoplasm 
 PF3D7_1406200 Conserved Plasmodium Protein, Unknown Function DNA/RNA Protein Activity Nucleus 
 PF3D7_1446500 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Cytoplasm 
 PF3D7_1449400 
Crossover Junction Endonuclease MUS81, Putative 
(MUS81) 
Metabolism Nucleotide Binding Organelle 
 PF3D7_1451200 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function Unknown 
 PF3D7_1452400 Conserved Plasmodium Protein, Unknown Function Unknown Function Unknown Function 
Cytoplasm 
Nucleus 
 PF3D7_1467600 Conserved Plasmodium Protein, Unknown Function Metabolism Unknown Function Cytoplasm 
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Chemical, Equipment or Kit Manufacture or Supplier 
Acid Citrate Dextrose Tubes BD Vacutainer, UK 
Acrodisc® PF 0.8/0.2 μm Filter Unit Pall Life Sciences, USA 
Acrylamide Promega, USA 
Agar Merck, Germany 
Agarose Sigma-Aldrich, USA 
Albumax II Life Technologies, USA 
Ammonium Chloride Saarchem, RSA 
Ammonium Persulfate Promega, USA 
Ampicillin Roche, Germany 
Anti-GST HRP Conjugated Primary Antibody Amersham Biosciences, UK 
Anti-His HRP Conjugated Blocking Solution Qiagen, Germany 
Anti-His HRP Conjugated Primary Antibody Qiagen, Germany 
Avanti® J-E Centrifuge Beckman Coulter, USA 
Axiostar Plus Transmitted Light Microscope Zeiss, Germany 
Biotin Polyclonal Antibody-HRP Conjugate Thermo Fisher Scientific, USA 
Bis-Acrylamide Sigma-Aldrich, USA 
Bovine Serum Albumen (BSA) Pierce, USA 
Bromophenol Blue Merck, Germany 
BtgZI New England Biolabs, USA 
BX41 Microscope Olympus, Japan 
Calcium Chloride Merck, Germany 
Centrifuge 5415 R Eppendorf, Germany 
Centrifuge 5702 R Eppendorf, Germany 
Chloramphenicol Roche, Germany 
Chloroform Merck, Germany 
Coomassie Brilliant Blue R-250 BDH, UK 
CPE 50 Circulator Labcon, RSA 
Cryotubes Nunc, Denmark 
Culture Flasks Thermo Fisher Scientific, USA 
DAPI Sigma-Aldrich, USA 
Dipotassium Phosphate Merck, Germany 
Disodium Phosphate Saarchem, RSA 
Dithiothreitol (DTT) Invitrogen, USA 
DMSO BDH, UK 
DNA Polymerase I Fermentas, USA 
DNaseI Fermentas, USA 
DP72 Camera Olympus, Japan 
DreamTaq Green PCR Master Mix Thermo Fisher Scientific, USA 
Dynabeads® mRNA Purification Kit Invitrogen, USA 
EDTA Merck, Germany 
EGTA BDH, UK 
Eppendorf Tubes Eppendorf, Germany 
Ethanol Merck, Germany 
Ethidium Bromide Sigma-Aldrich, USA 
Falcon™ Round Bottom Tubes Becton Dickinson, USA 
FastAP™ Thermosensitive Alkaline Phosphatase Thermo Fisher Scientific, USA 
FastDigest® Restriction Endonuclease Thermo Fisher Scientific, USA 
Filter Tips QSP, USA 
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Forma Incubated/Refrigerated Floor Orbital Shaker Thermo Fisher Scientific, USA 
Gas Mixture Afrox, RSA 
Gel Doc System Syngene, UK 
Gene Pulser Xcell™ Electroporation System Bio-Rad Laboratories, USA 
Gene Pulser®  Electroporation Cuvette Bio-Rad Laboratories, USA 
GenElute™ Plasmid Miniprep Kit Sigma-Aldrich, USA 
Gentamycin Sigma-Aldrich, USA 
Gibson Assembly® Master Mix New England Biolabs, USA 
Glacial Acetic Acid Merck, Germany 
Glucose Merck, Germany 
Glutathione, Reduced Sigma-Aldrich, USA 
Glycerol Merck, Germany 
Glycine Sigma-Aldrich, USA 
HEPES Merck, Germany 
High Fidelity PCR Enzyme Mix Thermo Fisher Scientific, USA 
Hoechst 33258 Pentahydrate Invitrogen, USA 
Hybond-C Extra Nitrocellulose Membrane Amersham Biosciences, UK 
Hypoxanthine Sigma-Aldrich, USA 
Imidazole Sigma-Aldrich, USA 
Intelli-Mixer ELMI, Latvia 
Isopropanol Merck, Germany 
Laminar Flow Hood Labotec, RSA 
Lithium Chloride Sigma-Aldrich, USA 
MagneGST™ Protein Purification System Promega, USA 
MagneHis™ Protein Purification System Promega, USA 
Magnesium Chloride Merck, Germany 
Magnesium Sulphate Merck, Germany 
MassRuler™ DNA Ladder Mix Fermentas, USA 
Mastercycler Gradient Thermocycler Eppendorf, Germany 
Methanol Merck, Germany 
Methylated dNTP Mix Fermentas, USA 
Microscope Slides Thermo Fisher Scientific, USA 
Mighty Small II SE250 Gel Cassette Hoefer Scientific Instruments, USA 
Monopotassium Phosphate Merck, Germany 
Monosodium Phosphate Merck, Germany 
NanoDrop® 1000 Spectrophotometer Thermo Fisher Scientific, USA 
Nuclease Free Water Fermentas, USA 
Nucleobond® Xtra Maxi Plus Plasmid Kit Macherey-Nagel, Germany 
Nucleospin® Gel and PCR Clean-Up Kit Macherey-Nagel, Germany 
Nucleospin® Plasmid Kit Macherey-Nagel, Germany 
Orbital Shaker Labotec, RSA 
OrientExpress™ cDNA Synthesis Kit Novagen, USA 
Overnight Express™ Instant TB Medium Novagen, USA 
Petri Dishes Costar, USA 
pH Meter Beckman Coulter, USA 
Phenol Merck, Germany 
Phusion Flash PCR Master Mix Thermo Fisher Scientific, USA 
Ponceau S Sigma-Aldrich, USA 
Potassium Acetate Merck, Germany 
Potassium Chloride Merck, Germany 
PR250 Mini Orbital Shaker Hoefer Scientific Instruments, USA 
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Chemical, Equipment or Kit Manufacture or Supplier 
Protease Inhibitor Cocktail Set III Calbiochem, USA 
QIAquick® PCR Purification Kit Qiagen, Germany 
Rapid DNA Ligation Kit Roche, Germany 
Rapi-Diff Stain Kit Diagnostic Media Products, RSA 
RNase A Thermo Fisher Scientific, USA 
RNase H Fermentas, USA 
RNaseZap™ Ambion, USA 
Rosetta™ 2 (DE3) Competent Cells Novagen, USA 
RPMI Culture Medium GibcoBRL, USA 
Saponin USB, USA 
Slide-A-Lyzer® Mini Dialysis Unit Pierce, USA 
Sodium Acetate Merck, Germany 
Sodium Bicarbonate PAL Chemicals, UK 
Sodium Chloride Merck, Germany 
Sodium Dodecyl Sulfate (SDS) Merck, Germany 
Sodium Hydroxide Merck, Germany 
Sonopuls HD 3100 Ultrasonic Homogenizer Bandelin Electronic, Germany 
Sorbitol Sigma-Aldrich, USA 
Spectra™ Multicolor Broad Range Protein Ladder Fermentas, USA 
Streptavidin Magnetic Particles Roche, Germany 
Sucrose Merck, Germany 
SuperScript™ III Reverse Transcriptase Invitrogen, USA 
SuperSignal® West Pico Chemiluminescent Substrate Thermo Fisher Scientific, USA 
T7Select®10-3 Cloning Kit Novagen, USA 
TEMED Promega, USA 
Thermo Biomate 5 Spectrophotometer Thermo Fisher Scientific, USA 
TRI Reagent® Sigma-Aldrich, USA 
Tris Sigma-Aldrich, USA 
Triton-X BDH, UK 
Tryptone [Pancreatic Digest of Casein] Merck, Germany 
Tween20 Calbiochem, USA 
U-25ND25 Neutral Density Filter Olympus, Japan 
U-MWB2 Filter Olympus, Japan 
U-MWU2 Filter Olympus, Japan 
Vacucap® 90 PF 0.8/0.2 μm Filter Unit Pall Life Sciences, USA 
Water Bath Lauda, Germany 
XL10-Gold Ultracompetent Cells Stratagene, USA 
Yeast Extract Oxoid, UK 
β-Mercaptoethanol Merck, Germany 
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